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 i 
ABSTRACT 
 
 
The structure, occurrence and biological relevance of G-quadruplex DNA structures 
has been reviewed, along with a review of several notable G-quadruplex binding 
compounds published in the literature to date. 
 
The synthetic route towards two G-quadruplex DNA binders previously developed 
within the Hannon group has been modified and improved. Electrospray ionisation 
mass spectrometry studies have been carried out to evaluate nucleotide binding. The 
in vitro biological activities of these compounds have been validated against the 
human ovarian carcinoma cell line A2780 via MTT and comet assays, flow cytometry 
and inductively coupled plasma mass spectrometry. Both compounds and the 
corresponding metal-free ligand exhibited higher drug efficiencies than cisplatin 
against A2780 cells. Both compounds display mild genotoxicity and induce G2/M 
phase cell cycle arrest. The overall cellular uptake and nuclear localisation 
demonstrated by both complexes exceeds that of cisplatin. 
 
A new class of palladium and platinum(II) complexes have been synthesised from 
methylthio-substituted terpyridine ligands. In addition to assessing their stability in 
solution via UV-Vis spectroscopy, initial DNA binding studies with both duplex and 
quadruplex-forming sequences of DNA have been carried out via circular dichroism 
and gel electrophoresis.  
 
The design and synthesis of alternative ligand systems proffering a range of 
desirable characteristics to aid future ligand and complex development has been 
investigated.    
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I. INTRODUCTION 
 
1.1 Deoxyribonucleic acid (DNA)  
1.1.1 Structure 
Deoxyribonucleic acid is the molecule that carries the genetic information in all 
cellular forms of life. Classified as a nucleic acid, this fundamental molecule consists 
of a long chain of nucleotides. Each nucleotide itself consists of three components; a 
pentose sugar, phosphate molecule and nitrogenous base: cytosine (C), adenine (A), 
guanine (G) and thymine (T). Phosphodiester covalent bonds between nucleotides 
form an alternating sugar-phosphate backbone of a polynucleotide strand.  
First elucidated in 1953 by Watson and Crick, hydrogen bonds form between 
complementary bases of two polynucleotide strands aligned anti-parallel to one 
another, resulting in the formation of a double helix structure resembling a spiral 
staircase.1,2 The spatial arrangement of the base pairs creates two recurring cavities 
of different magnitude, termed the major and minor groove,3 shown in  
Figure 1.1.1-1.  
Three common types of duplex DNA have been discovered, each 
distinguished by its characteristic direction of winding and the number of bases in 
one helical turn. The most common form encountered in biological systems is B-
DNA,3 which exists as a right-handed helix, with 10-10.5 bases per helical turn.4 A-
DNA is similarly right-handed,5 but exists as a shorter, wider helix, whilst Z-DNA is 
left-handed and also found in biological systems.6  
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Figure 1.1.1-1 DNA structure: complementary nucleotide base pairing, structure of double-
stranded helix,7 comparison of the B-, A- and Z-forms of DNA.8 
4 
 
1.1.2 Function 
DNA is a fundamental molecule, the ability of which to store and transmit information 
lies in its structure. Information is stored in the linear sequence of the nucleotides, 
specifically the order of the bases along a single strand, which constitutes the 
universal and degenerate genetic code. Crucially, the molecule can be replicated, 
whereby each strand acts as a template for the generation of a new complementary 
strand.  
 
1.2 Alternative DNA structures 
Nucleic acids may also adopt alternative, less familiar non-canonical structural 
conformations that are proving to be no less biologically relevant, such as Holliday 
junctions, three-way junctions, replication forks, bulges and G-quadruplexes. Formed 
during active processes such as replication, transcription and recombination,9,10 
these emerging structures may prove to be effective targets for anticancer agents, 
since the loss of control over such processes is often the cause for cancer 
proliferation.11,12  
 
1.2.1 Holliday junctions 
Junctions formed between DNA helices play an important role as intermediates in 
DNA rearrangements.13 Undoubtedly the most important of these structures, is the 
four-way junction, termed the Holliday junction after the geneticist Robin Holliday who 
proposed its existence in 1964.14 During homologous recombination, two helices 
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(four strands) stack pairwise to generate two coaxial, quasi-continuous helices that 
form an X-shaped structure (Figure 1.2.1-1).15   
 
Figure 1.2.1-1 Representative structure of four-stranded Holliday junction (4WJ).16 
1.2.2 Three-way helical junctions 
Three-way junctions are the simplest and most commonly occurring branched nucleic 
acids.17 Consisting of three double helical arms connected at a junction point, the Y-
shaped structure also features a hydrophobic cavity at the branch point18,19  (Figure 
1.2.2-1). The formation of these structures within genetically unstable genomic DNA 
has been linked to neurodegenerative disorders such as Huntington’s disease. 
Unstable DNA can accommodate looped out triplet-repeat expansions,18 the 
formation of which results in three-way junctions also being formed (at the loop-out) 
in the process, introducing considerable kinks and bends into the DNA. Sinden et al. 
have reported the occurrence of mutated DNA triplet-repeat expansions in fourteen 
genetic neurodegenerative disorders.20 
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Figure 1.2.2-1 Representative structure of three-way junction (3WJ).16 
1.2.3 Replication forks  
Replication forks form during DNA replication, when DNA helicases unwind the 
double stranded DNA helix to expose the nucleotides of a single strand in 
preparation for transcription. A Y-shaped junction emerges, with the separated single 
strands serving as templates for nascent leading and lagging strands, formed from 
complementary nucleotides joined together by DNA polymerase (Figure 1.2.3-1). The 
branch point consists of one base-pair and two unpaired bases, resulting in a cavity 
which represents a significant therapeutic target for synthetic agents intending to halt 
the replication process.21 
 
Figure 1.2.3-1 Representation of the Y-shaped junction formed during DNA replication.22  
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1.2.4 Bulges 
Base bulges form where a duplex section of DNA is interrupted by one or more 
single-stranded bases on one strand that are unopposed by bases on the other 
strand (Figure 1.2.4-1).23 Such bulges may arise as a consequence of DNA 
mismatches,24 which if left uncorrected by a mismatch repair pathway would result in 
recombination between imperfectly homologous DNA sequences, causing a bulge to 
emerge. Bulges bring about substantial destabilisation of DNA25–27 and are an 
important feature that can be exploited for specific recognition. 
 
Figure 1.2.4-1 The extended structure of Tp5abc showing the effect of the A-rich bulge on 3D 
conformation.28 
1.2.5 The importance of alternative DNA structures  
An understanding of the processes that occur during replication and gene 
expression, when DNA is often described as being in its ‘active’ state, is vital in the 
diagnosis and subsequent treatment of diseases such as cancer. This is because the 
rate of such processes is elevated in rapidly-proliferating cancer cells,29 thereby 
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implicating these processes in the development of the disease and prompting the 
investigation of their particular role as a potential therapeutic target.  
Currently, there exists a wide selection of metallo-anticancer agents, shown to 
interact with duplex DNA in order to alter its function. Most notably cisplatin (Figure 
1.2.5-1), which remains the most effective anticancer agent to date, effecting 
apoptosis in cells following its irreversible interaction with duplex DNA.  
      
Figure 1.2.5-1 Main reactions involved in the biochemical activity of cisplatin. Once cisplatin 
(a) has entered the cell, one water molecule is incorporated into the complex with 
displacement of one chlorine. The resulting activated aqua platinum complex (b) attacks the 
N7 positions of two adjacent GC base pairs (c) to form the Pt–DNA intrastrand cross-link 
adduct (d).30 
The discovery of alternative, more unusual DNA structures has prompted the 
development of complexes that display specificity and selectivity for a particular DNA 
structure. The advantage of such compounds lies in their ability to minimise the 
damage incurred by healthy cells, in that their cytotoxicity is targeted towards cells 
containing a particular DNA structure implicated in cancer progression. 
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1.3 G-quadruplex DNA 
1.3.1 Structure 
Of particular interest herein, and the subject of an ever-expanding area of research 
exploring non-duplex DNA, are G-quadruplex structures. These structures have been 
characterised as multiple-stranded assemblies, formed via folding of guanine-rich 
single stranded sequences into tetraplex structures. Whilst the N(1), N(2) and O(6) 
atoms of guanine are key atoms in establishing Watson-Crick hydrogen bonding in 
duplex DNA, alternative hydrogen bonding atoms are possible. Utilising the N(2) and 
N(3) atoms along the Hoogsteen face, hydrogen bonding can lead to triple or four-
stranded structures31 (Figure 1.3.1-1).  
                              
Figure 1.3.1-1 Molecular structure of a G nucleotide unit showing the Hoogsteen and 
Watson-Crick faces.31 
Formed from four guanine bases hydrogen-bonded to each other (involving both the 
Hoogsteen and Watson-Crick faces), the G-quartet (also referred to as G-tetrad) 
structure exhibits a large π-surface, with π-stacking interactions highly favoured in 
order to aid stability (Figure 1.3.1-2). Crystallographic evidence for G-quartets was 
first provided by Gellert et al. in 1962.32 G-quadruplexes are formed when the G-
quartets π-stack on top of one another. 
10 
 
 
Figure 1.3.1-2 The structure of a G-quartet,33 showing hydrogen bonds involving both faces 
of the guanine base, alongside the structure of a G-quadruplex formed from several G-
quartets stacked together.16 
The presence of a monovalent cation which can coordinate within the quadruplex 
core and engage in electrostatic interactions with the O(6) atoms strongly stabilises 
the G-quadruplex structure.34 The ability of the cation to undertake coordination to 
the guanine bases and thus facilitate stabilisation of the quadruplex is dependent 
upon the amount of energy released upon coordination and the energy required to 
dehydrate the solvated cation.35,36 Stabilisation using Na+ and K+ is well precedented, 
with K+ the strongest known coordinating cation for G-quadruplexes.35–40  
G-quadruplexes can form from both intermolecular and intramolecular 
interactions of guanine bases. Unimolecular, bimolecular, and tetramolecular forms 
have all been observed (Figure 1.3.1-3, b). Owing to the directionality possessed by 
nucleic acids (5’ end to 3’ end), both parallel and antiparallel conformations exist 
depending on the direction of the four strands relative to one another. The position of 
the guanine base relative to the phosphodiester backbone is determined by the 
11 
 
glycosidic angle χ, which is therefore related to the directionality of the strands (and 
the adopted conformation) (Figure 1.3.1-3, a).31  
 
 
 
Figure 1.3.1-3 (a) Preferred base geometries. Rotation around the glycosidic bond (χ defined 
as the angle O4’ C1’, N4-C8) causes interconversion between the syn and anti 
conformation.31 (b) Structure and topology of G-quadruplexes: (1) tetramolecular with parallel 
strands; (2) bimolecular with diagonal loops; (3) bimolecular with lateral loops; (4) 
unimolecular/intramolecular with lateral loops; and (5) unimolecular/intramolecular with one 
diagonal and two external (propeller) loops.33 
In contrast to intermolecular G-quadruplexes consisting of neighbouring strands that 
are independently aligned in the absence of covalent bonding, intramolecular G-
quadruplexes contain covalently linked loops that connect the guanine bases 
constituting the quadruplex structure. These loops may adopt several distinct 
conformations, imparting further diversity to G-quadruplex topology. In addition to 
12 
 
loops, all G-quadruplex structures contain grooves (defined as the cavities between 
two adjacent guanine bases bounded by the phosphodiester backbones),31 varying in 
size depending on the nature of the loops.41     
 
1.3.2 Prediction of G-quadruplex structure and stability 
Data obtained from biophysical analytical methods used to study G-quadruplex 
formation and topology (X-ray diffraction, NMR spectroscopy, UV-spectroscopy, 
circular dichroism and fluorescence resonance energy transfer) demonstrates that it 
is possible to predict the likelihood of in vitro G-quadruplex formation by a particular 
sequence using the ‘folding rule’:42 This states that any sequence GnX1-7GnX1-7Gn 
X1-7Gn where G = guanine, X = any base, 3 < n > 5, will form a G-quadruplex.  
This rule can be implemented algorithmically to scan a sequence of putative 
G-quadruplex sequences (PQS) for possible G-quadruplex formation. A scan of the 
human genome predicted the existence of 376,000 G-quadruplex forming 
sequences.42 Whilst potentially very informative, care must be taken when 
interpreting these predictive data, which neither prove in vitro or in vivo formation, nor 
take into account the numerous factors affecting the stability of any particular G-
quadruplex structure. For example, thermodynamic G-quadruplex stability is known 
to increase with increasing G-quartets involved due to additional π-π stacking.43 
Furthermore, short loops adopt the thermodynamically more favourable parallel 
conformation, in contrast to long loops which induce antiparallel G-quadruplexes.44–46 
Intermediate loop lengths thus exhibit structural polymorphism.47  
The accurate prediction of G-quadruplex stability from its sequence is vital in 
determining PQSs with a low error rate. A promising machine-learning approach to 
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predict the stability of an unknown G-quadrupex, based on an existing dataset of 
experimental values has been proposed by Stegle et al. and looks to offer an 
improved prediction tool.48  
 
1.4 Biological relevance of G-quadruplex structures 
Within the human genome, approximately 376,000 PQSs have been identified, often 
correlating with functional genomic regions.49 Of particular interest, is their 
abundance in both eukaryotic gene promotor regions and G-rich telomere sequences 
located at the end of chromosomes.50–53  
 
1.4.1 Telomeres 
Telomeres are single-stranded repeats of TTAGGG located at the ends of 
chromosomes. Containing no genetic information, telomeres act as a ‘cap’, protecting 
the chromosome from deterioration and genetic instability. Two opposing processes 
occur within telomeres, summarised in Figure 1.4.1-1. The first is telomere 
shortening, which occurs with each cell replication. The characteristic shortening of 
the telomeric sequence is due to the absence of hydroxyl groups at the 5’ end of the 
newly replicated strands, which prevents the replacement of RNA primers with DNA, 
and thus produces two daughter strands marginally shorter than the parent strands 
from which they were synthesised.  
The second process is telomere lengthening; the result of an enzyme called 
telomerase which is known to add telomeric repeats of TTAGGG to the 3’-end of the 
chromosome, causing elongation of the telomere.54 This process occurs in order to 
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maintain the genetic integrity of the chromosome and protect it from deterioration 
over time.   
The net effect of these two processes is that of a gradual shortening of the 
telomere length in normal cells with each successive cell replication. Following a 
certain number of divisions, termed the Hayflick limit, the telomere reaches a critical 
length and causes the cell to enter senescence, inducing apoptosis.55,56 This 
sequence of events prevents genomic instability in aged cells by limiting the number 
of cell divisions.   
 
 
Figure 1.4.1-1 Overview of the two processes occurring within telomeres (a) telomere 
shortening; (b) telomere lengthening57  
Telomere sequences were found to account for approximately 20,000 of the PQSs 
identified during algorithmic analysis of the whole genome.42 Of special interest, and 
thus the focus of research efforts, is the 12-200 base 3’-overhang sequence.58 
Containing repeats of guanine-rich motifs, these single-stranded sequences are 
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capable of adopting G-quadruplex structures under physiological conditions (Figure 
1.4.1-2).  
 
Figure 1.4.1-2 NMR structure of a human telomeric G-quadruplex.59 
G-quadruplex structures have been successfully visualised at the telomeres of ciliate 
macronuclei (selected as a model organism due to the higher concentration of 
telomeres found in their cells compared to other genomes) using fluorescent imaging 
of an antibody.47 Support for the presence of G-quadruplexes in human telomeres 
has been reported by Tang et al. following the use of a fluorescent cyanine dye that 
specifically binds to G-quadruplexes, allowing in vitro visualisation.60   
 
 
Figure 1.4.1-3 Localization of G-quadruplex structures in chromosomes: 
Immunofluorescence for BG4 on metaphase chromosomes. Discrete BG4 foci (red) DAPI 
counterstaining (blue).61 
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Confirmation of G-quadruplex formation in human telomeres has been subsequently 
reported by Balasubramanian et al., whose use of an engineered, structure-specific 
antibody has enabled quantitative visualisation of these structures in human cells 
(Figure 1.4.1-3).61 This approach utilises the single chain antibody clone BG4, 
selected from a library of over 1010 antibodies due to its high affinity for G-
quadruplexes. Treatment of BG4 with a second antibody to amplify the fluorescent 
signal, followed by a tertiary fluorochrome-labelled antibody yields a highly specific 
probe for G-quadruplex structures in the DNA of human cells.  
The enormous significance of the formation of G-quadruplex structures in 
telomeric regions is due to their ability to inhibit the activity of telomerase in vitro.62 
Whilst essential in maintaining the lifespan of frequently replicated cells such as 
white blood cells, telomerase is overexpressed and upregulated in 85-90% of cancer 
cells.63,64 Consequently, these cells evade the usual process of telomere shortening 
leading to the induced death of aged cells that is crucial for genomic stability. Rather, 
they replicate indefinitely, enabling cancer proliferation. The ability of G-quadruplex 
structures to inhibit telomerase renders them an important new therapeutic target, 
whereby G-quadruplex stabilisation has the potential to regulate telomerase activity, 
thereby inhibiting immortality in cancer cells (Figure 1.4.1-4).  
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Figure 1.4.1-4 Representation of the therapeutic strategy involving ligand binding to telomeric 
G-quadruplex structures in order to inhibit telomerase activity. 
1.4.2 Oncogene promoter regions 
Promoter regions have a regulatory role, controlling the transcription of a particular 
gene. Located upstream of an oncogene (5’ end) which has the potential to cause 
cancer, the promoter region often serves as the binding site for transcription factors 
that further regulate transcriptional activity.31 Activation of RNA polymerase initiates 
RNA synthesis from the coding part of the gene.65  
Mutation or transformation of an oncogene may lead to the abnormal 
regulation of processes, resulting in unfavourable cellular outcomes including 
evasion of apoptosis, insensitivity to anti-growth signals, continuous angiogenesis, 
infinite replicative potential and metastasis.65  
 
Computational studies have shown that promoter-associated G-quadruplex 
structures are frequently found proximal to or overlapping with transcription factor 
binding sites within promoter regions, suggesting that they could play some 
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regulatory role in gene epression.49,66,67 The presence of G-quadruplex forming 
sequences in promoter regions has been confirmed for a number of oncogenes in 
vitro, including c-Myc (Figure 1.4.2-1), c-kit, bcl-2, k-ras and VEGF.68–73  
 
Figure 1.4.2-1 NMR structure of cMyc G-quadruplex.59 
The effect of G-quadruplex formation within a promoter region, on transcriptional 
activity of a gene has been extensively studied for the c-Myc oncogene and its 
corresponding NHEIII-promoter region, which has been shown to regulate 90% of c-
Myc oncogene transcription in vitro.74 The c-Myc oncogene is overexpressed in the 
majority of human cancers and contributes to the cause of at least 40% of tumours,75 
including colon, breast, cervix, small cell lung, osteosarcomas and myeloid 
leukaemias.76,77 Termed a “master regulator”,78 c-Myc stimulates genes involved in 
protein biosynthesis, cancer metabolism, transcription factors and the cell cycle, 
while inhibiting the expression of some tumour suppressor genes.78,79 Owing to its 
ubiquitous regulatory role in human tumour initiation and progression, efforts to utilize 
c-Myc as a therapeutic target remain an attractive prospect.  
The region of most interest remains the nuclease hypersensitive element, 
NHEIII, due to the ability of G-quadruplex structures to form in Pu27 sequence of this 
region (Figure 1.4.2-2). G-quadruplex-stabilising compounds have been shown to 
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downregulate c-Myc expression levels80 and cause selective leukaemic cell death.81 
The ability to selectively target and stabilise G-quadruplex structures within the Pu27 
sequence has potentially widespread downstream effects regarding transcription and 
subsequent gene expression.  
 
 
Figure 1.4.2-2 Location of the NHE III 1 in the c-Myc gene and proposed biological function 
of G-quadruplex in this region.82  
 
1.5 G-quadruplex DNA-ligand binding 
1.5.1 Modes of binding 
The significant enrichment of PQSs in the functional parts of the genome suggest 
that G-quadruplexes very likely possess key biological regulatory function within the 
telomeric and promoter regions of the genome. Consequently, the development of 
compounds capable of interacting with and stabilising G-quadruplex structures 
remains the principal aim of the G-quadruplex nucleic acids research community.  
Generally, compounds consisting of planar aromatic systems containing 
delocalised electrons will undergo π-stacking onto the G-quartet face, whereas 
compounds containing cationic moieties will typically interact with the loops, grooves 
and anionic phosphate backbone of G-quadruplexes (Figure 1.5.1-1). 
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 Figure 1.5.1-1 Binding modes of ligands to G-quadruplex.83  
1.5.2 π-stacking compounds 
π-stacking refers to the stacked arrangement of aromatic systems, predominantly 
controlled by hydrophobic and Van der Waal interactions.33 Ligands capable of 
efficiently engaging in this mode of binding should possess a large aromatic surface 
for aromatic-aromatic overlap, sufficiently large to prohibit duplex binding, thus 
providing selectivity for G-quadruplex structures. The incorporation of protonable 
side-chains around the aromatic core assists water solubility. Such side-chains may 
also establish electrostatic interactions with atoms in the grooves and central  
G-quadruplex channel, further stabilising the structure. Ma et al. have reported a 
series of pyridyl-substituted corrole isomers (Figure 1.5.2-1) which show high 
selectivity for G-quadruplex structures over duplex DNA, all of which demonstrate π-
stacking as their mode of G-quadruplex interaction.84 
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Figure 1.5.2-1 π-stacking ligand pyridyl-substituted corrole, reported by Ma et al.84 
1.5.3 Loop/groove binding compounds 
Groove recognition is expected to impart higher G-quadruplex versus duplex 
selectivity due to the significant chemical and conformational differences between the 
grooves encountered in these two regions. The first compound proven to interact with 
G-quadruplex DNA using this binding mode was Distamycin A (Figure 1.5.3-1). 
Martino et al. discovered that Distamycin A adopts a crescent shape and lies side-by-
side (as a head-to-tail dimer) in the groove, binding with a 4:1 ratio (ligand:G4-
d[TGGGGT]4). Four hydrogen bonds are made with guanine, in addition to strong 
electrostatic interactions between the positively charged amidinium moiety of the 
ligand and the negatively charged G-quadruplex backbone.85  
 
                                         
Figure 1.5.3-1 Groove binder ligand Distamycin A, reported by Martino et al.85 
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It is worth noting that the implementation of octahedral metal complexes with planar 
ligands has been investigated by Vilar et al. with the intention of promoting 
groove/loop binding.86 Octahedral geometry prevents the metal centre from engaging 
in stacking interactions with the G-quartet, therefore promoting groove and loop 
recognition as an alternative binding mode.   
 
1.5.4 Central channel binding compounds 
The ability to mimic the cations that usually reside within the central channel of the G-
quadruplex stack may induce G-quadruplex formation. Rodriguez et al. developed an 
anthracene-based ligand containing ammonium centres that was shown to induce 
parallel G-quadruplex formation in a human telomeric sequence, in the absence of 
cations (Figure 1.5.4-1).87 With the aid of NMR studies, the binding mode was 
proposed to be a combination of threading and stacking.  
                                                    
Figure 1.5.4-1 Central channel binding ligand, reported by Rodriguez et al.87  
1.6 Methods for investigating G-quadruplex DNA-ligand interactions 
The following is by no means an exhaustive list of the techniques currently available 
for investigating G-quadruplex DNA-ligand interactions, rather it is intended to give 
an overview of the most commonly employed methods. 
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Biophysical  
 
Thermal melting temperature  (UV or CD) 
Demonstrates the stabilisation or 
destabilisation of a nucleic acid structure by 
a ligand. Characteristic signals of G4 DNA at 
295 nm are reduced upon denaturation by 
heating.33   
 
Output: Melting temperature T1/2 
An increase in T1/2 indicates preferential 
binding to the folded form corresponding to a 
stabilising ligand.  
 
 
33 
 
Circular dichroism spectroscopy (CD)         . 
Demonstrates the conformational changes 
of a nucleic acid structure. Characteristic 
signals of G4 DNA can be monitored during 
ligand titration.                          .  
 
Output: Increase or decrease in characteristic 
signal intensity. Emergence of induced peaks 
(ICD). 
88 
 
Fluorescent intercalator displacement 
Demonstrates G-quadruplex over duplex 
DNA selectivity. 
Displacement of thiazole orange (TO) from 
DNA causes a 1000-fold decrease in its 
fluorescence intensity.                   . 
 
Output: Fluorescence intensity. 
Ligand binding induces TO displacement 
causing a decrease in intensity. 
 
33 
Mass spectroscopy  
Demonstrates non-covalent interactions 
between small molecules and G4 
DNA/nucleobases.  
 
Output: Novel peaks in spectrum due to 
G4-ligand species.                   . 
59 
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NMR spectroscopy 
Demonstrates the process involved in 
small-molecule G4 recognition, providing 
structural information at an atomic level. 
 
Output: Structures of G4-ligand complexes 59 
Biological  
 
Telomere Repeat Amplification Protocol (TRAP-G4) assay 
Demonstrates the ability of a ligand to induce telomerase inhibition through stabilisation of 
a G4 structure (human telomeric sequence). 
 
Output: IC50-TRAP. Ligand concentration required to inhibit telomerase activity by 50%. 
Mitochondrial reductase (MTT) assay 
Demonstrates the cytotoxicity of a ligand. 
 
Output: Half maximal inhibitory concentration, IC50. Ligand concentration required to inhibit 
mitochondrial reductase activity by 50%. 
 
1.7 G-quadruplex binders 
The past twenty years has seen a spectacular emergence of molecules designed to 
selectively interact with G-quadruplex DNA structures. Such compounds can be 
classified into four different categories on the basis of their cationic structure; (1) non-
cationic (2) cationic upon in situ protonation of an amine appendage, (3) cationic via 
N-methylation of an aza-aromatic moiety, (4) cationic due to metal coordination.59 An 
overview of the structural design and molecular interaction with G-quadruplex of 
some of the key examples from each category will now be included.   
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1.7.1 Organic neutral macrocyclic ligands 
Telomestatin 
Isolated from Streptomyces annulatus by Shinya,89 telomestatin is a natural 
macrocyclic compound that has been shown to induce and stabilise G-quadruplex 
structures (ΔT1/2 = 24 °C), in addition to inhibiting the proliferation of telomerase-
positive cells (IC50-TRAP = 5 nM).90 Initially studied due to its known absence of 
affinity for canonical duplex-DNA (on account of its neutrality and cyclic structure), 
extensive studying of telomestatin has shown it to be one of the most selective G-
quadruplex ligands, exhibiting 70-fold selectivity for intramolecular G-quadruplex 
DNA structures over that of duplex DNA.91 Telomestatin binding is driven by stacking 
forces, with the macrocycle able to coordinate a monovalent cation such as K+, which 
sits between the ligand and G-quartet (Figure 1.7.1-1).92 The apparent drawback in 
the use of telomestatin for therapeutic purposes is its availability. Total synthesis of 
telomestatin is currently a sophisticated and small-scale process.93 
 
Figure 1.7.1-1 (a) Structure of telomestatin (b) Overlaid side- and top-view structures of 
telomestatin (yellow) over a G-quartet (blue) with a potassium ion in the central cavity 
(purple). The potassium ion sits directly between the two units.92 
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1.7.2 Organic in situ protonated G-quadruplex ligands 
BRACO-19 
BRACO-19 represents an optimized prototype, designed to incorporate binding mode 
duality into a well-studied and promising family of compounds. Initially based on the 
bisamidoanthraquinone family,94,95 modifications to the core and sidearms of early 
ligands resulted in a structure capable of both π-stacking onto the G-tetrad surface, 
coupled with electrostatic interactions between the three protonable sidechains and 
quadruplex grooves (Figure 1.7.2-1).96,97 Demonstrating a 31-fold binding preference 
for G-quadruplex over duplex DNA structures, in addition to inhibition of both 
telomerase (IC50-TRAP = 115 nM)98,99 and cancer cell proliferation,100,101 the 
acridine-based ligand has proved to be an efficient G-quadruplex binder. Further 
modification of BRACO-19 is ongoing. Recent developments include the 
incorporation of a monomethine cyanine dye to create a pH-sensitive, fluorescent 
and colorimetric G-quadruplex binder102 and the synthesis of a series of bifunctional 
hybrid acridine-HSP90 ligands demonstrating significant toxicity in the sub-µM 
range.103 
 
Figure 1.7.2-1 (a) Structure of BRACO-19 (b) Structure of BRACO-19 (orange) stacked 
between two G-quadruplex structures.104 
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MMQ3 
MMQ3 incorporates a feature introduced into G-quadruplex ligand design by Teulade-
Fichou, Mergny and coworkers. The use of pentacyclic quinacridines that contain a 
crescent shape was introduced as a means to maximise the overlap between the 
aromatic ligand surface and G-quartet (Figure 1.7.2-2). MMQ3 demonstrates 
excellent G-quadruplex stabilisation (ΔT1/2 = 20 °C) and high telomerase inhibition 
(IC50-TRAP = 28 nM).105 The quinacridine unit is able to overlap three of the G-
quartet guanines, whilst participating in further G-quadruplex recognition via 
protonated sidearms that can interact with grooves.106 
 
 
Figure 1.7.2-2 (a) Structure of MMQ (b) Side- and top-view NMR structures of MMQ (red) 
stacked on top of and between two G-quadruplex structures.59  
 
1.7.3 Organic N-methylated aromatic ligands 
TMPyP4 
TMPyP4 is a tetracationic porphyrin, representative of a family of ligands that are 
quaternized on the aromatic ring nitrogens, thus affording water solubility in the 
absence of cationic side-chains. Reduction of electron density of the aromatic core 
results in increased π-stacking availability of the ligand, enhancing its G-quadruplex 
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binding potential. Extensive studies of TMPyP4 by Hurley et al. have demonstrated 
high affinity for G-quadruplex structures (ΔT1/2 = 17 °C), in addition to an ability to 
inhibit telomerase (IC50-TRAP = 6 µM) and downregulate oncogenic expression. 
Despite this, TMPyP4 displays poor selectivity for these structures.107,108  
TMPyP4 exhibits diverse binding modes including intercalation between 
adjacent G-tetrads, π-stacking onto the external G-quartet surface (Figure 1.7.3-1)109 
and external stacking onto the TTA nucleotides with no direct contact with the G-
quartet itself.110 Consequently, there remains a great deal of interest in these 
fascinating molecules, with several structurally similar ligands being subsequently 
reported in the literature. Worth mentioning is the development of a porphyrazine 
derivative, 3,4-TMPyPz, which has shown a 100-fold increase in affinity, coupled with 
improved specificity (>30-fold preference) for G-quadruplex DNA over duplex DNA.111 
 
Figure 1.7.3-1 (a) Structure of TMPyP4 (b) Side- and top-view NMR structures of TMPyP4 
(red) stacked on top of a G-quadruplex.59 
RHPS4 
Reported by Stevens and coworkers,112,113 RHPS4 is an N-methylated pentacyclic 
acridinium that has been shown to decrease telomere length, acting as a modulator 
to the binding of telomere proteins (IC50-TRAP = 330 nM).114,115 This cationic small 
molecule, with its condensed aromatic structure, sandwiches the G-quadruplex 
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structure (Figure 1.7.3-2) and was one of the earliest ligands whose complex 
structure with G-quadruplex DNA was solved by NMR (Fig).116 
 
Figure 1.7.3-2 (a) Structure of RHPS4 (b) Side- and top-view NMR structures of RHPS4 (red) 
stacked on top of a G-quadruplex.59 
Phen-DC3 
Phen-DC3 is a phenanthroline-bisquinolinium compound, developed as part of a 
series of compounds intended to balance rapid synthetic access and efficient G-
quadruplex recognition. Following the earlier success of a series of bisquinolinium 
compounds that displayed exceptional properties, including a high degree of G-
quadruplex stabilisation, excellent G-quadruplex over duplex selectivity, efficient 
telomerase inhibition, delayed growth arrest and induction of apoptosis in 
immortalised cells,117  a series of phenanthroline analogues were subsequently 
developed. The Phen-DC series demonstrated a perfect geometrical match with a G-
quartet118 alongside remarkable G-quadruplex selectivity, exceeding that of 
telomestatin.  
Phen-DC3 is a particularly promising compound from the series, specifically 
targeting G-quadruplexes and demonstrating potent biological effects in vivo.119,120 
Utilising NMR spectroscopy to solve the structure of the complex formed between 
Phen-DC3 and an intramolecular G-quadruplex (derived from the c-Myc promoter), 
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Phen-DC3 was revealed to interact through extensive π-stacking with the G-tetrad121   
(Figure 1.7.3-3).  
 
Figure 1.7.3-3 (a) Structure of Phen-DC3 (b) Side- and top-view solution structures of Phen-
DC3 (magenta) stacked on top of a G-quadruplex.122  
 
1.7.4 Metallo-organic complexes 
The incorporation of a metal centre into a potential G-quadruplex binding compound 
is extremely advantageous on account of the unique properties metals can confer to 
these compounds: 
(1) Structural provision: Metals dictate complex geometry based on their 
electronic configuration. For example, Pt(II) is a d8 metal centre that will 
always form square planar complexes upon ligand binding. The ability to use 
the metal as a template in this way means that small changes in ligand design 
can be made, whilst retaining the geometry around the metal centre. 
Alternatively, incorporation of a different metal centre into the same ligand 
system may cause a change in geometry and optical properties.86 
(2) Cationic charge: The presence of a metal centre imparts cationic charge into 
the complex, which is essential in promoting association with the negatively-
charged backbone of the target DNA structure.  
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(3) Increasing π-stacking interactions: A positively charged metal ion will withdraw 
electron density from the coordinated ligand’s aromatic π-system. This acts to 
increase the strength of π-stacking interactions between the now electron-
deficient ligand and the G-quartets. Furthermore, the positively charged metal 
is able to imitate the sodium and potassium cations that usually occupy the 
central cavity between G-quartet layers, providing further electrostatic 
stabilisation.86 
(4) Direct nucleic acid interaction: Metals may interact directly with nucleic acids 
through coordinate bonding. 
(5) Detection: The presence of a metal enables complex examination by a variety 
of techniques including fluorescence, UV-Vis spectroscopy or redox 
electrochemistry.86  
 
Mn(III)-TMPyP4  
The first reported examples of metallo-organic G-quadruplex ligands featured the 
insertion of a metal centre, such as Cu(II)123,124 and Ni(II),125 into the central cavity of 
TMPyP4.126 Despite displaying modest telomerase inhibition (IC50-TRAP = 26 µM), 
Mn(III)-TMPyP4 (Figure 1.7.4-1) showed a 10-fold preference for G-quadruplex DNA 
over duplex DNA.125 
 
Figure 1.7.4-1 Structure of Mn(III)-TMPyP4. 
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Ni(II)-salphen 
A selection of metal-salphen complexes were first reported by Neidle and Vilar, with 
Ni(II)-salphens among the most promising compounds due to their excellent 
stabilisation of a human telomeric intramolecular G-quadruplex structure (ΔT1/2 =  
33 °C).127 Further studies of the Ni(II)-salphen shown in Figure 1.7.4-2 suggested a  
>50-fold selectivity for telomeric G-quadruplex over duplex DNA.128 Elucidation of the 
X-ray crystal structure of this complex bound to human telomeric G-quadruplex 
shows end-stacking as the binding mode, with the Ni(II) ion sitting almost in line with 
the potassium ions occupying the central cavity. This complex shows significant 
antiproliferative activity and telomerase inhibition (IC50-TRAP = 120 nM).59 
 
Figure 1.7.4-2 Structure of Ni(II)-salphen. 
Mn(III)-porphyrin 
A pentacationic manganese(III) porphyrin (Figure 1.7.4-3) was reported by Pratviel 
and coworkers to exhibit a 10 000-fold selectivity for telomeric G-quadruplex over 
duplex DNA. Combining a central aromatic core and four flexible cationic arms, the 
exceptional affinity of this metalloporphyrin for G-quadruplex DNA is associated with 
a good capacity to inhibit telomerase at submicromolar concentrations (IC50-TRAP = 
580 nM).129 The strong binding affinity arises from the π-stacking interactions 
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between the aromatic core and G-quartet, coupled with proposed interactions 
between the cationic sidearms and loops and/or grooves of the G-quadruplex 
stack.129 
 
Figure 1.7.4-3 Structure of Mn(III)-porphyrin. 
Metal-terpyridines 
Cu(ttpy) 
Metal terpyridine (2,2’:6’,2’’-terpyridine, tpy) complexes are synthetically attractive 
due to their relatively simple structure and straightforward preparation, often in two-
step processes. A range of metals including Cu(II), Pt(II), Zn(II) and Ru(III) can be 
easily accommodated by the ligand, allowing a series of complexes to be prepared 
with relative ease.130 Modified tpy ligands, such as tolyl-terpyridine (featuring a 
methylphenyl moiety on the central ring, ttpy) have also been extensively studied. 
Metal complexes incorporating both the tpy and ttpy ligands have been investigated 
for their potential as G-quadruplex binders by Teulade-Fichou and coworkers.131 
Such compounds proved to be both high affinity and highly selective G-quadruplex 
binders, particularly Cu(ttpy) (Figure 1.7.4-4) which showed a 22-fold selectivity for 
telomeric G-quadruplex DNA over duplex DNA (G4-FID assay) and excellent stability 
(ΔT1/2 = 15 °C).130 Highlighting the geometry of the metal centre as a key parameter 
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governing selectivity, the pseudo-square pyramidal structure of the Cu-ttpy 
compound was best able to maximise G-quartet interactions (planar aromatic surface 
engaging in stabilising π-stacking interactions, centrally positioned Cu(II) ion 
mimicking naturally occurring cations, highly polarised metal-ligand bonds favouring 
electrostatic interaction with negatively charged DNA), whilst also impeding duplex 
DNA intercalation (pyramidal shape).130 
 
Figure 1.7.4-4 Structure of Cu(ttpy). 
Dimetallic Cu(II) and Pt(II)  
Dimetallic complexes with terpyridine-based ligands have been investigated by Vilar 
et al.. Dicopper and diplatinum complexes (Figure 1.7.4-5) were shown to bind very 
strongly to G-quadruplex DNA (Htelo and cMyc) with up to 100-fold selectivity over 
duplex DNA.132 Consisting of a metal-terpyridine unit displaying either square-based 
pyramidal (Cu(II)) or square planar (Pt(II)) geometry linked by a three-atom spacer to 
a dipicolyl amine coordinated to the second metal, these complexes possess binding 
mode duality; (1) π-π stacking of the metal-terpyridine unit onto the external G-quartet 
(2) electrostatic interactions between the metal-dipicolyl amine fragment and the 
DNA backbone. Interestingly, the metal-free ligands did not display comparable 
activity, confirming the necessity of metal coordination in achieving the high binding 
affinities seen between these polydentate ligands and G-quadruplex DNA.132 
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Figure 1.7.4-5 Structure of dimetallic Cu(II) and Pt(II) species.  
Pt-MPQ 
Pt-MPQ is another example of a dual-modality G-quadruplex binder, this time 
achieved through a single metal moiety grafted in the periphery of the central metal 
core. Pt(II) was first exploited for this purpose following the discovery by Bombard 
and coworkers that terminal G-quartets could be platinated.133 Pt-MPQ (Figure 
1.7.4-6) is a platinum-quinacridine hybrid compound that achieves a dual covalent-
non-covalent binding mode via π-stacking interactions between the aromatic 
quinacridine unit and the G-quartet alongside covalent interactions with the platinum 
moiety.134  
 
Figure 1.7.4-6 Structure of Pt-MPQ. 
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1.8 Summary 
There exists a key requirement, common among G-quadruplex binding compounds 
such as those discussed, that must be met in order to facilitate G-quadruplex binding; 
a large, planar aromatic system prone to π-stacking with a G-tetrad platform 
(hydrophobic nature), while retaining reasonable water solubility (hydrophilic 
nature).59 
 
The preceding examples of G-quadruplex binding compounds demonstrate the wide 
scope and ongoing developments in the G-quadruplex nucleic acids research 
community. Targeting G-quadruplex DNA remains challenging due to the structural 
polymorphism displayed by G-quadruplexes as a result of differing strand sequences, 
loop lengths, metal cation stabilisation and folding patterns. The advantage of this 
polymorphic nature, however, lies in the potential to target a specific G-quadruplex 
structure implicated in a process of interest. The development of compounds that are 
capable of discriminating not only G-quadruplex DNA from duplex DNA, but also 
between different structures of G-quadruplex is therefore vital, and represents a large 
proportion of recent advances in the field.   
 
1.9 Thesis aims 
The work contained within this thesis focuses on the development of ligands and 
complexes for G-quadruplex nucleic acid binding. It will commence with the further 
synthetic exploration of two complexes incorporating 3,3-biisoquinoline. These 
complexes possess large, planar aromatic surfaces suitable for π-stacking, 
coordinated around a central cationic metal ion capable of engaging in electrostatic 
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interactions whilst mimicking naturally occurring sodium and potassium cations. By 
way of extension from previous biophysical studies (reviewed in Chapter II), the first 
in vitro biological studies of these complexes will be carried out. This will include 
investigating the cytotoxicity, cell uptake, induced DNA damage and cell cycle arrest 
effects of each complex.  
The design, synthesis and characterisation of novel terpyridine-based metal 
complexes will be carried out and these complexes assessed for their suitability as 
G-quadruplex binders by UV-Vis spectroscopy, circular dichroism and gel 
electrophoresis. The key aim is to establish a terpyridine platform. A variety of 
synthetic strategies towards novel G-quadruplex ligands will be tested, in order to 
expand our understanding of the suitability and scope of particular routes and aid the 
future development of novel complexes. 
 
 
 
 
 
 
 
 
 
 
 
38 
 
1.10 References 
1 J. D. Watson and F. H. C. Crick, Cold Spring Harb. Symp. Quant. Biol., 1953, 
18, 123–131. 
2 J. D. Watson and F. H. C. Crick, Nature, 1953, 171, 737–738. 
3 M. J. Hannon, Chem. Soc. Rev., 2007, 36, 280–295. 
4 M. Levitt, Proc. Natl. Acad. Sci. U. S. A., 1978, 75, 640–4. 
5 J. M. Berg, J. L. Tymoczko and L. Stryer, Biochemistry, 5th Edition, W H 
Freeman, 2002. 
6 A. Rich and S. Zhang, Nat. Rev. Genet., 2003, 4, 566–72. 
7 University of Tokyo, Nucleic Acids, 2016. 
8 D. Buck, Proc. Symp. Appl. Math., 2009, 66, 1–33. 
9 J. Zlatanova and K. van Holde, FASEB J., 1998, 12, 421–31. 
10 P. Gottipati and T. Helleday, Mutagenesis, 2009, 24, 203–210. 
11 M. Micco, G. W. Collie, A. G. Dale, S. A. Ohnmacht, I. Pazitna, M. 
Gunaratnam, A. P. Reszka and S. Neidle, J. Med. Chem., 2013, 56, 2959–
2974. 
12 A. C. G. Hotze, N. J. Hodges, R. E. Hayden, C. Sanchez-Cano, C. Paines, N. 
Male, M.-K. Tse, C. M. Bunce, J. K. Chipman and M. J. Hannon, Chem. Biol., 
2008, 15, 1258–1267. 
13 D. R. Duckett and D. M. Lilley, EMBO J., 1990, 9, 1659–64. 
14 R. Holliday, Genet. Res., 1964, 5, 282. 
15 D. R. Duckett, A. I. H. Murchie, S. Diekmann, E. von Kitzing, B. Kemper and D. 
M. J. Lilley, Cell, 1988, 55, 79–89. 
16 L. Stefan, B. Bertrand, P. Richard, P. Le Gendre, F. Denat, M. Picquet and D. 
Monchaud, Chembiochem, 2012, 13, 1905–12. 
17 B. Wu, F. Girard, B. van Buuren, J. Schleucher, M. Tessari and S. Wijmenga, 
Nucleic Acids Res., 2004, 32, 3228–3239. 
18 S. Muhuri, K. Mimura, D. Miyoshi and N. Sugimoto, J. Am. Chem. Soc., 2009, 
131, 9268–80. 
19 S. Vuong, L. Stefan, P. Lejault, Y. Rousselin, F. Denat and D. Monchaud, 
Biochimie, 2012, 94, 442–50. 
20 R. R. Sinden, V. N. Potaman, E. A. Oussatcheva, C. E. Pearson, Y. L. 
39 
 
Lyubchenko and L. S. Shlyakhtenko, J. Biosci., 2002, 27, 53–65. 
21 J. Malina, M. J. Hannon and V. Brabec, Chem. - A Eur. J., 2007, 13, 3871–
3877. 
22 N. Campbell, J. Reece, L. Urry, M. Cain, S. Wasserman, P. Minorsky and R. 
Jackson, Biology (8th edition), Pearson Education Inc. Benjamin Cummings, 
2008. 
23 D. M. J. Lilley, Proc. Natl. Acad. Sci. U. S. A., 1995, 92, 7140–7142. 
24 R. J. Ernst, H. Song and J. K. Barton, J. Am. Chem. Soc., 2009, 131, 2359–66. 
25 D. J. Patel, S. A. Kozlowski, L. A. Marky, C. Broka, J. A. Rice, K. Itakura and K. 
J. Breslauer, Biochemistry, 1982, 21, 428–36. 
26 P. T. Henderson, E. Boone and G. B. Schuster, Helv. Chim. Acta, 2002, 85, 
135–151. 
27 D. A. LeBlanc and K. M. Morden, Biochemistry, 1991, 30, 4042–4047. 
28 M. Zheng, M. Wu and I. Tinoco, Proc. Natl. Acad. Sci. U. S. A., 2001, 98, 
3695–700. 
29 G. M. Cooper, The Cell: A Molecular Approach (2nd Edition), Sinauer 
Associates, 2000. 
30 J. P. Cerón-Carrasco, D. Jacquemin and E. Cauët, Phys. Chem. Chem. Phys., 
2012, 14, 12457. 
31 S. L. B. König, A. C. Evans and J. L. Huppert, Biomol. Concepts, 2010, 1, 197–
213. 
32 I. Gellert, M. N. Lipsett and D. R. Davies, Proc. Natl. Acad. Sci. U. S. A., 1962, 
48, 2013–2018. 
33 P. Murat, Y. Singh and E. Defrancq, Chem. Soc. Rev., 2011, 40, 5293–5307. 
34 J.-L. Mergny, A. De Cian, A. Ghelab, B. Saccà and L. Lacroix, Nucleic Acids 
Res., 2005, 33, 81–94. 
35 N. V Hud, F. W. Smith, F. A. L. Anet and J. Feigon, Biochemistry, 1996, 35, 
15383–15390. 
36 J. Gu and J. Leszczynski, J. Phys. Chem. A, 2002, 106, 529–532. 
37 C. C. Hardin, T. Watson, M. Corregan and C. Bailey, Biochemistry, 1992, 31, 
833–841. 
38 A. Włodarczyk, P. Grzybowski, A. Patkowski and A. Dobek, J. Phys. Chem. B, 
40 
 
2005, 109, 3594–3605. 
39 W. Guschlbauer, J.-F. Chantot and D. Thiele, J. Biomol. Struct. Dyn., 1990, 8, 
491–511. 
40 E. A. Venczel and D. Sen, Biochemistry, 1993, 32, 6220–6228. 
41 S. Burge, G. N. Parkinson, P. Hazel, A. K. Todd and S. Neidle, Nucleic Acids 
Res., 2006, 34, 5402–15. 
42 J. L. Huppert and S. Balasubramanian, Nucleic Acids Res., 2005, 33, 2908–16. 
43 Y. Wang and D. J. Patel, Structure, 1993, 1, 263–282. 
44 A. Risitano and K. R. Fox, Nucleic Acids Res., 2004, 32, 2598–2606. 
45 Y. Wang and D. J. Patel, J. Mol. Biol., 1993, 234, 1171–1183. 
46 M. Vorlíčková, J. Chládková and I. Kejnovská, Nucleic Acids Res., 2005, 33, 
5851–5860. 
47 C. Schaffitzel, I. Berger, J. Postberg, J. Hanes, H. J. Lipps and A. Pluckthun, 
Proc. Natl. Acad. Sci. U. S. A., 2001, 98, 8572–8577. 
48 O. Stegle, L. Payet, J. Mergny and D. MacKay, Bioinformatics, 2009, 25, 374–
382. 
49 H. Lipps and D. Rhodes, Trends Cell Biol., 2009, 19, 414–422. 
50 L. Petraccone, E. Erra, I. Duro, V. Esposito, A. Randazzo, L. Mayol, C. A. 
Mattia, G. Barone and C. Giancola, Nucleosides, Nucleotides and Nucleic 
Acids, 2005, 24, 757–760. 
51 H. M. Wong, O. Stegle, S. Rodgers and J. L. Huppert, J. Nucleic Acids, 2010, 
2010, 1–6. 
52 J. Johnson, J. Smith, M. Kozak and F. Johnson, Biochimie, 2008, 90, 1250–
1263. 
53 N. Maizels, Nat. Struct. Mol. Biol., 2006, 13, 1055–1059. 
54 A. G. Bodnar, M. Ouellette, M. Frolkis, S. E. Holt, C. P. Chiu, G. B. Morin, C. B. 
Harley, J. W. Shay, S. Lichtsteiner and W. E. Wright, Science, 1998, 279, 349–
52. 
55 L. Hayflick and P. S. Moorhead, Exp. Cell Res., 1961, 25, 585–621. 
56 L. Hayflick, Exp. Cell Res., 1965, 37, 614–636. 
57 R. Calado and N. Young, Telomeres in disease, 2012. 
58 V. L. Makarov, Y. Hirose and J. P. Langmore, Cell, 1997, 88, 657–66. 
41 
 
59 D. Monchaud and M.-P. Teulade-Fichou, Org. Biomol. Chem., 2008, 6, 627–
36. 
60 Q. Yang, J. Xiang, S. Yang, Q. Zhou, Q. Li, Y. Tang and G. Xu, Chem. 
Commun., 2009, 350, 1103. 
61 G. Biffi, D. Tannahill, J. McCafferty and S. Balasubramanian, Nat. Chem., 
2013, 5, 182–186. 
62 A. Zahler, J. Williamson, T. Cech and D. Prescott, Nature, 1991, 350, 718–720. 
63 J. E. Reed, A. J. P. White, S. Neidle and R. Vilar, Dalt. Trans., 2009, 14, 2558–
68. 
64 J. Williamson, Proc. Natl. Acad. Sci. United States Am., 1993, 90, 3124. 
65 T. A. Brooks, S. Kendrick and L. Hurley, FEBS J., 2010, 277, 3459–3469. 
66 A. K. Todd and S. Neidle, Nucleic Acids Res., 2008, 36, 2700–2704. 
67 J. Eddy and N. Maizels, Nucleic Acids Res., 2007, 36, 1321–1333. 
68 S. Cogoi and L. E. Xodo, Nucleic Acids Res., 2006, 34, 2536–2549. 
69 R. De Armond, S. Wood, D. Sun and L. Hurley, Biochemistry, 2005, 44, 
16341–16350. 
70 T. Simonsson, M. Kubista and P. Pecinka, Nucleic Acids Res., 1998, 26, 1167–
1172. 
71 S. Rankin, A. P. Reszka, J. Huppert, M. Zloh, G. N. Parkinson, A. K. Todd, S. 
Ladame, S. Balasubramanian and S. Neidle, J. Am. Chem. Soc., 2005, 127, 
10584–10589. 
72 J. Dai, T. Dexheimer, D. Chen and M. Carver, J. Am. Chem. Soc., 2006, 128, 
1096–1098. 
73 D. Sun, K. Guo, J. Rusche and L. Hurley, Nucleic Acids Res., 2005, 33, 6070–
6080. 
74 A. Siddiqui-Jain and C. Grand, Proc. Natl. Acad. Sci. U. S. A., 2002, 99, 
11593–11598. 
75 C. V Dang, A. Le and P. Gao, Clin. Cancer Res., 2009, 15, 6479–83. 
76 V. González and L. H. Hurley, Annu. Rev. Pharmacol. Toxicol., 2010, 50, 111–
129. 
77 J. A. Nilsson and J. L. Cleveland, Oncogene, 2003, 22, 9007–9021. 
78 D. M. Miller, S. D. Thomas, A. Islam, D. Muench and K. Sedoris, Clin. Cancer 
42 
 
Res., 2012, 18, 5546–53. 
79 M. Eilers and R. N. Eisenman, Genes Dev., 2008, 22, 2755–66. 
80 R. V Brown, F. L. Danford, V. Gokhale, L. H. Hurley and T. A. Brooks, J. Biol. 
Chem., 2011, 286, 41018–27. 
81 K. C. Sedoris, S. D. Thomas, C. R. Clarkson, D. Muench, A. Islam, R. Singh 
and D. M. Miller, Mol. Cancer Ther., 2012, 11, 66–76. 
82 T. Ou, Y. Lu, C. Zhang and Z. Huang, J. Med. Chem., 2007, 50, 1465–1474. 
83 E. Largy, A. Granzhan, F. Hamon, D. Verga and M.-P. Teulade-Fichou, in 
Quadruplex Nucleic Acids, Springer Berlin Heidelberg, 2013. 
84 H. Ma, M. Zhang, D. Zhang, R. Huang, Y. Zhao, H. Yang, Y. Liu, X. Weng, Y. 
Zhou, M. Deng, L. Xu and X. Zhou, Chem. - An Asian J., 2010, 5, 114–122. 
85 L. Martino, A. Virno, B. Pagano, A. Virgilio, S. Di Micco, A. Galeone, C. 
Giancola, G. Bifulco, L. Mayol and A. Randazzo, J. Am. Chem. Soc., 2007, 
129, 16048–16056. 
86 S. N. Georgiades, N. H. Abd Karim, K. Suntharalingam and R. Vilar, Angew. 
Chemie Int. Ed., 2010, 49, 4020–4034. 
87 R. Rodriguez, G. D. Pantoş, D. P. N. Gonçalves, J. K. M. Sanders and S. 
Balasubramanian, Angew. Chemie, 2007, 119, 5501–5503. 
88 H. L. Pritchard, Thesis, University of Birmingham, 2015. 
89 K. Shin-ya, K. Wierzba, K. Matsuo and T. Ohtani, J. Am. Chem. Soc., 2001, 
123, 1262–1263. 
90 T. Doi, K. Shibata, M. Yoshida, M. Takagi, M. Tera, K. Nagasawa, K. Shin-ya 
and T. Takahashi, Org. Biomol. Chem., 2011, 9, 387–393. 
91 H. Tahara, K. Shin-Ya, H. Seimiya, H. Yamada and T. Tsuruo, Oncogene, 
2006, 25, 1955–1966. 
92 F. Rosu, V. Gabelica, N. Smargiasso, G. Mazzuchelli, K. Shin-ya and E. De 
Pauw, J. Nucleic Acids, 2010, 2010, 1–7. 
93 T. Doi, M. Yoshida, K. Shin-ya and T. Takahashi, Org. Lett., 2006, 8, 4165–
4167. 
94 P. Perry, S. M. Gowan, A. P. Reszka, P. Polucci, T. C. Jenkins, L. R. Kelland 
and S. Neidle, J. Med. Chem., 1998, 41, 3253–3260. 
95 P. Perry, A. Reszka, A. Wood and M. Read, J. Med. Chem., 1998, 41, 4873–
43 
 
4883. 
96 C. Schultes, B. Guyen, J. Cuesta and S. Neidle, Bioorg. Med. Chem. Lett., 
2004, 14, 4347–4351. 
97 M. J. B. Moore, C. M. Schultes, J. Cuesta, F. Cuenca, M. Gunaratnam, F. A. 
Tanious, W. D. Wilson and S. Neidle, J. Med. Chem., 2006, 49, 582–599. 
98 N. Kim, M. Piatyszek, K. Prowse and C. Harley, Science, 1994, 266, 2011–
2015. 
99 J. Cuesta, M. Read and S. Neidle, Mini Rev. Med. Chem., 2003, 3, 11–21. 
100 A. Burger, F. Dai, C. Schultes and A. Reszka, Cancer Res., 2005, 65, 1489–
1496. 
101 S. Gowan, J. Harrison, L. Patterson and M. Valenti, Mol. Pharmacol., 2002, 61, 
1154–1162. 
102 C. Percivalle, T. Mahmood and S. Ladame, Med. Chem. Commun., 2013, 4, 
211–215. 
103 S. Roe, M. Gunaratnam, C. Spiteri, P. Sharma, R. D. Alharthy, S. Neidle and J. 
E. Moses, Org. Biomol. Chem., 2015, 13, 8500–8504. 
104 S. Neidle, Curr. Opin. Struct. Biol., 2009, 19, 239–250. 
105 J.-L. Mergny, L. Lacroix, M.-P. Teulade-Fichou, C. Hounsou, L. Guittat, M. 
Hoarau, P. B. Arimondo, J.-P. Vigneron, J.-M. Lehn, J.-F. Riou, T. Garestier 
and C. Helene, Proc. Natl. Acad. Sci. U. S. A., 2001, 98, 3062–3067. 
106 C. Hounsou, L. Guittat, D. Monchaud, M. Jourdan, N. Saettel, J.-L. Mergny and 
M.-P. Teulade-Fichou, ChemMedChem, 2007, 2, 655–666. 
107 J. Ren and J. Chaires, Biochemistry, 1999, 38, 16067–16075. 
108 A. De Cian, L. Guittat, K. Shin-ya and J. Riou, Nucleic acids Symp. ser, 2005, 
49, 235–236. 
109 I. Haq, J. Trent and B. Chowdhry, J. Am. Chem. Soc., 1999, 121, 1768–1779. 
110 G. Parkinson, R. Ghosh and S. Neidle, Biochemistry, 2007, 46, 2390–2397. 
111 D. P. N. Gonçalves, R. Rodriguez, S. Balasubramanian and J. K. M. Sanders, 
Chem. Commun., 2006, 266, 4685–4687. 
112 J. Stanslas, D. J. Hagan, M. J. Ellis, C. Turner, J. Carmichael, W. Ward, T. R. 
Hammonds and M. F. G. Stevens, J. Med. Chem., 2000, 43, 1563–1572. 
113 J. Cookson and R. Heald, J. Med. Chem., 2005, 48, 7198–7207. 
44 
 
114 P. Phatak, J. C. Cookson, F. Dai, V. Smith, R. B. Gartenhaus, M. F. G. Stevens 
and A. M. Burger, Br. J. Cancer, 2007, 96, 1223–1233. 
115 E. Salvati, C. Leonetti, A. Rizzo, M. Scarsella, M. Mottolese, R. Galati, I. 
Sperduti, M. F. G. Stevens, M. D’Incalci, M. Blasco, G. Chiorino, S. Bauwens, 
B. Horard, E. Gilson, A. Stoppacciaro, G. Zupi and A. Biroccio, J. Clin. Invest., 
2007, 117, 3236–3247. 
116 E. Gavathiotis, R. Heald and M. Stevens, Angew. Chemie, 2001, 40, 4749–
4751. 
117 T. Lemarteleur, D. Gomez, R. Paterski and E. Mandine, Biochem. Biophys. 
Res. Commun., 2004, 323, 802–808. 
118 A. De Cian, E. Delemos, J.-L. Mergny, M.-P. Teulade-Fichou and D. 
Monchaud, J. Am. Chem. Soc., 2007, 129, 1856–7. 
119 A. Piazza, J.-B. Boulé, J. Lopes, K. Mingo, E. Largy, M.-P. Teulade-Fichou and 
A. Nicolas, Nucleic Acids Res., 2010, 38, 4337–48. 
120 J. Lopes, A. Piazza, R. Bermejo, B. Kriegsman, A. Colosio, M.-P. Teulade-
Fichou, M. Foiani and A. Nicolas, EMBO J., 2011, 30, 4033–46. 
121 W. J. Chung, B. Heddi, F. Hamon, M.-P. Teulade-Fichou and A. T. Phan, 
Angew. Chemie Int. Ed., 2014, 53, 999–1002. 
122 W. Chung, B. Heddi and F. Hamon, Angew. Chemie, 2014, 53, 999–1002. 
123 S. E. Evans, M. A. Mendez, K. B. Turner, L. R. Keating, R. T. Grimes, S. 
Melchoir and V. A. Szalai, J. Biol. Inorg. Chem., 2007, 12, 1235–1249. 
124 L. R. Keating and V. A. Szalai, Biochemistry, 2004, 43, 15891–15900. 
125 I. M. Dixon, F. Lopez, J.-P. Estève, A. M. Tejera, M. A. Blasco, G. Pratviel and 
B. Meunier, ChemBioChem, 2005, 6, 123–132. 
126 E. Izbicka, R. T. Wheelhouse, E. Raymond, K. K. Davidson, R. A. Lawrence, D. 
Sun, B. E. Windle, L. H. Hurley and D. D. Von Hoff, Cancer Res., 1999, 59, 
639–44. 
127 A. Arola-Arnal, J. Benet-Buchholz, S. Neidle and R. Vilar, Inorg. Chem., 2008, 
47, 11910–9. 
128 J. E. Reed, A. A. Arnal, S. Neidle and R. Vilar, J. Am. Chem. Soc., 2006, 128, 
5992–3. 
129 I. M. Dixon, F. Lopez, A. M. Tejera, J.-P. Estève, M. A. Blasco, G. Pratviel and 
45 
 
B. Meunier, J. Am. Chem. Soc., 2007, 129, 1502–1503. 
130 H. Bertrand, D. Monchaud, A. De Cian, R. Guillot, J.-L. Mergny and M.-P. 
Teulade-Fichou, Org. Biomol. Chem., 2007, 5, 2555. 
131 E. Largy, F. Hamon, F. Rosu, V. Gabelica, E. De Pauw, A. Guédin, J.-L. 
Mergny and M.-P. Teulade-Fichou, Chem. - A Eur. J., 2011, 17, 13274–83. 
132 K. Suntharalingam, A. J. P. White and R. Vilar, Inorg. Chem., 2010, 49, 8371–
8380. 
133 H. Bertrand, S. Bombard, D. Monchaud, E. Talbot, A. Guedin, J.-L. Mergny, R. 
Grunert, P. J. Bednarski and M.-P. Teulade-Fichou, Org. Biomol. Chem., 2009, 
7, 2864–2871. 
134 H. Bertrand, S. Bombard, D. Monchaud and M.-P. Teulade-Fichou, J. Biol. 
Inorg. Chem., 2007, 12, 1003–1014. 
 
 
 Chapter II 
 
 
 
 
 47 
2.1 Introduction 
Part I of this chapter explores the synthetic methodology that has been employed in 
recent years within the Hannon group to prepare novel complexes capable of binding 
G-quadruplex (G4) forming DNA sequences. Improvements to the synthetic routes 
utilised, in addition to further biophysical analyses are detailed herein.  
 
Organic compounds such as porphyrins and acridine-based structures form the basis 
of much of the research into G4 binding molecules. Whilst often effective binders, 
selectivity for G4 structures is not always observed,1 and synthetic routes towards 
these products are often complex and low yielding, particularly in the case of 
porphyrins. The introduction of metals into complexes can significantly improve 
binding by providing a central ion to mimic cations (e.g. Na+, K+) already present in 
the centre of the G-quadruplex, as well as strengthening π-stacking interactions. The 
cationic charge also aids binding to the anionic DNA target. Furthermore, it is 
possible to synthesise multiple complexes relatively easily, by changing the metal 
used, resulting in structural diversity between complexes with the same ligand 
framework. It is evident that an excellent size match between complex and DNA 
target is essential in maximising the binding affinity.2,3 Therefore, the design and 
synthesis of a G-quadruplex binder which shows a more accurate size match than 
those observed in salphen and phenanthroline metal complexes1,4,5 would maximise 
the G-quartet coverage, ensuring all possible π-stacking interactions are explored, 
resulting in maximum binding affinity.  
Owing to its demonstrated binding preference for G4-DNA over duplex DNA, 
as observed for derivatives of the natural alkaloid berberine,6 the isoquinoline 
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structure was selected as the starting point for the molecular design of a new G-
quadruplex binder. Found in many medicinal products,7 the isoquinoline unit is able 
to facilitate side by side stacking of the berberine unit onto a G-quartet at the 3’ and 
5’ ends of the G-quadruplex, as observed by X-ray crystallography (Figure 2.1.1-1).7  
              
Figure 2.1.1-1 (a) Structure of berberine; (b) DNA topology and binding sites in the Ber/h-
Tel23 adduct.7 
Coupling isoquinoline to itself results in the formation of 3,3-biisoquinoline (i-biq). 
This bidentate ligand can bind to platinum in a 2:1 ratio to furnish a square planar 
complex, as demonstrated by Kato et al..8 This complex has great potential as a G-
quadruplex binder on account of its excellent size match for a G-quartet, as shown in 
Figure 2.1.1-2. Furthermore, the complex benefits from a large aromatic surface to 
maximise π-stacking interactions, along with the central platinum cation, which will 
enhance electrostatic interactions. Consequently, investigation of this complex and 
its derivatives formed the basis of the initial research into G-quadruplex recognition, 
carried out by Hannah Pritchard.9 A summary of the notable developments thus far 
within the Hannon group is now included for the purposes of context. 
O
O
N+
O
O
            (a)                                                        (b) 
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Figure 2.1.1-2 Comparison of the structure and size of (a) [Pt(i-biq)]2+; (b) G-quartet 
2.1.1 Summary of previous group research into G-quadruplex recognition 
The 3,3-biisoquinoline (i-biq) ligand, along with palladium and platinum complexes 
incorporating the ligand were synthesised in low to moderate yields (ligand: 10%, Pd: 
50%, Pt: 27%).9 The stability and binding properties of the two complexes with both 
duplex DNA and G-quadruplex types of DNA were explored using a variety of 
spectroscopic techniques.  
Using circular dichroism (CD) to analyse DNA binding, both complexes were 
shown to interact well with duplex DNA and Htelo DNA (forms antiparallel hybrid G-
quadruplex). Strong ICD (induced CD) peaks were observed with both types of DNA 
for both complexes. When testing with cMyc DNA (forms parallel G-quadruplex), only 
the platinum complex showed an interaction. With no interaction observed between 
the palladium complex and cMyc DNA, this complex clearly demonstrates a degree 
of selectivity for antiparallel hybrid G-quadruplex conformations (such as Htelo).  
UV-Vis titration experiments showed a large red shift in the complex absorption 
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spectrum upon addition of DNA. This observation, along with the strong ICD signals 
observed in the CD spectra indicated that the mode of binding between the 
complexes and G4 structures was end-stacking. In the case of the platinum complex, 
there was also evidence of intercalative binding, resulting in the proposal of dual-
modality end-stacking and intercalative binding.  
The selectivity of each complex towards G-quadruplex binding over duplex 
binding was investigated by fluorescence indicator displacement assays. Both 
complexes were able to displace thiazole orange (fluorescent indicator) at 
concentrations below the 0.5 µM threshold in both Htelo and cMyc DNA. 
Furthermore, both complexes were less able to displace the dye from duplex DNA, 
requiring concentrations above 2 µM. Differences in the binding ability of the two 
complexes was suggested to be linked to the extent of planarity each complex is able 
to achieve, and the resultant quality of the ‘fit’ with the G-quartet surface. The crystal 
structures of the two complexes showed very subtle differences, with the platinum 
complex being slightly less planar than the palladium analogue (26° vs. 24° between 
planes). Since the platinum complex was the better match for G4 binding, the G-
quartet was proposed to be slightly distorted itself and it was suggested that this 
resulted in preferential binding. However, such a small structural difference in the 
solid state may not be reflected in solution, and so the precise reason for the 
difference in preference remains to be elucidated. 
Whilst both complexes were shown to bind to both duplex and G-quadruplex 
DNA sequences, their demonstrated preference for G-quadruplex binding coupled 
with their high affinities for such structures warrants their continued study as 
promising G4-binding therapeutic drugs.  Acting as a direct continuation of the initial 
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studies, Part I of this chapter details the synthesis of both the palladium and platinum 
3,3-biisoquinoline complexes, with particular attention paid to improvements in the 
routes previously employed, or alternative methodologies utilised. As an extension to 
previous binding studies carried out, the results of electrospray ionisation mass 
spectrometry (ESI-MS) model nucleobase binding studies are also discussed. 
Part II of this chapter explores the biological activity of the palladium and 
platinum analogues in vitro. Several biological assays have been carried out to 
assess cell uptake, DNA damage, cell cycle arrest and toxicity effects as a result of 
complex treatment on cells.  
 
PART I: SYNTHESIS AND CHARACTERISATION OF 3,3-BIISOQUINOLINE 
METAL COMPLEXES 
 
2.2 Overview of synthetic methodology 
2.2.1 Isoquinoline building blocks 
The required 3-chloroisoquinoline precursor to enable synthesis of 3,3-biisoquinoline 
can be synthesised in high yield in a three-step procedure commencing with 
homophthalic acid (Figure 2.2.1-1).10 This starting reagent is both readily available 
and inexpensive, enabling bulk batches of precursor to be prepared.  
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Figure 2.2.1-1 Synthesis of 3-chloroisoquinoline under the following conditions: i. NH4OH, 
1,2-dichlorobenzene, 200 °C; ii. PhP(O)Cl2, 160 °C; iii. Method 1: Sn(0), HOAc/HCl, 60 °C, 
Method 2: HI(aq)-Pred/HOAc, 125 °C. 
Step i. The first step results in the formation of isoquinoline-1,3-dione following a 
two-step process. Carboxylic acids do not undergo nucleophilic substitution reactions 
under basic conditions unless a coupling agent such as dicyclohexylcarbodiimide 
(DCC) is used. In the absence of DCC, the strong base (NH4OH) will undergo an 
acid-base reaction leading to the deprotonation of the carboxylic acid to form an 
ammonium carboxylate salt (Figure 2.2.1-2-i). Once the carboxylic acid is 
deprotonated, substitutions are prevented because there are almost no nucleophiles 
that will attack the carboxylate anion formed.11 In fact, the formation of the resultant 
amide can only be achieved upon strong heating of the ammonium salt to force its 
dehydration (Figure 2.2.1-2-ii). The resulting amide can then react intramolecularly in 
the same manner, with the second carboxylic acid moiety.  
                  
Figure 2.2.1-2 Two step formation of an amide via an ammonium carboxylate salt 
intermediate: i. acid-base reaction with NH4OH; ii. heat-induced dehydration of intermediate. 
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Step ii. The cyclic compound generated in step i. undergoes chlorodehydroxylation 
in the second step, using phenylphosphonic dichloride. The participation of the 
nitrogen lone pair electrons into the six-membered ring leads to the release of 
chloride ions that are now able to participate in nucleophilic addition reactions at the 
carbonyl site (Figure 2.2.1-3). Phenylphosphonic acid and its salt are formed as 
hydrolysis products of the reaction, both of which are water-soluble and thus easily 
isolated from the desired chlorodehydroxylation product.12  
      
Figure 2.2.1-3 Mechanism of chlorodehydroxylation using phenylphosphonic dichloride. 
Step iii. The final step requires the removal of the chloro-substituent in the 1-
position, to yield 3-chloroisoquinoline. This was previously achieved within the group 
using tin powder with hydrochloric acid.9 Nucleophilic attack by tin can occur at two 
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sites around the isoquinoline rings following delocalisation of the charge to either 
C(1) or C(3) (the two positions capable of undergoing loss of a chloride) (Figure 
2.2.1-4). In establishing these charges, it is evident that a positive charge held on 
C(3) is only achieved following disruption to the aromaticity of the benzene ring. By 
contrast, the charge can be held on C(1) with very little interruption to the aromaticity 
of the benzene ring.13 Consequently, whilst C(3) is a possible site for nucleophilic 
attack, in practice it occurs regioselectively at C(1) due to a more readily established 
electron deficient state.                   
 
Figure 2.2.1-4 Charged structures of isoquinoline with charge held on C(1) or C(3). 
Whilst this method was successful in producing 3-chloroisoquinoline, the yields 
obtained were consistently poor (averaging 10%), prompting the need to investigate 
alternative routes to the desired product. The literature reports that it is possible to 
remove the chloride using a combination of hydriodic acid and red phosphorus.14 The 
HI(aq)-Pred method has been used to reduce carbonyl groups, nitriles, alcohols and 
halides.15,16 
Exploiting the reversible dissociation of HI at high temperatures (Figure 
2.2.1-5-a), this reduction method involves cyclic oxidation of the iodide anion to 
iodine followed by reduction of the liberated iodine back to the anion by red 
N 1 N
N N
3
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phosphorus, which is itself converted to phosphoric acids and phosphorus.17,18 
Concomittant regeneration of HI occurs, with oxidation of red phosphorus by iodine 
acting as the driving force. The proposed reaction mechanism (Figure 2.2.1-5-b) 
displays the regenerative role of the red phosphorous, whereby the presence of this 
reagent in the couple allows recycling of the HI and enhances its reducing 
efficiency.19 Upon implementing this route, which proved to be more successful for 
this transformation, yields of 30% (following purification) were routinely secured. 
 
                   
Figure 2.2.1-5 (a) Reversible dissociation of HI at high temperatures; (b) HI(aq)-Pred 
mechanism. 
2.2.2 Metal-catalysed homocoupling 
The formation of 3,3-biisoquinoline is achieved by the metal-catalysed homocoupling 
of 3-chloroisoquinoline. A variety of methods exist, including the use of either 
copper20,21 or palladium22 in Ulmann-type coupling reactions. The use of copper is 
limited in its application due to the harsh reaction conditions required, limited range of 
substrates upon which it can act, and typically poor yields. By contrast, palladium can 
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H3PO4
H2
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I2/H2O
I2/H2O
(a)    2HI                I2 + H2
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be used in Ulmann-type reactions under relatively mild conditions, and has been 
shown to successfully couple electron-rich and electron-deficient aromatic bromides 
and iodides.22 Chlorides, however, couple far less successfully and usually in low 
yield. The palladium complexes required can also prove to be very expensive, due to 
the use of equimolar quantities in some cases, or the inability to reuse the palladium 
despite its use in catalytic quantities.23,24 Both copper and palladium catalysed 
Ulmann-type coupling routes were thus discounted.  
An attractive alternative was found in the use of nickel in a Colon-type 
coupling. These reactions require mild conditions to proceed and occur relatively 
undisturbed in the presence of other functionalities such as aldehydes and ketones. 
The specific selection of nickel catalyst, along with solvents and additional reagents 
determines the yield obtained.25,26 Furthermore, nickel catalysts are both readily 
available and relatively cheap, compared to their palladium analogues.27  
The reactive nickel(0) reagent, must first be prepared from a mixture of 
nickel(II) hexahydrate, zinc powder and triphenylphosphine in DMF.27 Due to the air 
sensitivity of nickel(0), this reaction occurs in situ under an argon atmosphere. Upon 
heating, the activated zinc reduces the nickel(II) to nickel(0), accompanied by a 
distinctive colour change as the solution changes from teal green to deep red. This 
confirms the formation of the active nickel(0) reagent. The aryl halide can then be 
added to the solution (maintaining the inert atmosphere). As the reaction proceeds, 
the formation of the homocoupled biaryl product results in the oxidation of the 
nickel(0) back to a nickel(II) species, causing the colour of the solution to turn green 
again (albeit a different shade). The desired bidentate ligand can be easily removed 
from the nickel scaffold by the addition of a weak ammonia solution. The proposed 
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reaction scheme is shown in (Figure 2.2.2-1).28 Oxidative addition of the aryl halide to 
nickel(0) is followed by its metathesis to a diarylnickel(II) species and corresponding 
nickel halide. The desired biaryl is generated through reductive elimination of the 
nickel(II) species,28 regenerating the nickel(0) reagent.  
 
 
 
Figure 2.2.2-1 Proposed scheme for nickel-mediated biaryl formation via oxidative addition 
and reductive elimination. L = PPh3 
This synthetic procedure was selected to prepare the desired homocoupled product, 
3,3-biisoquinoline from 3-chloroisoquinoline (Figure 2.2.2-2). Synthesis of the desired 
ligand (i-biq) was followed by the preparation of pre-existing and novel metal 
complexes consisting of two ligands bound in a bidentate fashion to form square 
planar compounds.  
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Figure 2.2.2-2 Nickel-mediated 3,3-biisoquinoline formation. 
A more detailed consideration of these general routes, including the specifics for 
preparation of the target compounds will now be discussed. 
 
2.3 3-chloroisoquinoline precursor synthesis and characterisation 
2.3.1 Isoquinoline-1,3-dione (1) 
In accordance with literature procedure,29 the first step towards the synthesis of 3-
chloroisoquinoline involved the conversion of homophthalic acid into isoquinoline-1,3-
dione (Figure 2.3.1-1).  
              
Figure 2.3.1-1 Synthesis of isoquinoline-1,3-dione. 
Homophthalic acid was suspended in 1,2-dichlorobenzene and heated to 200 °C to 
aid dissolution. The dropwise addition of excess ammonium hydroxide solution 
allowed the ammonium carboxylate salt to be formed in situ, followed by a further 
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period of intense heating to force the dehydration of the amine to the amide. During 
this time, the constant removal of the dehydration by-product (water) by evaporation 
drives the reaction to completion. The reaction proceeded well, with the product 
obtained in very good yield, and requiring no further purification before continuing. 
Electrospray ionisation mass spectrometry and nuclear magnetic resonance data 
were in accordance with those reported in the literature.  
 
2.3.2 1,3-dichloroisoquinoline (2) 
The second step of precursor synthesis involved the chlorodehydroxylation of 
isoquinoline-1,3-dione using phenylphosphonic dichloride (Figure 2.3.2-1).  
       
Figure 2.3.2-1 Synthesis of 1,3-dichloroisoquinoline. 
In accordance with literature procedure,10 the two were heated under reflux for 3 
hours. Upon cooling to room temperature, the solution solidifies and is subsequently 
treated with THF and water. This enables the unwanted water-soluble hydrolysis  
by-products to be easily separated from the desired product, which is extracted into 
ethyl acetate. Once again, the desired product is isolated in good yield and requires 
no further purification. Electrospray ionisation mass spectrometry and nuclear 
magnetic resonance data were in accordance with those reported in the literature. 
Comparison of the 1H-NMR spectra obtained for compounds (1) and (2) shows the 
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loss of two peaks corresponding to the aliphatic CH2 protons located on C(4) and the 
NH proton. All remaining peaks now reside in the aromatic region between 7.82 – 
8.30 ppm, proving the formation of a fully aromatic system (Figure 2.3.2-2).  
        
 
Figure 2.3.2-2 1H-NMR spectra overlay of isoquinoline-1,3-dione (1) and  
1,3-dichloroisoquinoline (2) (300 MHz, d6-DMSO, 298 °K). 
2.3.3 3-chloroisoquinoline (3) 
Selective removal of the 1-chloro substituent was initially achieved using tin powder 
under acidic conditions (Figure 2.3.3-1, Method a). The tin(II) chloride generated 
during the nucleophilic attack was isolated by the addition of ammonium hydroxide, 
resulting in the precipitation of SnO or SnO.H2O.30 The reaction progress was 
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monitored by TLC to ensure completion, before isolation and purification of the crude 
waxy solid by column chromatography. Unfortunately, the yield of product was 
repeatedly poor (~10%).  
            
Figure 2.3.3-1 Synthesis of 3-chloroisoquinoline by two alternative methods. 
2.3.4 An alternative route to 3-chloroisoquinoline (3) 
As detailed in 2.2.1, a new synthetic procedure was chosen, avoiding the use of tin 
powder altogether. This new route utilises a HI(aq)-Pred mixture to selectively remove 
the chloride substituent (Figure 2.3.3-1, Method b). Compound (2) was added to a 
slurry of red phosphorus in hydriodic acid and acetic acid. An excess of Pred was 
used, to drive the regeneration of the HI, allowing the reduction to proceed rapidly. 
The reaction mixture was heated under reflux for 24 hours before isolation and 
purification via column chromatography produced compound (3) in moderate yield 
(30%). Despite the increased reaction time for this route (24 h vs. 3 h), the reaction 
proceeded well, resulting in a three-fold increase in yield following a straightforward 
purification. Consequently, this is the preferred route towards this product on account 
of its improved yield, which ultimately saves both time and money. Electrospray 
ionisation mass spectrometry and nuclear magnetic resonance data were in 
accordance with those reported in the literature. The 1H-NMR spectrum shows a new 
peak at 9.23 ppm due to a new proton (H(1)) environment formed following the 
selective removal of the chloride group on C(1) (Figure 2.3.4-1). This peak appears 
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downfield compared to the remaining aromatic peaks. This is due to the close 
proximity of this new proton to the strongly electron-withdrawing nitrogen that sits 
adjacent in the isoquinoline ring.  
            
Figure 2.3.4-1 1H-NMR spectrum of 3-chloroisoquinoline (3) (300 MHz, MeOD, 298 °K). 
2.4 3,3-biisoquinoline synthesis and characterisation 
2.4.1 Nickel-catalysed homocoupling of aryl chlorides 
As described previously in 2.2.2, an activated nickel(0) species created in situ is able 
to mediate the formation of the desired biisoquinoline ligand; acting as a scaffold for 
homocoupling to occur. 
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2.4.2 3,3-biisoquinoline (4) 
Nickel catalysed homocoupling of the prepared 3-chloroisoquinoline precursor was 
carried out to furnish the desired bidentate 3,3-biisoquinoline ligand ready for 
complex formation (Figure 2.4.2-1).  
         
Figure 2.4.2-1 Synthesis of 3,3-biisoquinoline (i-biq). 
Immediately prior to the reaction, zinc powder was washed with dilute hydrochloric 
acid, water, acetone and diethyl ether before drying under vacuum.31 Washing was 
carried out to activate the zinc, which acts as the reducing agent for the nickel 
catalyst. Once dry, it was added to nickel(II)chloride hexahydrate and 
triphenylphosphine, and the vessel thoroughly degassed before the addition of 
anhydrous DMF. Upon heating, the activated zinc is able to successfully reduce 
nickel(II) to nickel(0) in situ, as evidenced by the distinct colour change in solution 
(Figure 2.4.2-2). Only once this colour change is observed can compound (3) be 
added to the vessel (as a solution in anhydrous DMF) to begin the coupling process. 
The reaction mixture was heated at 70 °C under an argon atmosphere for 4 hours, 
with the completion of the reaction marked by a return in colour of the mixture to a 
green complexion. This signals the oxidation of the nickel(0) species back to a 
nickel(II) species; a result of the oxidative addition of the bidentate ligand to the 
nickel.  
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Figure 2.4.2-2 Observable colour changes marking reaction progression; reduction of Ni(II) to 
Ni(0), followed by oxidation of Ni(0) back to Ni(II). 
The newly formed bidentate ligand was removed from the nickel by pouring the 
cooled solution onto a 7% solution of ammonium hydroxide. This causes dissociation 
of the ligand, which is replaced by NH3 ligands. A purple aqueous solution is formed 
as a result of the formation of this new nickel complex, [Ni(NH3)6]2+. This could be 
seen in the water layer following extraction of compound (4) into 2:1 DCM:Et2O.  
The crude product was heavily contaminated with triphenylphosphine oxide 
(TPPO, a by-product resulting from the oxidation of triphenylphosphine), which is 
notoriously difficult to remove. Due to the reported sparing solubility of TPPO in 
diethyl ether,32 the crude product was dissolved into ether and filtered to remove the 
insoluble TPPO, however this method proved to be rather ineffective. As an 
alternative, column chromatography utilising a two-solvent system was carried out 
cautiously and under gravity alone to remove the TPPO and other impurities (eluting 
with DCM) before isolating compound (4) (eluting with Et2O). Despite flash column 
chromatography typically providing better separation of components, gravity alone 
       Ni(II)                                           Ni(0)                                           Ni(II)  
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proved far more effective at separation in this particular instance. The addition of 
pumping caused many of the components to merge, making it very difficult to isolate 
the desired product from the many impurities. Pure product was obtained as a very 
pale cream solid, in 10% yield.  
Electrospray ionisation mass spectrometry analysis was in accordance with 
that previously reported, with a molecular ion peak at m/z 257.2 [M + H]+ confirming 
successful synthesis of the product. The 1H-NMR spectrum of the coupled biaryl 
product shows a large downfield shift of the C(4) proton peak when compared to its 
position in the uncoupled ligand (Figure 2.4.2-3). This is due to an increased area of 
aromaticity resulting from the coupling. 
      
Figure 2.4.2-3 1H-NMR spectra overlay of 3-chloroisoquinoline (3) and 3,3-biisoquinoline (4) 
(300 MHz, MeOD, 298 °K). 
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The literature reports alternative methods for the attempted synthesis of this biaryl 
compound, using bis(triphenylphosphine)palladium chloride, [Pd(PPh3)2Cl2] or 
bis(triphenylphosphine)nickel bromide, [Ni(PPh3)2Br2]. Both routes were 
unsuccessful, yielding no product.28,33 The encountered difficulties in synthesising the 
homocoupled product emanate from the relative unreactivity of the heteroaryl 
chlorides when compared to their bromide or iodide counterparts. The bond strength 
of the C-X bond decreases significantly as the size of the halogen atom increases 
from F to I (Table 2.4.2-1). The Ar-Cl bond is stronger than the Ar-Br bond. 
Consequently, the Cl acts as a poorer leaving group, and the ligand is reluctant to 
engage in oxidative addition to the nickel metal centre.34  
 
Bond Dissociation energy (kJ mol-1) 
Ph-F 533 
Ph-Cl 407 
Ph-Br 346 
Ph-I 280 
 
 
Table 2.4.2-1 Bond dissociation energies of aryl halides 
Despite this reduced reactivity, aryl chlorides are frequently used since they are the 
most attainable aryl halides due to low cost and widespread availability. 
 
2.4.3 An alternative route to 3,3-biisoquinoline: aryl-bromide vs. aryl-chloride  
Given that the yields obtained for compound (4) were reasonably poor, and that the 
aryl chlorides are known to couple less successfully than other aryl halides, an 
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alternative route exploring the use of an aryl bromide to obtain 3,3-biisoquinoline was 
investigated. A bromine analogue can be successfully synthesised with a single 
alteration to the 3-step procedure used to synthesise 3-chloroisoquinoline (Figure 
2.4.3-1).  
                       
Figure 2.4.3-1 Synthesis of 3-bromoisoquinoline under the following conditions: i. NH4OH, 
1,2-dichlorobenzene, 200 °C; ii. POBr3, 120 °C, 35 m; iii. HI(aq)-Pred/HOAc, 125 °C. 
During the second step, phosphorus oxybromide is used in place of 
phenylphosphonic dichloride to facilitate a bromodehydroxylation rather than 
chlorodehydroxylation. The first and final steps remain identical to those utilised 
previously. Following the success of the the HI(aq)/Pred route, this method was again 
used to isolate the bromine analogue.  
 
2.4.4 3-bromoisoquinoline precursor synthesis and characterisation 
2.4.5 1,3-dibromoisoquinoline (5) 
Following its successful synthesis (see 2.3.1), bromodehydroxylation of compound 
(1) was achieved using phosphorus oxybromide (Figure 2.4.5-1).  
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Figure 2.4.5-1 Synthesis of 1,3-dibromoisoquinoline. 
POBr3 reacts violently with water to release toxic fumes so must be handled with 
extreme caution.35 Consequently, in contrast to chlorodehydroxylation, this procedure 
was carried out under an inert atmosphere, using anhydrous solvents. Addition of 
compound (1) to the reaction vessel occurred under a strong flow of argon and in 
small portions. The reaction time is considerably shorter in this instance (35 minutes 
at reflux cf. 3 h when preparing the chlorine analogue) due to the increased reactivity 
of bromine reagents. The desired product was collected by vacuum filtration and 
washed thoroughly with propan-2-ol to yield a powdery cream solid in moderate yield 
(61%). No further purification was required. Electrospray ionisation mass 
spectrometry and nuclear magnetic resonance data were in accordance with those 
reported in the literature. The location of all peaks within the aromatic region between 
7.70 - 8.28 ppm is once again evidence for the formation of a fully aromatic system, 
along with the loss of the NH proton peak at 11.18 ppm.  
 
2.4.6 3-bromoisoquinoline (6) 
1,3-dibromoisoquinoline (5) was reduced using the HI(aq)-Pred method, following its 
successful use with the Cl-analogue. The procedure was not amended, however an 
alternative solvent system was employed during column chromatographic purification 
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to efficiently elute the desired product (Br: DCM:MeOH (9:1) Cl: EtOAc: Hexane (9:1), 
Figure 2.4.6-1).  
                 
Figure 2.4.6-1 Synthesis of 3-bromoisoquinoline. 
Product was obtained as a pale yellow solid in higher yield than the Cl-analogue 
(57% cf. 30%). Electrospray ionisation mass spectrometry and nuclear magnetic 
resonance data were in accordance with those reported in the literature. The 
appearance of a new peak at 9.04 ppm confirms that a new proton environment is 
present as a result of the selective removal of bromine previously substituted at C(1).  
Preparation of the aryl bromide analogue is a far more expensive route than 
preparation of the aryl chloride precursor. This is due to the increased cost of the 
phosphorus oxybromide, compared with the relatively inexpensive phenylphosphonic 
dichloride required for the chloride precursor. Despite the increased expense, and 
the poorer yield experienced in the initial preparation of compound (5), the mono-
substituted product (6) can be prepared in higher overall yield. This is demonstrated 
in Figure 2.4.6-2, detailing how 82.5 mmol of homophthalic acid will ultimately yield 
approximately 25.0 mmol of aryl bromide compared to only 18.0 mmol aryl chloride. 
The cost of preparing the two precursor ligands on this scale is approximately fifteen 
times higher for the aryl bromide route, which was typically carried out on a much 
smaller scale (< 5g) due to cost and safety precautions surrounding the use of 
N
Br
Br
N
Br
HI(aq)-Pred /AcOH 
Reflux 24 h (125 °C) 
            57%
5 6
 70 
POBr3. Synthesis of 3-bromoisoquinoline is also achieved more quickly than 3-
chloroisoquinoline due to a shorter period of heating at reflux during the second step, 
and yields a far ‘cleaner’ crude product, which requires less purification by column 
chromatography.  
Ultimately, the trade-off between the increased expense of the bromide route 
and the increased product yield is only favourable if the aryl bromide proves to be a 
more reactive species, capable of undergoing more efficient homocoupling to yield 
the desired ligand 3,3-biisoquinoline in improved yield. 
               
Figure 2.4.6-2 Comparison of the yield of halide-isoquinoline obtained through the chloride or 
bromide synthetic route. 
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2.4.7 Nickel-catalysed Colon-coupling of aryl bromides 
Nickel-catalysed homocoupling of the newly prepared aryl bromide precursor was 
carried out under the same conditions used previously (Figure 2.4.7-1).  
       
Figure 2.4.7-1 Synthesis of 3,3-biisoquinoline from 3-bromoisoquinoline. 
The crude product was purified by column chromatography eluting with DCM initially 
to remove some impurities, followed by EtOAc to elute the desired biaryl ligand as 
pale cream solid. A 24% yield was recorded for this route, which is an improvement 
upon the 10% yield obtained as a result of aryl chloride coupling. Although perhaps 
not as significant an improvement in yield as one might have hoped for, the aryl 
bromide route still results in a 140% increase in the yield of desired product, and 
crucially, provides a reasonable amount of material to work with in subsequent 
syntheses. Consequently, due to improved yields of both the ligand precursor (3) and 
ligand (4), the aryl bromide route was selected as the preferred route. 
 
2.5 Synthesis and characterisation of palladium, platinum and gold  
3,3-biisoquinoline complexes 
2.5.1 [Pd(i-biq)2](BF4)2 (7) 
Two bidentate 3,3-biisoquinoline ligands were bound to a palladium metal centre 
following a ligand substitution reaction. Tetrakis(acetonitrile)palladium 
tetrafluoroborate was chosen as the starting palladium complex, whereby addition of 
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3,3-biisoquinoline in a 2:1 ratio results in the formation of the desired complex 
following overnight stirring in acetonitrile under an inert atmosphere (Figure 2.5.1-1).  
     
 
Figure 2.5.1-1 Synthesis of [Pd(i-biq)2](BF4)2. 
The product was carefully washed in chloroform, methanol and diethyl ether to 
remove any unreacted starting materials before drying under vacuum to yield pure 
[Pd(i-biq)2](BF4)2 as pale yellow solid in 64% yield. The complex is soluble in both 
CH3CN and DMSO. The ESI-MS spectrum shows peaks at m/z 309, 618 and 653 
corresponding to [Pd(C18H12N2)2]2+, [Pd(C18H12N2)2]+ and [Pd(C18H12N2)2Cl]+ 
respectively. The 1H-NMR spectrum shows the same splitting pattern and number of 
proton peaks as those observed for the unbound ligand. Comparison of the two 
spectra shows a downfield shift of all signals due to the electron withdrawing effect of 
the palladium metal centre upon complex formation (Figure 2.5.1-2).  
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Figure 2.5.1-2 1H-NMR spectra overlay of 3,3-biisoquinoline (4) and [Pd(ibiq)2](BF4)2 (7) (300 
MHz, CD3CN, 298 °K). 
2.5.2 [Pt(i-biq)2](PF6)2 (8) 
In a similar manner to the approach used to form the palladium analogue, 3,3-
biisoquinoline was reacted in a 2:1 ratio with a platinum complex capable of 
undergoing ligand substitution to form the desired product. Potassium 
tetrachloroplatinate was dissolved in water, before the addition of a suspension of 
3,3-biisoquinoline in acetonitrile. The use of a 1:1 H2O:CH3CN solvent mixture aids 
dissolution of the biisoquinoline ligand.8 The mixture was heated under reflux 
overnight (Figure 2.5.2-1).  
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Figure 2.5.2-1 Synthesis of [Pt(i-biq)2](PF6)2. 
The resulting solution was filtered to remove any unreacted ligand or [Pt(i-biq)Cl2] 
that may have formed. A methanolic solution of ammonium hexafluorophosphate was 
added to cause the precipitation of the desired complex from solution. The product 
was carefully washed with chloroform, methanol and diethyl ether before drying 
under vacuum to yield pure [Pt(i-biq)2](PF6)2 as a very pale yellow solid in 29% yield. 
This is a poorer yield than that obtained when preparing the palladium analogue. This 
is most likely due to the rapid formation of some mono-substituted product  
[Pt(i-biq)Cl2] (Figure 2.5.2-2), which has previously been reported to exhibit poor 
solubility in dimethyl sulphoxide, and is insoluble in all other common solvents.8 
Consequently, the complex precipitates out of solution upon formation and is unable 
to react further to form the desired disubstituted complex.  
        
Figure 2.5.2-2 Rapid formation of mono-substituted [Pt(i-biq)Cl2] during [Pt(i-biq)2](PF6)2 
synthesis. 
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Similarly to palladium, the platinum complex is soluble in both acetonitrile and 
dimethyl sulphoxide. The ESI-MS spectrum showed peaks at m/z 353 and 743 
corresponding to [Pt(C18H12N2)2]2+, and [Pt(C18H12N2)2Cl + H]+ respectively. The 1H-
NMR spectrum shows only the six proton signals attributed to 3,3-biisoquinoline, but 
with an observable downfield shift (compared to unbound ligand) arising from the 
removal of electron density from the aromatic system (Figure 2.5.2-3). This is 
evidence of complex formation, whereby the proximity of the platinum metal centre 
results in electron density withdrawal from the ring. Furthermore, 195Pt-1H coupling 
satellites are clearly visible, confirming metal coordination of the ligand.                           
 
Figure 2.5.2-3 1H-NMR spectra overlay of 3,3-biisoquinoline (4) and [Pt(ibiq)2](PF6)2 (8)  
(300 MHz, CD3CN, 298 °K). 
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2.5.3 Gold(III) complexes: an emerging new class of anticancer drugs 
Gold(III) complexes were first considered as a possible alternative to platinum 
complexes due to the observation that they possess the same electronic 
configuration (d8) as platinum(II) complexes, and thus exhibit the same preference 
towards square-planar complex formation. Following the discovery of the 
antiproliferative effects of cisplatin, there arose great interest in gold(III) complexes 
as a new family of anticancer drugs, with much attention devoted to the potential use 
of gold(III) as an alternative to platinum(II) in drugs.36,37 Unfortunately, the relatively 
poor chemical stability of gold(III) complexes in solution hindered any progress in this 
area for quite some time. Indeed, only a handful of reports describing the cytotoxic 
properties and antitumour effects of such complexes38–40 existed in the literature up 
until the mid-90’s. Despite the small volume of research reported, gold(III) complexes 
had been reported to produce toxic effects.36  
From 2000 onwards, gold(III) compounds showing stability under 
physiologically relevant conditions were reported,41,42 with the stability attributed to an 
appropriate choice of ligands, in most cases bearing N atoms (Figure 2.5.3-1). These 
compounds have also been shown to manifest relevant antiproliferative properties 
against selected human tumour cell lines, prompting a renewed interest in the field. 
                              
Figure 2.5.3-1 Two representative gold(III) complexes shown to be stable under physiological 
conditions and to manifest antiproliferative properties against human ovarian cells A2780, as 
reported by Messori et al.43 
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Owing to their reported biological activity in vitro, gold(III) complexes remain a 
promising new class of anticancer agents. The ability to prepare a gold(III) analogue 
of the i-biq complexes was therefore a natural progression, as well as an attractive 
target. Bearing the required nitrogen atoms as donor groups, the i-biq ligand should 
promote the formation of a stable gold(III) complex, exhibiting the crucial square-
planar geometry required for G-quadruplex binding.  
 
2.5.4  [Au(i-biq)2](3Cl) (9) 
Synthesis of [Au(i-biq)2](3Cl) was attempted several times, with varying degrees of 
success. The method employed to attach two biisoquinoline ligands around a single 
gold metal centre was similar to that used in preparing the palladium and platinum 
analogues. Sodium tetrachloroaurate(III) dihydrate and 3,3-biisoquinoline were 
heated under reflux in methanol overnight (Figure 2.5.4-1). The resulting solution was 
hot filtered and concentrated in vacuo to afford a dark yellow solid.  
       
Figure 2.5.4-1 Synthesis of [Au(i-biq)2](3Cl). 
On the first attempt, the 1H NMR spectrum of crude product showed a single product 
only when initially recorded in DCM. This proved to be the unbound ligand (by 
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comparison with a ligand spectrum recorded in DCM). A further spectrum of the 
crude product recorded in MeOD clearly showed two sets of signals, one of which 
was easily attributed to the free ligand, the other of which showed the same pattern 
of signals but with a downfield shift. It became evident that the free ligand could be 
removed from the crude product by washing and filtration, due to its solubility in 
DCM. 
Following careful washing, the NMR spectrum (in MeOD) showed a single set 
of six signals; ligand proton peaks having undergone a significant downfield shift 
(Figure 2.5.4-2). This is strong evidence towards the formation of the gold i-biq 
complex, since complex formation would result in removal of electron density from 
the aromatic ring system, resulting in the observed downfield shift in signals.  
       
Figure 2.5.4-2 1H-NMR spectra overlay of 3,3-biisoquinoline (4) and [Au(ibiq)2](3Cl) (9)  
(300 MHz, MeOD, 298 °K). 
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The ESI-MS spectrum showed peaks at m/z 488 and 709 corresponding to 
[(Au(C18H12N2)(OH)2) + H]+ and [Au(C18H12N2)2]+ respectively. Whilst there appears to 
be a peak corresponding to the desired product (m/z 709), its presence points 
towards a Au(I) metal complex, rather than the anticipated Au(III) central ion. 
Furthermore, there is a noticeable absence of peaks corresponding to a Au(III) metal 
centre (expected at m/z 236). Whilst the absence of this peak does not necessarily 
confirm that this species is not present in the sample, the presence of the m/z 709 
peak is definitive evidence of the corresponding species’ existence. These 
observations call into question whether or not the desired species (Au(III), 4 
coordinate, square planar) has actually been prepared.  
Subsequent attempts at synthesising the Au(III) complex yielded similar 
compounds producing identical NMR spectra. The ESI-MS spectra, however, 
showed some variation over a further two attempts; the peak at m/z 709 was not 
observed in one, whilst alternative peaks also arose, unfortunately none of which 
corresponded to the Au(III) target complex. Unfortunately, insufficient material was 
obtained for elemental CHN analysis to be carried out. Attempts to grow a crystal of 
the compound have so far been unsuccessful. 
 
2.6 Binding of Pd(II) and Pt(II) complexes toward model nucleobases 
2.6.1 ESI-MS binding studies 
Previously, several biophysical techniques have been employed to probe the 
interaction between the palladium and platinum metal-biisoquinoline complexes and 
both duplex and G-quadruplex-forming DNA (summarised in 2.1.1). To better 
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understand the interaction between the complexes and DNA, electrospray ionisation 
mass spectrometry (ESI-MS) studies were carried out. The use of ESI-MS as a 
means by which to demonstrate complex-DNA binding is becoming increasingly 
common in the literature.44 To identify the proposed binding of these complexes to 
guanine-rich regions of the DNA sequence (capable of forming G-quadruplex 
structures), preliminary studies with model nucleobase 9-ethyl guanine (9EG) were 
carried out to establish if either complex binds to guanine.  
In order to assess the potential selectivity of these complexes for guanine, 
further studies were undertaken with model nucleobases 1-methylthymine, 9-
methylguanine, 1-methylcytosine and 9-methyladenine. These studies were 
undertaken to assess the ability of each complex to bind alternative nucleobases, 
and determine if any preferences for a particular nucleobase exist in solution.  
 
2.6.2 Preliminary ESI-MS studies with 9-ethylguanine 
Solutions of 9EG and each complex were mixed in equal quantities and analysed by 
mass spectrometry. 9EG was solubilised in sodium cacodylate buffer whilst each 
complex was dissolved in DMSO to aid solubility. The spectrum for 9EG is shown in 
Figure 2.6.2-1, showing a peak at m/z 739 that can be attributed to G-quadruplex 
formation in solution (stabilised by a sodium cation). A full range of solvent controls 
were analysed alongside the experimental samples (data not shown) to enable 
accurate peak assignments to be made.  
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Figure 2.6.2-1 Mass spectrum of a 1 mM solution of 9EG in sodium cacodylate buffer. The 
peak at m/z 739.2 is due to G-quadruplex formation in solution. 
 
Both complexes show binding to 9EG, as evidenced by the presence of new adducts 
in the spectra, corresponding to novel complex-base species. The palladium complex 
(7) spectra displayed in Figure 2.6.2-2 show the presence of new peaks at m/z 540, 
575 and 1080 corresponding to [Pd(i-biq)(9EG – H)]+, [Pd(i-biq)(9EG)Cl]+ and [Pd2(i-
biq)2(9EG – H)2]+, respectively. The platinum complex (8) spectra displayed in Figure 
2.6.2-3 show the presence of new peaks at m/z 629 and 1257 corresponding to  
[Pt(i-biq)(9EG – H)]+ and [Pd2(i-biq)2(9EG – H)2]+, respectively. The peak at m/z 1028 
has not yet been assigned, however it appears in the complex only control spectrum 
and is therefore not due to complex-nucleobase binding. 
 Although in neither case do these new complex-nucleobase peaks constitute 
the major species, their presence alone is still encouraging evidence towards 
guanine interaction.   
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Figure 2.6.2-2 Mass spectra of [Pd(i-biq)2(BF4)2] (7) in DMSO (top) and 1 mM  
[Pd(i-biq)2(BF4)2] in DMSO + 1 mM 9EG in sodium cacodylate (bottom). 
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Figure 2.6.2-3 Mass spectra of [Pt(i-biq)2(PF6)2] (8) in DMSO (top) and 1 mM [Pt(i-biq)2(PF6)2] 
in DMSO + 1 mM 9EG in sodium cacodylate (bottom). 
 
2.6.3 Further ESI-MS studies with 1-methylthymine, 9-methylguanine,  
1-methylcytosine and 9-methyladenine. 
Following preliminary studies that identified binding interactions between both 
complexes and 9-ethylguanine, each complex was tested with four further 
nucleobases (representative of A, C, T and G; 9-methyladenine, 1-methylcytosine, 1-
methylthymine and 9-methylguanine, Figure 2.6.3-1) both individually and combined 
in solution. 
 
 84 
              
Figure 2.6.3-1 Structures of nucleobases. 
Individual bases + complex 
Solutions of each individual base and each complex were mixed in equal quantities 
and analysed by mass spectrometry. Owing to the complexity observed in previous 
spectra as a consequence of using sodium cacodylate buffer, the bases were 
solubilised in DMSO instead. Each complex was again dissolved in DMSO. The 
results, displayed in Table 2.6.3-1 show that the palladium complex (7) interacts with 
all four bases in solution, whilst the platinum complex (8) interacts with three out of 
four bases. There is no evidence of Pt-T binding in solution.  
  
 
9-methyl 
adenine (9MA) 
1-methyl 
cytosine (1MC) 
1-methyl 
thymine (1MT) 
9-methyl 
guanine (9MG) 
[Pd(i-biq)2](BF4)2 
510 
[PdL(9MA – H)]+ 
488 
[PdL(1MC – H)]+ 
501 
[PdL(1MT – H)]+ 
526 
[PdL(9MG – H)]+ 
[Pt(i-biq)2(PF6)2 
599 
[PtL(9MA – H)]+ 
575 
[PtL(1MC – H)]+ 
- 
615 
[PtL(9MG – H)]+ 
 
Table 2.6.3-1 Mass spectra peaks observed upon mixing individual nucleobases (1 mM in 
DMSO) with 1 mM [Pd(i-biq)2(BF4)2] (7) in DMSO and 1 mM [Pt(i-biq)2(PF6)2] (8) in DMSO. 
N
N
NH2
N
N
9-methyladenine
N
ONH2N
1-methylcytosine
N
ON
H
O
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N
N
NH2N
HN
O
9-methylguanine
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Given the interaction between both complexes and all four nucleobases in almost all 
cases (except between platinum complex and 1MT), further experiments were 
conducted to establish whether or not each complex displays a preference for one 
nucleobase over another.  
 
Four base mix + complex 
Creating a competitive environment, a solution containing all four bases in DMSO 
was mixed with each complex solution in equal quantities and analysed by mass 
spectrometry. With all four bases combined in solution, each complex may select its 
preferred binding partner, whereby the most dominant species observed in the 
spectrum gives an indication of this preference.  
The results obtained are shown in Figure 2.6.3-2 with asterisks denoting 
significant complex-nucleobase peaks. Enhanced views of these peaks, showing 
their intensities relative to one another are shown in Figure 2.6.3-3. 
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Figure 2.6.3-2 Mass spectra of 1 mM complex in DMSO + 1 mM ACTG mix in DMSO. 
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It is clear from both spectra that the species observed in the single base experiments 
are also present when all four bases are available in solution. Of particular note, is 
the presence of a new peak in the platinum complex spectrum. Located at m/z 1033, 
this peak could be attributed to [Pt(i-biq)2(9MG – H)4Na] i.e. it may be due to the 
formation of G-quadruplex structures in solution, which are subsequently bound by 
the platinum species (8). A comparable peak (G-quadruplex structure) does not 
appear in the spectrum for 9MG alone, possibly pointing towards the ability of the 
platinum species to induce G-quadruplex formation and then stabilise the structure in 
solution through binding interactions. It is also worth noting that the equivalent peak 
is not observed in the palladium spectrum.  
Comparison of both spectra (see enhanced views in Figure 2.6.3-3) shows the 
same general pattern: the [ML(G – H)]+ guanine species dominate in both cases 
(followed by 1MC and 9MA). This is strongly supportive of preferential binding to 
guanine above alternative nucleobases; an extremely promising characteristic for 
complexes intended for G-quadruplex binding.  
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Figure 2.6.3-3 Enhanced views of the mass spectra obtained when 1 mM complex in DMSO 
is mixed with 1 mM ACTG mix in DMSO. 
 
2.7 Part I: Conclusions 
Both palladium and platinum 3,3-biisoquinoline complexes have been successfully 
synthesised, in addition to the attempted synthesis of a gold analogue. An alternative 
method was used to achieve selective removal of a single halide substituent at the 
C(1) position in the isoquinoline building block, resulting in a three-fold increase in 
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yield compared with the method previously used. Preparation of 3,3-biisoquinoline 
via nickel-catalysed homocoupling of an aryl bromide is described. Whilst more 
expensive, this route secured a higher yield of ligand and was a cleaner method. 
Suitable quantities of both the palladium and platinum complexes were obtained 
(several milligrams) to enable the biological studies discussed in Part II to be carried 
out. The successful preparation of the gold complex remains unconfirmed, for this 
reason biological studies were not pursued on this compound. ESI-MS binding 
studies have demonstrated the ability of both palladium and platinum species to 
interact with several model nucleobases to form new adducts. Preferential binding to 
guanine has been observed. 
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PART II: IN VITRO BIOLOGICAL ACTIVITY OF PALLADIUM AND PLATINUM  
3,3-BIISOQUINOLINE COMPLEXES 
 
2.8 Introduction 
Since its approval in 1978, cisplatin continues to be one of the most effective 
anticancer drugs used in the treatment of solid tumours including testicular, ovarian, 
cervical and small-cell lung cancers.45 Despite its widespread use, upon binding to 
double-stranded DNA cisplatin is known to be genotoxic and carcinogenic in 
mammalian cells, resulting in damage to healthy cells and an increased risk of 
inducing secondary malignancies.46 Consequently, the ability to develop new 
complexes that demonstrate cytotoxic activity against cancer cells, without also 
inducing genotoxic or mutagenic damage to cells is an area of great interest. 
The targeting of an alternative DNA structure in cells, such as the G-
quadruplex, requires a different mode of binding and therefore an alternative 
mechanism of action which can be useful when circumventing cisplatin resistance. G-
quadruplexes represent an ideal target since they are formed during active 
processes such as translation and replication; the frequencies of which are up-
regulated in rapidly proliferating cells, such as cancer cells.47 
In order to demonstrate activity in vitro, compounds must be capable of 
entering cells to reach their desired target. In the case of targeting DNA, this would 
require the compound to cross both the cell and nuclear membranes.48 Several 
pathways may gain the compound entry into the cell through the cell membrane, the 
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choice of which will affect the speed of complex uptake and subsequent distribution 
throughout the cell environment.48  
Several in vitro biological assays were carried out in order to investigate the 
biological activity of both the palladium and platinum complexes in cells.   
 
2.8.1 Choice of cell line 
In the past decade, a large proportion of the cell work carried out to assess the 
biological activity of novel compounds developed within the Hannon group, has been 
completed in the A2780 cell line. With established cell culture protocols in place, it is 
advantageous to continue working on this same cell line.  
The A2780 cell line used in all the cellular studies discussed hereafter is a 
human ovarian carcinoma line originating from a human ovary. The line was 
established from tumour tissue obtained from an untreated patient.49 Cells are 
adherent and grow as a monolayer in culture, with epithelial morphology (Figure 
2.8.1-1). 
                               
Figure 2.8.1-1 A2780 human ovarian carcinoma cell morphology 
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2.9 Cell viability 
2.9.1 MTT assay 
To study the cytotoxic activity, and therefore the potential chemotherapeutic 
properties of the palladium and platinum biisoquinoline compounds, the MTT assay 
was performed to yield half maximal inhibitory concentration (IC50) values.50 These 
values measure how effective a compound is, by assessing what concentration is 
required to inhibit a given biological process by half. In the case of an MTT assay, it 
is the biological activity of mitochondrial reductase enzymes that is being measured, 
following inhibition as a result of compound addition.  
In metabolically active cells, the addition of a solution of yellow tetrazolium 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) will result in its 
reduction to violet formazan crystals through electron transport processes involving 
mitochondrial reductase (Figure 2.9.1-1).51 The extent to which a colour change has 
occurred can be determined spectrophotometrically following dissolution of the violet 
crystals with dimethylsulfoxide. The intensity of the violet colour is an indicator of the 
proportion of functional mitochondria and consequently the proportion of viable 
cells.52  
 
Figure 2.9.1-1 The reduction of MTT to formazan by mitochondrial reductase in living cells. 
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A range of concentrations per compound is tested, whereby a graph of concentration 
vs. absorbance can be plotted. The point at which the absorbance has decreased by 
50% will correspond to the IC50 concentration. The lower the IC50 value, the more 
cytotoxic a compound is; since less is needed to reduce cell viability by 50%.  
 
2.9.2 IC50 results 
A2780 cells were treated with eight different concentrations of [Pd(i-biq)2](BF4)2 (7), 
[Pt(i-biq)2](PF6)2 (8), 3,3-biisoquinoline (4) and cisplatin as a positive control to 
assess cell viability (mitochondrial MTT reduction). Cisplatin was tested as a well-
studied comparison, whilst the unbound i-biq ligand (4) was tested to verify that the 
metal-bound complexes are still intact upon entry into the cell (as evidenced by a 
different IC50 value), as well as to compare the activity of the ligand alone. The 
results of the assay are detailed in Table 2.9.2-1 and displayed in Figure 2.9.2-1, with 
the average IC50 values of three independent runs reported in micromolar (µM). To 
confirm that cytotoxicity was not observed due to adverse solvent effects, vehicle 
controls of 2% DMSO/98% RPMI media were tested. No significant cytotoxic effects 
(assessed by MTT assay) were observed under these conditions (data not shown).  
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Compound IC50 (µM) 
[Pd(i-biq)2](BF4)2 (7) 2.47 ± 0.10 
[Pt(i-biq)2](PF6)2 (8) 6.19 ± 0.20 
i-biq (4) 17.4 ± 1.6 
cisplatin 17.1 ± 0.8 
 
Table 2.9.2-1 Evaluation of cytotoxic effects of treatment of [Pd(i-biq)2](BF4)2,  
[Pt(i-biq)2](PF6)2, 3,3-biisoquinoline (i-biq) and cisplatin using the MTT assay. A2780 cells 
were treated for 24 hours prior to obtaining IC50 values. Values are mean ± S.E.M. for data 
from three independent experiments.                          
                  
Figure 2.9.2-1 Evaluation of cytotoxic effects of treatment of [Pd(i-biq)2](BF4)2,  
[Pt(i-biq)2](PF6)2, 3,3-biisoquinoline (i-biq) and cisplatin using the MTT assay. A2780 cells 
were treated for 24 hours prior to obtaining IC50 values. Values are mean ± S.E.M. for data 
from three independent experiments. Significant difference from cisplatin (*) and 3,3-
biisoquinoline (i-biq)(*) (p<0.01 **) (One-way ANOVA followed by Tukey test). 
A statistically significant difference between the activity of both complexes and 
cisplatin can be immediately observed (p<0.01). For the 24 hour treatment period 
studied, both complexes show cytotoxic activity exceeding that of cisplatin. The 
greatest difference in cytotoxicity is observed between cisplatin and the palladium 
** 
         
** 
** 
** 
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complex (7), which exhibits approximately 6-fold greater cytotoxic activity than 
cisplatin on this cell line. In comparison, the platinum complex (8) shows 
approximately 3-fold greater activity than cisplatin, which, despite being less active 
than it’s palladium analogue, is still a notable improvement upon the activity of 
cisplatin.  
The observed differences in activity between both complexes and cisplatin can 
likely be explained by differences in biological target, uptake and stability of these 
compounds. The mechanism of action of cisplatin has been widely researched and is 
well documented. Targeting both nuclear and mitochondrial DNA, cisplatin is 
hydrolysed upon entry into the cell and then binds to the N(7) position on guanines 
featured in double-stranded DNA. The resulting adduct initiates apoptotic pathways, 
leading to cell death. By contrast, complexes (7) and (8) are proposed to be 
interacting with G-quadruplex structures in addition to duplex DNA, as determined by 
previous spectrographic studies (on isolated DNA) (2.1.1). The combination of 
binding to both duplex and G-quadruplex cellular targets could account for the 
increased cytotoxicity observed for these compounds, due to their dual-mode ability 
to inhibit DNA replication.  
Alternatively, the increased cytotoxicity observed may be less to do with the 
number of cellular targets bound and more to do with the type of target bound. Where 
both types of DNA are available in a single system, each complex has been shown to 
have a preference for G-quadruplex binding.9 The observed increase in cytotoxicity 
may therefore be due to the downstream effects of binding the more unusual G-
quadruplex target structures over DNA, rather than as a cumulative result of binding 
to both targets.  
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Despite the comparatively low occurrence of G-quadruplex structures for 
interaction (compared to the availability of double stranded DNA), the lower IC50 
values obtained for the complexes targeting these structures leads to the suggestion 
that such a mode of binding produces a greater cytotoxic effect. This would account 
for the increased cell death observed at much lower treatment concentrations (cf. 
cisplatin), despite the limited availability of G-quadruplex binding sites. Further 
explanations for the observed differences in cytotoxicity between cisplatin and 
complexes (7) and (8) could be related to the uptake and localisation of the 
compounds, which will be investigated further.  
 
In addition to differences between the activity of cisplatin and complexes (7) and (8), 
there is a statistically significant difference between each complex and unbound i-biq 
ligand (4) (p<0.01), whereby the unbound ligand is much less cytotoxic than both 
complexes formed upon its binding to a metal centre. This information supports the 
assertion that the complex is intact upon entry into the cell and has not undergone 
any degradation into free ligand and metal; either in solution or following uptake. 
Consequently, it is believed that the cytotoxic effect being observed is due to the 
biological activity of compounds (7) and (8) in their complex form.  
 
Although the palladium complex (7) was more toxic than the platinum complex (8), 
this was not statistically significant (p=0.07). The cause of the observed difference in 
IC50 values (the platinum complex requires a treatment concentration approximately 
2.5-fold greater than the palladium complex in order to produce the same cytotoxic 
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effect) is unlikely due solely to G-quadruplex binding in cells, since it is the platinum 
complex that has been shown to bind more favourably to these regions.9 
It is possible that the cell uptake and localisation mechanism for each complex 
varies, resulting in lower bioavailability of the platinum form, and consequently limited 
complex-DNA binding. This could explain why, despite a greater affinity for G4-
interaction, the platinum complex is unable to reach its biological target as readily 
and thus requires a greater concentration of treatment to produce the same cytotoxic 
effect as the palladium compound. Exploration of cell uptake was thus prompted, with 
ICP-MS experiments completed in order to assess cell uptake and localisation 
(discussed in 2.12).  
 
The literature reports a variety of G-quadruplex binding compounds that have been 
studied in vitro to assess their cytotoxicity across a range of cell lines (detailed in 
Figure 2.9.2-2). These include (a) metal-salphen complexes that bind to human 
telomeric DNA quadruplexes with antiproliferative activity,4 (b) 3,6,9-trisubstituted 
acridine complexes that bind to G-quadruplexes and display potent inhibitory activity 
against human telomerase,54 (c) platinum Schiff base complexes that bind to G-
quadruplexes located in cMyc gene promoter regions, thus inhibiting oncogene 
expression55 and (d) copper terpyridine complexes that selectively bind and stabilise 
antiparallel G-quadruplex DNA, displaying greater cytotoxicity than cisplatin.56  
The IC50 values obtained for both G-quadruplex binding compounds (7) and 
(8) are comparable to those reported in the literature, typically falling in the low 
micromolar range (broadly between 1-10 µM). The palladium i-biq compound (8) in 
particular has a similar IC50 value (approximately 2.5 µM) to many of those quoted, 
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with the platinum i-biq compound (7) exhibiting a higher IC50 value, though still 
demonstrating comparable cytotoxicity to several of the literature compounds.  
Accounting also for their demonstrated increase in cytotoxicity compared to 
cisplatin, both the palladium and platinum i-biq compounds show great potential as 
anticancer agents. Subsequently, further investigation into the cell uptake and mode 
of action of these compounds was carried out. 
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Compound Cell line IC50 (µM) 
(
a)4  
        
SRB assay, 96 h 
 
MCF-7 
A549 
RCC4 
W138 
 
2.3(14.556) 
2.3(20.456) 
2.3 
2.4 
 
(
b)54 
 
                                                      
SRB assay, 96 h 
 
A2780 
 
 
2.7(1.5857) 
 
 
(
c)55  
           
MTT assay, 48 h 
 
HeLa 
NC1-H460 
CCD-19 Lu 
HepG2 
 
1.3 (12.5) 
4.8 (16.5) 
46.1 (85.2) 
1.1 (11.5) 
 
(
d)56   
         
MTT assay, 48 h 
Bel-7402 
A549 
HL-60 
HeLa 
MCF-7 
 
1.0 (8.1) 
1.3 (20.4) 
2.3 (2.9) 
2.2 (20.3) 
1.5 (14.5) 
 
 
Figure 2.9.2-2 G-quadruplex binding complexes reported in the literature and their 
determined IC50 values across a range of cell lines. Values in parentheses represent the 
IC50 values for cisplatin determined within the study, or (where available) in other work for 
comparison. Cancer cell lines: A2780 (ovarian), MCF-7 (breast), A549 (lung), RCC4 (renal), 
HeLa (cervical), HepG2 (hepatocellular), NC1-H460 (lung), Bel-7402 (hepatocellular), HL-60 
(promyelocytic leukaemia). Normal cell lines: W138 (human fibroblast), CCD-19 Lu (lung 
fibroblast). Values taken from literature and quoted to 1 decimal place for comparison. 
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2.10 Genotoxicity 
2.10.1 Comet assay for DNA double strand breaks 
Human cells typically accumulate at least 10,000 DNA lesions daily,58 with their 
efficient repair a mandatory biological process to avoid apoptosis. Failure to repair 
DNA damage can lead to an accumulation of genetic mutations causing genomic 
instability that may also result in the development of secondary tumours following the 
cessation of chemotherapeutic treatment.59 
Genotoxic chemicals exert their adverse effects through interaction with the 
DNA of cells. Such compounds have the potential to be carcinogens and/or 
mutagens, ultimately inducing cancer and/or heritable defects. Genotoxicity testing is 
carried out to identify compounds that are capable of inducing genetic damage 
directly or indirectly by various mechanisms of action. 
First developed in 1984 by Ostling and Johason,60 the comet assay (also 
called the single cell gel electrophoresis (SCGE) assay) is a well-established, 
sensitive and relatively simple method for detecting DNA damage (specifically strand 
breaks) at the individual eukaryotic cell level.61,62 Requiring only small numbers of 
cells per sample, electrophoresis is performed on exposed cells that have been 
embedded in agarose gel. During the migration process the effect of DNA damage is 
detectable as DNA fragments that lag behind the intact, undamaged DNA, thus 
producing a comet tail effect when visualised under the microscope (Figure 2.10.1-1) 
Analysis of each comet allows the amount of DNA present in the tail region to 
be calculated as a percentage of the total DNA present in both the tail and head 
regions combined, giving a percentage tail intensity value. A large percentage tail 
intensity value would be characteristic of a compound which is capable of causing 
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severe DNA strand breaks (i.e genotoxic), resulting in the majority of genetic material 
accumulating in the tail region.  
Comparison of median percentage tail intensity values for different 
compounds enables the degree of genotoxicity to be determined. Furthermore, 
analysis of a single compound at varying concentrations can give an indication of the 
relationship between compound concentration and DNA damage induced. 
  
               
Figure 2.10.1-1 (a) Screenshot of the COMETIV user interface showing the graphical 
analysis of a selected comet. (b) Representative images demonstrating the increase in DNA 
occupying the tail region as a result of increasing severity of DNA damage. 
The use of buffers with either neutral or alkaline pH results in two variations of the 
assay. The alkaline assay identifies both single (SSB) and double strand breaks 
(DSB), whilst the neutral assay is said to identify the occurrence of double strand 
breaks only.63 There is, however, some discussion as to whether the use of a pH 
close to neutral is sufficient to specifically distinguish double-stranded breaks only.64  
 
                        (a)                                                    (b) 
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2.10.2 DNA strand break results 
The comet assay was performed under neutral conditions to enable detection of DNA 
double-strand breaks (DSB). Among the various types of damage experienced by a 
cell, DSBs represent the most lethal form and are frequently introduced by cellular 
processes such as stalled replication forks.58,65,66 Since stabilisation of G-quadruplex 
structures (as a result of complex binding) is proposed to interfere with cell 
replication, DSBs were deemed the most relevent type of damage expected to occur 
to cellular DNA following treatment with quadruplex-binding compounds (7) and (8). 
The neutral assay was therefore chosen as the most appropriate method to analyse 
DNA damage following compound treatment.  
Neutral comet assays were performed on A2780 cells following 24 hours 
incubation with either the palladium (7) or platinum (8) complex. Untreated control 
samples were also analysed. Three concentrations related to the IC50 of each 
compound were tested ([IC50], [IC50/2], [IC50/4]) to determine if there is a 
concentration-response between the amount of compound administered and the 
severity of damage observed. Treatments at concentrations above the IC50 were 
excluded, since this would result in a large amount of cell death during the treatment 
period and thus limit the number of viable cells available for collection and 
examination. Treated cells were lysed and electrophoresed, after which time they 
were stained with SYBR gold to enable visualisation of the DNA under the 
microscope.  
During the scoring process, one hundred cells were manually selected and 
analysed. Whilst this process is unbiased, there are some considerations when 
selecting a particular cell for analysis. When viewing the slides, there are regions of 
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non-cellular debris that have been stained, and could be mistaken for cells without 
closer inspection (Figure 2.10.2-1). Care must be taken to avoid selecting these 
regions. If mistakenly selected, it is clear that these regions are not representative of 
DNA, as there is no variation in the pixel intensity across the region, in which case, 
the erroneous selection must be deleted from the overall count. In addition to debris, 
cells which are too close in proximity to surrounding cells or debris on the slide are a 
poor choice, since the software is not able to distinguish the two objects as 
independent, and will therefore process the second cell (the neighbouring cell not 
selected) as the tail region of the first (Figure 2.10.2-1). Again, it is wise to avoid 
selecting these cells to ensure the median percentage tail intensity values generated 
from the software are representative and accurate.  
                
Figure 2.10.2-1 Screenshots of the COMETIV user interface showing (a) appearance of 
‘cells’ pre-selection; (b) comparison of selection of debris vs. cell; (c) cell in close proximity to 
debris; (d) selection of such a cell produces inaccurate results due to the inclusion of the 
debris. 
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To assess the extent of DNA damage, the median percentage tail intensity was 
calculated as an average of three independent runs. The results of this assay are 
detailed in Table 2.10.2-1 and displayed in Figure 2.10.2-2. The measurement of 
percentage tail intensity was chosen because it is less dependent on electrophoresis 
voltage and run time, and has been shown to exhibit less inter-run variation due to 
this.67 On account of its reliability, this parameter is also the most frequently quoted 
within the literature when presenting comet assay data. 
 
Compound 
Median (%) tail intensity 
IC50/4 IC50/2 IC50 
Control - 1.25 ± 0.76 - 
[Pd(i-biq)2](BF4)2 (7) 2.84 ± 0.24 5.42 ± 0.76 7.76 ± 1.03 
[Pt(i-biq)2](PF6)2 (8) 3.56 ± 0.57 5.72 ± 0.85 6.26 ± 1.48 
cisplatin 1.62 ± 0.38 1.92 ± 0.57 3.78 ± 0.51 
 
Table 2.10.2-1 Evaluation of genotoxic effects of treatment of [Pd(i-biq)2](BF4)2,  
[Pt(i-biq)2](PF6)2 and cisplatin using the neutral comet assay. A2780 cells were treated with 
three concentrations of compound for 24 hours prior to obtaining median % tail intensity 
values. Values are mean ± S.E.M. for data from three independent experiments. 
             
 105 
            
Figure 2.10.2-2 Evaluation of genotoxic effects of treatment of [Pd(i-biq)2](BF4)2,  
[Pt(i-biq)2](PF6)2 and cisplatin using the neutral comet assay. A2780 cells were treated with 
three concentrations of compound for 24 hours prior to obtaining median % tail intensity 
values. Values are mean ± S.E.M. for data from three independent experiments. Significant 
difference from control (p<0.05 *; p<0.01 **) (One-way ANOVA followed by Tukey test). 
The data shows that there is a statistically significant difference between the median 
percentage tail intensities of each complex and the untreated control cells (p<0.05) at 
the IC50/2 and IC50 concentrations tested. No significant difference was observed at 
the IC50/4 concentration for either complex. This demonstrates that at concentrations 
exceeding the IC50/2 concentration, both the palladium and platinum complexes 
induce a greater number of DSBs compared to untreated control cells, indicating a 
degree of genotoxicity in their behaviour. 
At each concentration tested, both complexes appear to cause comparable 
amounts of DNA damage. Since the treatment concentrations are related to the IC50 
value for each compound independently, this means that the same degree of 
damage is induced by different concentrations of each compound. This might be 
expected, as it reflects the difference in cytotoxicity of the two compounds. It is no 
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surprise therefore, to observe that treatment at the IC50 concentration induces a 
similar degree of damage, despite cells being exposed to an approximately 2.5–fold 
greater concentration of platinum complex versus palladium complex. Both 
complexes caused a concentration-dependent increase in DNA strand breaks that 
became statistically significant at concentrations greater than IC50/2. 
 
Compared to cisplatin, both complexes induce more DSBs, resulting in higher 
median % tail intensities at each concentration tested. Indeed, the differences in 
median % tail intensities observed for cisplatin are not statistically significant when 
compared to untreated control cells. The genotoxicity with respect to DSBs is 
therefore greater for both the palladium and platinum complex than for cisplatin. This 
is not entirely surprising given that cisplatin’s genotoxicity is predominantly due to 
SSBs that occur as a result of DNA repair mechanisms attempting to remove the 
crosslinked adducts from the affected DNA regions.68 Consequently, cisplatin alone 
would not be expected to exhibit significant tail moments when analysed under 
neutral assay conditions.  
The genotoxicity displayed by both complexes is reasonably minimal, with less 
than 8% of the cell’s DNA occupying the tail region upon treatment of either complex 
at its cytotoxic (IC50) concentration. At this biologically relevant concentration, there is 
no statistically significant difference in tail intensities between the two complexes, 
indicating that their mechanisms of action may well be similar. The significance of the 
role that genotoxicity plays towards the overall cytotoxicity of both compounds is 
likely the same, since the occurrence of DSBs is the same at cytotoxic 
concentrations. 
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2.11 Cell cycle analysis 
2.11.1 Cell cycle 
Cells undergo a regular cycle of division separated by periods of cell growth, known 
as the cell cycle and defined by three stages; interphase, nuclear division and cell 
division (Figure 2.11.1-1).  
 
Figure 2.11.1-1 The cell cycle 
Often termed the resting phase because no division takes place, interphase is 
divided into three stages. First gap phase (G1) involves the production of proteins that 
are essential for the synthesis of cell organelles. Synthesis phase (S) involves the 
semi-conservative replication of DNA, in order that the resulting daughter cells may 
be genetically identical. Second gap phase (G2) is a time when cell organelles grow 
and divide and energy stores are increased in preparation for nuclear and cell 
division.  
Nuclear division can take place by either mitosis or meiosis to produce either 
two genetically identical daughter nuclei or four genetically distinct daughter nuclei, 
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respectively. The latter occurs exclusively in sexual reproduction. During mitosis, the 
nucleus divides into two identical daughter cells (clones). Cell division follows, 
whereby the whole cell divides into two in a process called cytokinesis.  
Typically, a mammalian cell takes about 24 hours to complete a cell cycle, 
with approximately 90% of that time spent in interphase. To ensure cell division 
occurs correctly, control mechanisms known as cell cycle checkpoints exist. Typically 
consisting of a network of regulatory proteins, these checkpoints are used by the cell 
to monitor and regulate the progress of the cell cycle, preventing progression to the 
next phase until checkpoint requirements have been met. There are three main 
checkpoints (G1, G2, M) responsible for ensuring that incomplete or damaged DNA 
is not inherited by daughter cells. 
 
2.11.2 Flow cytometry with propidium iodide staining 
First described in 1969, cell cycle analysis by quantification of DNA content 
was one of the earliest applications of flow cytometry.69 Staining of the DNA with 
propidium iodide (PI) allows cells to be categorized by phase, based on their 
fluorescence output.70 This is based on the premise that PI binds stoichiometrically to 
DNA. Cells that are in S phase will have more DNA than cells in G1, taking up 
proportionally more dye and exhibiting a greater fluorescent output until they have 
doubled their DNA content. Cells in G2 will be approximately twice as bright as cells 
in G1.  
This process allows the cell cycle to be probed, providing insight into the stage 
at which normal cell activity is interrupted, resulting in cell cycle arrest. The phase in 
which cell cycle arrest occurs in treated cells can be directly compared to control cells 
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(untreated, PI stained). Knowledge of the stage in which cell cycle arrest occurs 
following compound treatment provides information about the types of processes that 
may be experiencing interference. This information is invaluable in elucidating a 
possible mechanism of action of the drug.  
 
2.11.3 Cell cycle arrest results 
Cells were treated at two different concentrations of compound ([IC50/10], 
[IC50/2]) for a period of 24 hours prior to sample preparation. Cells were fixed in 
ethanol to ensure permeability of the cell membranes to ribonuclease A and 
propidium iodide for the following stages. Ribonuclease A was first added to the fixed 
cells to degrade RNA, resulting in only the remaining DNA being stained with 
propidium iodide. Following sample preparation, the passage of cells through the flow 
cytometer’s laser generates a fluorescence pulse that correlates with the amount of 
PI and therefore the total amount of DNA in the cell. Plots of forward scatter (FS) vs. 
side scatter (SS) and pulse width vs. pulse area were recorded during sample 
analysis.  
Following sample analysis, cell doublets were excluded from the data 
analysis. This is crucial, because a doublet of two cells in G0/G1 has the same total 
amount of DNA and thus the same fluorescence output as a single cell in G2/M.71 
These doublets would therefore create false positive results for G2/M cells. The 
identified single cell population was manually gated (excluding debris), and the gate 
applied to a PI histogram displaying the distribution of cells. Application of a curve 
cell cycle fit to the histrogram generated cell cycle statistics. This scheme of post-
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processing, shown in Figure 2.11.3-1, enabled quantification of the percentage of 
cells per cell cycle phase (G0/G1, S phase, G2/M). 
      
 
Figure 2.11.3-1 (a) Representative scatter plot of raw data showing gated region; (b) 
Histogram showing curve fitting to determine cell cycle stage proportions; (c-d) Overlay of 
histograms (control, complex [IC50/10]) showing the redistribution of cells following 24 hour 
treatment with (c) [Pd(i-biq)2](BF4)2 (d) [Pt(i-biq)2](PF6)2. 
The percentage of cells per phase was calculated as an average of two or three 
independent experiments, with the results listed in Table 2.11.3-1, and displayed in 
Figure 2.11.3-2. 
gated cells 
(a)                                                             (b)  
 
 
 
 
 
 
(c)                                                             (d) 
cell debris 
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Compound 
Cell cycle phase (%) 
[IC50/10] 
G0/G1 S G2/M 
Control 65.9 ± 5.7 27.8 ± 5.7 6.3 ± 1.2 
[Pd(i-biq)2](BF4)2 45.4 ± 1.2 31.3 ± 0.9 23.4 ± 0.4 
[Pt(i-biq)2](PF6)2 47.7 ± 1.2 29.0 ± 0.2 23.3 ± 1.0 
cisplatin 29.8 ± 0.7 61.0 ± 2.6 8.5 ± 2.0 
	
[IC50/2] 
		
G0/G1 S G2/M 
Control - - - 
[Pd(i-biq)2](BF4)2 53.1 ± 0.7 23.0 ± 2.1 24.0 ± 1.4 
[Pt(i-biq)2](PF6)2 59.2 ± 1.1 22.9 ± 0.8 18.0 ± 1.8 
cisplatin 30.6 ± 0.3 63.8 ± 0.7 5.6 ± 0.4 
 
Table 2.11.3-1 Evaluation of cell cycle arrest following treatment of [Pd(i-biq)2](BF4)2,  
[Pt(i-biq)2](PF6)2, and cisplatin using PI-stained flow cytometry. A2780 cells were treated with 
two concentrations of compound for 24 hours prior to obtaining percentage of cells per phase 
(indicating the phase at which cell cycle arrest has occurred). Values are mean ± S.E.M. for 
data from three (control, cisplatin) or two independent experiments (palladium, platinum). 
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Figure 2.11.3-2 Evaluation of cell cycle arrest following treatment of [Pd(i-biq)2](BF4)2,  
[Pt(i-biq)2](PF6)2, and cisplatin using PI-stained flow cytometry. A2780 cells were treated with 
two concentrations of compound for 24 hours prior to obtaining percentage of cells per phase 
(indicating the phase at which cell cycle arrest has occurred). Values are mean for data from 
three (control, cisplatin) or two independent experiments (palladium, platinum). 
 
The data shows a marked shift in the phase at which cell cycle arrest occurs when 
comparing control cells to treated cells. Control cells predominantly occupy the 
G0/G1 phase (~66%), with a reasonable number of cells in the S phase (~28%) and 
the remaining cells found in the G2/M phases (~6%). 
The majority of cells treated with cisplatin accumulate in the S phase (~61%). 
Fewer cells are found in the G0/G1 phases compared to the control (~30%). In 
accordance with its reported activity, this demonstrates that cisplatin arrests cells 
during the S-phase of the cell cycle.72 
Treatment with either the palladium or platinum i-biq complex at the lower of 
the two concentrations tested ([IC50/10]) results in a noticeable change in cell phase 
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distribution, whereby the G0/G1 occupancy has decreased (~45-48%) alongside a 
significant increase in G2/M occupancy (~23%). The S phase occupancy is 
comparable to that seen in the control. These observations are indicative of G2/M 
phase arrest following complex treatment. The ability to observe such a striking shift 
at such low concentrations of either complex demonstrates the potent activity of 
these complexes in vitro. Indeed, at the higher concentration tested ([IC50/2]), the 
distribution of cells is largely unaltered (compared to the lower concentration 
[IC50/10]), indicating that the desired effect is achieved with minimal complex, and 
thus no further alteration in the distribution of cells occurs upon exposure to higher 
concentrations. Additional complex availability at high treatment concentrations 
appears to act as somewhat of an excess, with G2/M phase arrest already 
accomplished. The similarity between the two complexes is unsurprising, given that 
the concentrations were again related to their IC50 concentrations, and that the 
results of the comet assay have already shown that their modes of action are very 
likely to be similar on account of their comparable genotoxicity.  
G2/M cell phase arrest has previously been reported in G-quadruplex binding 
ligands including the cationic porphyrin TMPyP4.73 Paralleled by telomerase 
inhibition, Hurley et al. noted the ability of TMPyP4 to inhibit telomerase activity at 
concentrations that do not have general toxic effects on the cells. This type of effect 
has been witnessed herein, with a dramatic shift in cell cycle arrest occurring at 
treatment concentrations far below those that induce cytotoxicity. 
 
The arrest of the cell cycle at a different phase (compared to cisplatin) following 
treatment with these complexes likely indicates an alternative mode of action. The 
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arrest of cells is known to be regulated by complex pathways described as cell-cycle 
checkpoints,74 the best known checkpoint being mediated by the tumour-suppressor 
protein p53.75,76 Arrest at different stages of the cell cycle may indicate the 
perturbation of different checkpoint processes, enabling comparison of the 
mechanisms of action.  
Arrest in G2/M suggests that DNA replication is able to proceed as normal 
(since S phase is not arrested) however, once replicated, the cells may be unable to 
separate successfully during cytokinesis, therefore preventing cell cycle progression 
into G2/M. It may be that compound treatment inhibits some process involving the 
newly-replicated DNA, such as spindle formation or separation of the chromosomes 
during mitosis. One such example, is that of paclitaxel (Taxol), a chemotherapy drug 
used to treat various cancers including ovarian, breast and non-small cell lung 
carcinoma. Taxol-treated cells have defects in mitotic spindle disassembly, inhibiting 
chromosome segregation and cell division, ultimately triggering apoptosis or 
reversion to the G-phase without cell division.  
 
2.12 Cell uptake and localisation 
2.12.1 Inductively coupled plasma mass spectrometry 
Inductively coupled plasma mass spectrometry (ICP-MS) is a highly sensitive 
analytical technique used for elemental determinations. Detection limits below parts 
per billion levels (sub-ppb) are routinely achieved for most elements. This technique 
can therefore be utilised to determine the cellular uptake of metal complexes in vitro. 
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Implementation of a suitable cell fractionation procedure prior to analysis can further 
enable cellular localisation to be determined.  
 
2.12.2 Cell uptake results 
To enable direct comparison between samples, cells were treated with a single 
concentration of compound for a single time period and the quantity of either 
platinum or palladium analysed by ICP-MS. A period of 3 hours incubation was 
chosen, since platinum compounds have been shown to enter the cell environment 
relatively quickly, in a couple of hours in some cases.77 Cells were treated with 20 µM 
compound. This concentration was selected because it was deemed high enough to 
ensure cell uptake took place in the 3 hour timeframe, whilst avoiding the premature 
cell death that would inevitably occur with higher concentrations and therefore 
prevent accurate analysis.  
Following compound treatment, samples were processed to isolate nuclear 
and cytoplasmic fractions, with the uptake in these portions compared to whole cell 
uptake. Untreated control samples and cisplatin-treated samples were prepared for 
comparison. The elemental concentration in parts per billion for one set of samples is 
detailed in Table 2.12.2-1 and displayed in Figure 2.12.2-1. 
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Compound 
Concentration (parts per billion) 
Pt Pd 
whole 
cell 
cytoplasmic 
fraction 
nuclear 
fraction 
whole 
cell 
cytoplasmic 
fraction 
nuclear 
fraction 
Control < 0.05 0.08 0.08 < 0.2 < 0.2 < 0.2 
[Pd(i-biq)2][BF4]2 - - - 2.31 1.14 1.40 
[Pt(i-biq)2][PF6]2 2.66 1.02 2.34 - - - 
cisplatin 1.00 0.79 0.20 - - - 
 
Table 2.12.2-1 Evaluation of cell uptake and localisation following treatment of  
[Pd(i-biq)2](BF4)2, [Pt(i-biq)2](PF6)2, and cisplatin using ICP-MS. A2780 cells were treated with 
20 µM compound for 3 hours prior to obtaining palladium and platinum concentrations. 
Values are from one independent experiment. 
 
Figure 2.12.2-1 Evaluation of cell uptake and localisation following treatment of  
[Pd(i-biq)2](BF4)2, [Pt(i-biq)2](PF6)2, and cisplatin using ICP-MS. A2780 cells were treated with 
20 µM compound for 3 hours prior to obtaining palladium and platinum concentrations. 
Values are from one independent experiment. 
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It is immediately evident that the concentration of both palladium and platinum 
present in treated cells is much greater than that present in untreated control cells. 
Regarding platinum, it is exciting to observe a greater concentration of platinum in 
cells following treatment with compound (8) compared to cisplatin. The ability to 
achieve cell uptake exceeding that of one of the most widely used and effective 
chemotherapeutic drugs is potentially very important and reflects the increased 
cytotoxicity observed for this compound (compared to cisplatin). In addition to 
exhibiting approximately 2.6-fold greater uptake across the whole cell, it is 
encouraging to examine the distribution. Whilst the majority of internalised cisplatin is 
located in the cytoplasmic fraction (~80%), with only a small proportion finding its way 
into the nucleus (~20%), platinum complex (8) shows a much higher localisation in 
the nuclear fraction demonstrating improved nuclear uptake. The palladium complex 
(7) shows greater uptake than the platinum complex (see Appendix B for data 
analysis quantifying the approximate concentration (µM) inside cells), with the 
majority of complex again localised in the nucleus. It is worth noting that this data 
was recorded at a relatively early time point (3 hours exposure) and that the 
distribution may change over time. 
In light of the intended cellular target of these complexes, namely  
G-quadruplex forming regions of DNA, and their nuclear location within the cell 
environment, it is very promising to see increased overall cellular uptake coupled with 
improved nuclear uptake. These observations also account for the improved 
cytotoxicity (lower IC50 values) of these compounds compared to cisplatin (which also 
has non-nuclear DNA targets) (see 2.9.2), whereby their increased whole cell and 
nuclear localisation permits enhanced complex-DNA interaction. 
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In theory, the sum of the elemental concentration in the nuclear and cytoplasmic 
fractions should total the concentration observed in the whole cell portion. Whilst this 
is observed for both the palladium complex (7) and cisplatin, it is not the case for the 
platinum complex (8) analysed, where the two fractions combined exceed the 
concentration detected in the whole cell.  
Since the overall and cytoplasmic uptake is comparable (within the same 
order of magnitude based on a single set of data) for both complexes, it is suggested 
that the recorded nuclear concentration of platinum is higher than the actual value, 
which is proposed to be similar to the nuclear concentration of palladium. Repeat 
measurements would enable mean and error values to be calculated, which would be 
highly beneficial in corroborating this theory, with the expectation that the 
concentration of platinum in the nuclear fraction would decrease to approximately the 
proportion of palladium observed in palladium-treated cells. 
It is regrettable that only a single set of ICP-MS data was available for 
inclusion in this thesis. Disappointingly, due to the breakdown of the ICP-MS 
instrument, a further two sets of samples currently await analysis. Consequently, the 
initial conclusions discussed herein are preliminary in nature, with completion of the 
outstanding analysis certainly required before reliable conclusions can be drawn. 
Nevertheless, the early indication that substantial cellular uptake and nuclear 
localisation is occurring following treatment with either complex is very promising and 
supports the ongoing study of these exciting new compounds.  
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2.13 Part II: Conclusions 
Both metal-biisoquinoline compounds have shown cytotoxicity exceeding that of 
cisplatin against A2780 cells, following a 24-hour incubation period. Demonstrating 
IC50 values in the low micromolar range, the palladium compound shows 
approximately 2.5-fold greater activity than the platinum complex in this cell line. Cell 
uptake studies demonstrated the ability of both complexes to successfully enter the 
cell, accumulating in the nucleus in approximately 7-fold greater concentration than 
that observed for cisplatin. This is highly likely to contribute to the improved 
cytotoxicity observed for these complexes. Furthermore, there is preliminary 
evidence of increased cell uptake and localisation of the palladium complex, which 
would account for its increased cytotoxicity, although this difference requires future 
validation and analysis for its significance through repeat experiments and statistical 
analysis.  
Both compounds display some evidence of genotoxicity, as indicated by the 
occurrence of DNA double-strand breaks following treatment. Comparable levels of 
DSBs were observed for both complexes upon treatment at their respective IC50 
concentrations. Further investigation into the incidence of single strand breaks would 
be beneficial. In contrast to the characteristic S phase cell cycle arrest induced as a 
result of cisplatin treatment, cells overwhelmingly undergo G2/M phase arrest upon 
exposure to very low concentrations of both complexes (<1 µM).  
The observed similarities between the two complexes indicate a similar 
mechanism of action within cells, resulting in comparable outcomes.  
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2.14 Experimental materials and methods 
2.14.1 General chemistry 
Reagents and solvents were obtained from Sigma Aldrich, Fisher Scientific, Scientific 
Lab Supplies, Acros Organics and VWR. All solvents were of standard grade and 
were used without purification. Unless otherwise stated, all reactions were carried out 
under standard conditions (298 °K, 1 atm pressure).  
 
2.14.2 Analytical characterisation techniques 
All characterisation techniques were conducted within the School of Chemistry at the 
University of Birmingham. Nuclear Magnetic Resonance (NMR) spectra were 
recorded in deuterated CDCl3, CD3CN, CD3OD and d6-DMSO. 1H-NMR spectra were 
recorded on a Bruker AV(III)300 and AV(III)400 instruments, operating at 300 and 
400 MHz respectively. 13C-NMR spectra were recorded on a Bruker AV(III)400 
instrument operating at 100 MHz. Electrospray Ionisation Mass Spectrometry (ESI-
MS) spectra were carried out by Dr. Chi Tsang and Dr. Peter Ashton (Analytical 
Facility). Spectra were recorded on a Waters LCT Time of Flight Spectrometer. UV-
Visible (UV-Vis) spectra were recorded on a Varian Cary 5000 spectrometer.  
 
2.14.3 Chemical synthesis 
Isoquinoline-1,3-dione (1)  
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Homophthalic acid (15.0 g, 82.5 mmol) was dissolved in 1,2-dichlorobenzene (70 
mL) by heating to 200 °C. Following the removal of the condenser, concentrated 
NH4OH (10 mL) was added cautiously to the solution dropwise over a period of 1 h. 
The reaction was heated for a further 30 minutes, allowing some solvent to 
evaporate. Upon cooling to room temperature, MeOH (70 mL) was added and the 
mixture left to stand for 3 h. The precipitate was collected by filtration, washed with 
MeOH and dried under reduced pressure to afford (1) as peach shards (11.4 g, 
86%).  
1H NMR (300 MHz, d6-DMSO): δ 11.32 (1H, s, NH(2)), 8.02 (1H, d, J = 6.0, H(9)), 7.64 
(1H, t, J = 6.0, H(7)), 7.45 (1H, t, J = 6.0, H(8)), 7.38 (1H, d, J = 6.0, H(6)), 4.03 (2H, s, 
H(4)). 13C NMR (100 MHz, d6-DMSO): δ 171.0, 165.3, 136.6, 133.5, 127.9, 127.4, 
127.2, 124.9, 35.9. m/z (ESI +): 162 ([C9H7O2N + H]+). 
 
1,3-dichloroisoquinoline (2)  
 
Phenylphosphonic dichloride (22.0 mL, 155 mmol) was added to (1) (11.0 g, 68.7 
mmol) and the solution heated at 160 °C under reflux for 3 h. The reaction was left to 
cool to room temperature before leaving to stand for 3 h. The yellow solid which 
formed was dissolved in THF (345 mL) and water (105 mL) and the solution 
concentrated in vacuo to remove the THF. The remaining aqueous slurry was 
neutralized with concentrated NH4OH before being extracted with EtOAc. The 
organic phases were combined, washed with water and brine, and dried over Na2SO4 
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before being concentrated in vacuo to afford (2) as yellow powdery solid (11.5 g, 
85%). 
1H NMR (300 MHz, d6-DMSO): δ 8.27 (1H, d, J = 9.0, H(9)), 8.13 (1H, s, H(4)), 8.07 
(1H, d, J = 8.7, H(6)), 7.94 (1H, t, J = 8.9, H(7)), 7.83 (1H, t, J = 8.9, H(8)). 
13C NMR (100 MHz, d6-DMSO): δ 224.3, 149.6, 132.8, 129.8, 126.9, 125.7, 120.4, 
100.5, 77.2.  m/z (ESI +): 198 ([C9H5Cl2N]+) . 
 
3-chloroisoquinoline (3) 
 
A mixture containing (2) (10.0 g, 50.5 mmol), red phosphorus (3.44 g, 111 mmol) and 
a solution of hydriodic acid (21 mL) in acetic acid (50 mL) was heated at 125 °C 
under reflux for 24 h. The red-brown reaction mixture was cooled to room 
temperature and poured onto ice, and the resulting solution neutralised to pH 7 by 
the addition of conc. NaOH solution. The solution was extracted with DCM (2 × 300 
mL), and the organic phases combined and filtered before being dried over MgSO4 
and concentrated in vacuo. The residue was purified by column chromatography on 
silica gel, eluting with EtOAc:hexane (9:1) to afford (3) as yellow solid (2.54 g, 30%). 
1H NMR (300 MHz, d6-DMSO): δ 9.23 (1H, s, H(1)), 8.19 (1H, d, J = 9.0, H(9)), 8.06 
(1H, s, H(4)), 7.97 (1H, d, J = 9.0, H(6)), 7.81 (1H, t, J = 9.0, H(7)), 7.72 (1H, t,  J = 9.0, 
H(8)). 13C NMR (100 MHz, d6-DMSO): δ 153.0, 144.5, 137.3, 131.7, 127.9, 127.7, 
127.1, 125.8, 119.5. m/z (ESI +): 164 ([C9H6ClN + H]+) . 
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3,3-biisoquinoline (4) 
 
Operating under an argon atmosphere [NiCl2.6H2O] (247 mg, 1.04 mmol), PPh3 (1.09 
g, 4.16 mmol) and zinc dust (washed in dilute HCl, dd. H2O, EtOH, acetone and 
Et2O; 73.1 mg, 1.10 mmol) were added to a Schlenk tube. DMF (12 mL) was then 
added via syringe into the sealed vessel. The brick-red solution that formed upon 
heating to  70°C was left to stir for 1 h. Aryl halide (see below, 1.04 mmol) dissolved 
in DMF (6 mL) was then added and the mixture left to heat at 70 °C for a further 4 h. 
After heating, and when the reaction returned to its original green colour, the mixture 
was cooled to room temperature and poured onto 7% NH4OH (18 mL). A small 
amount of concentrated NH4OH was added to ensure complete precipitation of the 
product. The product was extracted into 2:1 DCM:Et2O (3 × 60 mL) before removal of 
the organic solvent in vacuo. The remaining yellow-orange oil was diluted with DCM 
(40 mL) and the solution washed with water (4 × 13mL) and brine (26 mL) before 
drying over MgSO4 and removing the solvent in vacuo to yield pale yellow solid. 
Purification was achieved by column chromatography on silica gel, eluting the 
impurities with DCM and the product with EtOAc to afford (4) as pale yellow solid.  
Ar-X: (3), 3-chloroisoquinoline (170 mg, 1.04 mmol): (38.7 mg, 15%). 
Ar-X: (6), 3-bromoisoquinoline (215 mg, 1.04 mmol): (63.0 mg, 24%). 
1H NMR (300 MHz, d4-MeOD): δ 9.39 (2H, s, H(1)), 8.84 (2H, s, H(4)), 8.14 (2H, d, J = 
8.1, H(9)), 8.08 (2H, d, J = 8.1, H(6)), 7.83 (2H, t, J = 7.0, H(7)), 7.75 (2H, t, J = 7.0, 
H(8)). 13C NMR (100 MHz, d4-MeOD): δ 167.3, 164.0, 153.6, 138.2, 132.4, 129.2, 
N
3
N
2 1
10
54
9
8
76
 124 
128.9, 128.6, 119.2.  m/z (ESI +): 257 ([C12H18N2 + H]+) . 
 
1,3-dibromoisoquinoline (5) 
 
Operating under an argon atmosphere, phosphorus oxybromide (11.6 g, 41.0 mmol) 
was dissolved in 1,4-dioxane (42 mL) at room temperature. (1) (3.00 g, 18.7 mmol) 
was added in small portions over 5 minutes under a strong flow of argon (no stirring 
during addition) and the solution then heated at 120 ˚C under reflux for 35 minutes. 
The reaction solution was cooled, dissolved in CHCl3 (150 mL) and MeOH (25 mL) 
and the solvent removed in vacuo until solid formed. The resulting yellow crystals 
were collected by vacuum filtration, washed with 2-propanol, and dried at 50 ˚C to 
yield (5) as off-white solid (3.26 g, 61%). 
1H NMR (300 MHz, CDCl3): δ 8.26 (1H, d, J = 9.1, H(9)), 7.87 (1H, s, H(4)), 7.70-7.77 
(3H, m, H(6-8)).  13C NMR (100 MHz, CDCl3): δ 144.1, 138.9, 132.7, 132.1, 128.9, 
127.9, 127.6, 126.2, 124.2.  m/z (ESI +): 288 ([C9H5Br2N] + H]+) . 
 
3-bromoisoquinoline (6) 
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A mixture of (5) (5.91 g, 20.6 mmol), red phosphorus (1.40 g, 45.3 mmol) and a 
solution of hydriodic acid (6.50 mL) in acetic acid (25 mL) was heated at 125 °C 
under reflux for 24 h. The red-brown reaction mixture was cooled to room 
temperature and poured onto ice, and the resulting solution neutralised to pH 7 by 
the addition of conc. NaOH solution. The solution was extracted with DCM (2 × 300 
mL), and the organic phases combined and filtered to remove insoluble material, 
before being dried over MgSO4 and concentrated in vacuo. The red-brown residue 
was purified by column chromatography on silica gel, eluting with DCM:MeOH (9:1) 
to afford (6) as pale yellow solid (2.42 g, 57%). 
1H NMR (300 MHz, CDCl3): δ 9.04 (1H, s, H(1)), 7.97 (1H, d, J = 9.0, H(9)), 7.91 (1H, 
s, H(4)), 7.75 (2H, d, J = 9.1, H(6)), 7.72 (2H, t, J = 9.3, H(7)), 7.63 (1H, t, J = 9.4, H(8)). 
13C NMR (100 MHz, CDCl3): δ 152.7, 137.8, 135.8, 131.3, 127.7, 127.6, 127.5, 
125.6, 123.7. m/z (ESI +): 208 ([C9H6BrN + H]+) . 
 
[Pd(i-biq)2](BF4)2 (7) 
 
Under an argon atmosphere, i-biq (4) (5.00 mg, 19.0 µmol) was dissolved in dry 
acetonitrile (3 mL). Tetrakis(acetonitrile)palladium(II) tetrafluoroborate (4.50 mg, 10.0 
µmol) was then added under a strong flow of argon and the solution stirred overnight 
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at room temperature. The solution was filtered through a fine filter membrane and the 
filtrate concentrated in vacuo to form a yellow solid. The solid was washed with 
chloroform (2 mL), acetone (2 mL) and diethyl ether (2 mL) and left to dry under 
vacuum to yield [Pd(i-biq)2](BF4)2 as bright yellow solid (5.00 mg, 64%).  
1H NMR (300 MHz, CD3CN): δ 9.56 (4H, s, H(1)), 9.07 (4H, s, H(4)), 8.50 (4H, d, J = 
8.0, H(9)), 8.36 (4H, d, J = 8.0, H(6)), 8.21 (4H, t, J = 7.0, H(7)), 8.05 (t, 4H, J = 7.1, 
H(8)). m/z (ESI +): 309 ([Pd(C18H12N2)2]2+), 618 ([Pd(C18H12N2)2]+), 637 
([Pd(C18H12N2)2F]+), 653 ([Pd(C18H12N2)2Cl]+) . UV-Vis (15 % DMSO:85 % milliQ 
water):  λmax (nm) (εmax/dm3mol-1cm-1):  251 (95600), 305 (31600), 328 (27500), 370 
(16400). 
 
[Pt(i-biq)2][PF6]2 (8) 
 
Potassium tetrachloroplatinate (4.50 mg, 10.0 µmol) was dissolved in water (5 mL) 
before the addition of a suspension of i-biq (4) (5.50 mg, 20.0 µmol) in acetonitrile (5 
mL). The mixture was heated under reflux (105 °C) overnight, resulting in a yellow 
solution which was hot filtered through a fine membrane. A methanolic solution of 
NH4PF6 (slight excess 0.15 mmol) was then added to the filtrate, resulting in the 
immediate precipitation of an off-white solid. The product was collected by filtration 
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and carefully washed with chloroform (2 mL), methanol (2 mL) and diethyl ether (2 
mL) before drying under vacuum to afford [Pt(i-biq)2][PF6]2  as pale cream solid (2.80 
mg, 29%).  
1H-NMR (300 MHz, CD3CN): δ 9.56 (4H, s, H(1)), 9.07 (4H, s, H(4)), 8.50 (4H, d, J = 
8.1, H(9)), 8.36 (4H, d, J = 8.2, H(6)), 8.21 (4H, t, J = 7.4, H(7)), 8.05 (4H, t, J = 7.2, 
H(8)). m/z (ESI +): 353 ([Pt(C18H12N2)2]2+), 743 ([Pt(C18H12N2)2Cl + H]+). UV-Vis (15 % 
DMSO:85 % milliQ water):  λmax (nm) (εmax/dm3mol-1cm-1): 262 (72400), 335 (19300), 
382 (13000). 
 
[Au(i-biq)2](3Cl) (9) 
 
A mixture of sodium tetrachloroaurate(III) dihydrate (3.90 mg, 9.70 µmol) and i-biq (4) 
(5.00 mg, 19.5 µmol) in MeOH (10 mL) was heated under reflux (90 °C) overnight. 
The resulting yellow solution was hot filtered through a fine membrane and reduced 
in vacuo to yield dark yellow-orange solid. Following careful washing with DCM and 
drying under vacuum, tan solid remained (4.70 mg, 59%).  
1H-NMR (300 MHz, MeOD): δ 10.32 (4H, s, H(1)), 9.37 (4H, s, H(4)), 8.63 (4H, d, J = 
8.4, H(9)), 8.38 (4H, d, J = 8.2, H(6)), 8.28 (4H, t, J = 7.8, H(7)), 8.11 (4H, t, J = 7.5, 
H(8)). m/z (ESI +): 488 ([Au(C18H12N2)(OH)2 + H]+), 709 ([Au(C18H12N2)2]+) . 
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2.14.4 ESI-MS nucleotide binding studies 
9-ethylguanine (9EG) was stored at 4 ˚C in a dessicator and freshly dissolved in  
sodium cacodylate buffer (1 mM, pH 6.8) before each experiment. 9-methyladenine 
(9MA), 1-methylcytosine (1MC), 1-methylthymine (1MT) and 9-methylguanine (9MG) 
were stored at 4 ˚C in a dessicator and freshly dissolved in DMSO (1 mM) before 
each experiment. A solution of all four bases was prepared in DMSO (1 mM). Stock 
solutions of both palladium (7) and platinum (8) complexes in DMSO were prepared. 
Equal volumes of nucleobase and complex solutions were added together, to mix 
complex and nucleobase(s) in 1:1 ratio. The solutions were incubated at 37 ˚C in the 
dark for 72 h. ESI-MS spectra were recorded periodically. ESI-MS spectra of solvent 
control samples (buffer, buffer + DMSO, buffer + base, buffer + base + DMSO) were 
also recorded, to account for peaks arising from solvent effects. 
 
2.14.5 General cell culture 
Preparation of complete media 
Cells were cultured in GIBCO® Roswell Park Memorial Institute (RPMI-1640) media 
supplemented with foetal bovine serum, FBS (10% v/v), penicillin (100 U/mL), 
streptomycin (100 ug/mL) and L-glutamine (2 mM), along with antimitotic solution (1 
% v/v, 1×). Complete media was stored at 4 °C and warmed to 37 °C in a water bath 
before use.  
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Cell line thawing and initiation 
The A2780 human ovarian carcinoma cell line was obtained from ECACC (European 
Collection of Cell Cultures). Cryovials containing cells were removed from liquid 
nitrogen storage and quickly thawed in a water bath (37 °C) before immediate 
transfer of the contents to a 75 cm3 tissue culture flask (T75, Corning Costar) 
containing warm complete media (20 mL). Cultures were incubated at 37 °C in 5% 
CO2, 95% air (Sanyo, MCO-17A) for 6 hours to allow cell adhesion. Due to the 
presence of DMSO in the media from the cryopreservation process, a media change 
must be carried out as soon as adhesion has occurred. 
 
Cell passage 
Upon reaching 80% confluency, cells were passaged (approximately twice weekly). 
Complete RPMI-1640 media, phosphate buffered saline (PBS, 0.01 M) and trypsin-
EDTA (1×) were warmed to 37 °C in a water bath. Media was removed from the T75 
flask and PBS added (10 mL). The flask was tilted back and forth to ensure the entire 
surface was thoroughly washed to remove dead cells and cell debris. The PBS was 
removed and trypsin-EDTA (3 mL) added, followed by incubation at 37 °C for 5 
minutes. To ensure cell detachment, flasks were gently tapped and checked under 
the microscope to confirm detachment of the cell monolayer before proceeding. 
Fresh media (10 mL) was then added to inhibit the trypsin-EDTA. Following thorough 
rinsing of the flask surface, the cell suspension was transferred to a 15 mL falcon 
tube. Cells were collected by centrifugation (Rotofix 32, Hettich Zentrifugen, 
Germany) at 1500 rpm for 5 minutes at room temperature. The supernatant was 
discarded, with the cell pellet resuspended in 1 mL complete media, before aliquoting 
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into new T75 flasks. 
 
Cell counting 
To enable accurate and uniform cell seeding across wells, cells were counted using a 
Neubauer haemocytometer. Following resuspension of the cell pellet in 1 mL fresh 
media, 10 µL of this cell suspension was added to 90 µL PBS in an eppendorf (1:10 
dilution). 10 µL of this mixture was pipetted underneath each side of the coverslip 
placed onto the haemocytometer slide. Viewed under a microscope (10× objective 
lens), cells present in two of the grids on each end of the haemocytometer were 
counted and averaged (Note. Cells positioned along the top and left hand edges 
were included in the count, with cells falling along the bottom and right edges 
excluded). The number of cells per millilitre was calculated using the following 
equation: 
Cell density (cells/mL) = Average number of cells counted × dilution factor (10) × 104 
Multiplication of this value by both the desired number of cells per well and the 
number of wells to be seeded gives a required volume (mL), allowing a media-cell 
suspension to be made up. This mixture can then be equally aliquoted out between 
all wells to ensure an even distribution of cells.  
 
Cryopreservation of cell line 
To ensure a stock of viable cells was maintained for future use, low passage 
confluent cultures were cryopreserved. Cells were collected and the cell pellet 
resuspended in freezing medium (3 mL, 10% v/v DMSO in FBS) and 1 mL aliquots 
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transferred to cryovials (Nunc). Following overnight storage in a freezer (-80 °C), 
cryovials were transferred to vapour phase liquid nitrogen for long term storage. 
 
2.14.6  MTT assay for cell viability 
Thiazolyl blue tetrazolium bromide (MTT) and Hybriderm-DMSO were obtained from 
Sigma, UK. Cells were seeded into 96 well microtiter plates (Corning Costar) at 4,000 
cells per well, with a total volume of 100 µL complete media cell suspension in each 
well. The plates were incubated for 24 hours before treatment to allow cell adhesion 
to the well base. The two biisoquinoline complexes required DMSO to aid solubility. 
The volume of DMSO per well did not exceed 2 % v/v. Cisplatin was dissolved in 
complete media alone. Eight different concentrations were tested for each 
compound. Compound treatments were made up into 100 µL total volume (at twice 
the desired treatment concentration to account for the dilution) before addition to the 
100 uL cell solution already in the wells. Two control lanes (B and K) were prepared 
by treating with complete media alone (B5-8 and K5-8) or 2 % DMSO/98 % complete 
media as a vehicle control (B1-4 and K1-4). Each test was run in quadruplicate and 
repeated three times. The treated plates were returned to the incubator for 24 hours. 
The cell viability was determined by adding 20 µL of a 5 mg/mL MTT solution in PBS 
to each well (final concentration 0.5 mg/mL), excluding one set of control wells (K1-
8), followed by a further 2 hours incubation. The medium was carefully removed by 
aspiration from all wells, before washing with PBS (200 µL) followed by the addition 
of 200 µL DMSO to all wells to dissolve the purple formazan crystal product. The 
plates were rocked for 2 hours before the absorbance was measured at 590 nm 
using a microplate reader (BioRad). Plotting the absorbance values measured versus 
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the concentration of treatment allows the IC50 to be determined.  
 
2.14.7  Neutral comet assay for DNA double strand breaks 
Cells were seeded into a 12 well plate (Corning Costar) at 80,000 cells per well, with 
a total volume of 800 µL complete media cell suspension in each well. The plates 
were incubated for 24 hours before treatment to allow cell adhesion to the well base. 
Both biisoquinoline complexes required DMSO to aid solubility. The volume of DMSO 
per well did not exceed 2% total. Cisplatin was directly dissolved in complete media 
and further diluted. Three different concentrations were tested for each compound. 
Compound treatments were made up into 800 µL total volume in media, which was 
added fresh into wells following removal of the seeding media and a single wash with 
PBS (500 µL). Control wells received fresh complete media. Treated plates were 
returned to the incubator for 24 hours. Following removal of media, cells were 
washed with 1 ml PBS and collected by scraping into 300 µL PBS before transferring 
into eppendorfs and centrifuging at 13000 rpm for 5 minutes. Cell pellets were 
resuspended in 80 µL PBS. An aliquot of resuspended cells (15 µL) was placed into 
a sterile tube containing 150 µL low melting point agarose (0.5% w/v LMPA warmed 
for 1 minute in the microwave, 600 W) and aspirated to aid mixing. A portion of this 
cell suspension (150 µL) was then transferred to coat a glass microscope slide (VWR 
International), precoated with normal melting point agarose (0.5% w/v NMPA). Glass 
coverslips were added to the slides before placing them on a metal tray over ice for 
20 minutes to solidify. Coverslips were removed (horizontal sliding away from the gel 
surface) and the slides incubated at 4 °C for 1 hour in a Coplin jar containing lysis 
buffer (146 mM NaCl, 30 mM Na2EDTA, 1 mM Tris-HCl, 1% sodium N-lauryl 
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sarcosinate, pH 9). Following lysis, slides were transferred to a horizontal 
electrophoresis tank containing cold electrophoresis buffer (0.4 M Tris base, pH 8.3) 
for 20 minutes in the dark to allow DNA unwinding to occur. DNA was then subjected 
to electrophoresis (32 V) for a further 20 minutes. Slides were removed from the tank 
and washed three times (5 minutes) with neutralisation buffer (0.4 M Tris base, 
adjusted to pH 7.5 with HCl) and once with dH2O. Slides were subsequently stained 
with 75 µL/slide SYBR Gold solution (Invitrogen 1 µL/mL in dH2O) before addition of 
a coverslip and overnight incubation at 4 °C in a moist box in the dark. The slides 
were examined on a Zeiss Axiovert 10 inverted fluorescence microscope (Zeiss Ltd, 
Gottingen, Germany) fitted with a 515-560 nm excitation filter and a 590 nm barrier 
filter. A USB digital camera (Merlin, Allied Vision Technologies) received the images, 
which were analysed using a computer-based image analysis system, Comet Assay 
IV (Perceptive Instruments). One hundred randomly selected nuclei were scored and 
analysed per slide. Median percentage tail intensity was the parameter chosen for 
assessing the extent of DNA damage. For each condition tested, median values were 
obtained from three independent experiments and analysed.  
 
2.14.8  Flow cytometry (inc. PI staining) for cell cycle analysis 
Cells were seeded into a 6 well plate (Corning Costar) at 300,000 cells per well, with 
a total volume of 2 mL complete media cell suspension in each well. The plates were 
incubated for 24 hours before treatment to allow cell adhesion to the well base. Both 
biisoquinoline complexes required DMSO to aid solubility. The volume of DMSO per 
well did not exceed 2% v/v. Cisplatin was dissolved in complete media. Two different 
concentrations were tested for each compound. Compound treatments were made 
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up into 2000 µL total volume in media, which was added fresh into wells following 
removal of the seeding media. Two control wells received fresh media alone. Each 
test was repeated two or three times. The treated plates were returned to the 
incubator for 24 hours. Each well was washed with 2 mL PBS following removal of 
media. Cells were collected following the standard trypsin-EDTA protocol and the cell 
pellet washed with 2 mL PBS. The cell pellet was vortexed gently to prevent 
aggregation, as 3 mL ice cold 70% ethanol was carefully added dropwise. The 
sample was then placed on ice for 30 min. Fixed cells were stored at 4 °C overnight. 
Cells were centrifuged at 1500 rpm for 5 mins (ensuring a visible pellet is observed). 
Following careful aspiration of the supernatant, the pellets were washed with 3 mL 
PBS before being resuspended in 500 µL PBS. Samples were treated with RNAse A 
solution  
(50 µL, 1 mg/mL) and propidium iodide (10 µL, 1 mg/mL) and incubated at room 
temperature for 30 min in the dark. Samples were mixed (vortex mixer) for 10 
seconds before analysis. Propidium iodide has a maximum emission of 605 nm. 
 
2.14.9  Inductively coupled plasma mass spectrometry for cell uptake  
Cells were seeded into 25 cm3 flasks, T25 (Corning Costar) at 2,000,000 cells per 
well, with a total volume of 3 mL complete media cell suspension in each. Flasks 
were incubated for 24 hours before treatment to allow cell adhesion to the flask 
surface. Both biisoquinoline complexes required DMSO to aid solubility. The volume 
of DMSO per well must not exceed 2% v/v total. Cisplatin was dissolved in complete 
media. A single concentration was tested for each compound, for a single time 
period. Compound treatments were made up into 3 mL media and administered to 
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flasks following the removal of the seeding media and washing with PBS. The control 
flask received fresh media alone. Flasks were returned to the incubator for 3 hours, 
after which time the media was removed and the flask washed three times with PBS 
(5 mL) to remove any excess compound not taken up into cells. Cells were collected 
following the standard trypsin-EDTA protocol and the cell pellet isolated following 
removal of the supernatant. Following resuspension in 1 mL media, the pellet was 
split into two 500 µL aliquots, each containing approximately 1 million cells. The first 
aliquot was pelleted and washed twice with PBS (200 µL), before resuspension in 
200 µL PBS ready for whole cell digestion. The second aliquot was processed to 
enable separation and isolation of the nuclear and cytoplasmic fractions. This was 
achieved using a Nuclear/Cytosol Fractionation Kit (BioVision Inc, Catalog  K266-25), 
following the protocol accompanying the kit (Appendix: A). Upon collecting the three 
fractions (whole cell, nuclear and cytoplasmic), concentrated (69%) nitric acid (200 
µL) was added to all samples except those containing palladium, to which aqua regia 
(3:1 HCl (32%):HNO3 (69%), 42% acid total, 200 µL) was added as an alternative. 
Samples were transferred to vials1 (3 mL screw-top V-Vials® with solid-top cap, 
Sigma) and left overnight to digest at 80 ºC in an oven. Each sample was diluted with 
an appropriate volume of milliQwater to bring the final acid concentration down to 
2%.2 Samples were stored in plastic falcon tubes at 4 ºC before analysis. 
 
                                            
1 The use of V-vials® ensures there is no loss of acid due to evaporation during the 
2 The ICP-MS instrument cannot withstand higher concentrations of acid in the 
system 
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2.14.10 Statistical analysis of data 
Completed by Dr. N. Hodges 
Statistical analysis of data was carried out where possible (n ≥ 3) using SPSS 
statistics 20. Parametric statistics were used for normally distributed data showing 
homogeneity of variances (One-way ANOVA with Post-hoc: Tukey test).  
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III. DEVELOPING A TERPYRIDINE PLATFORM FOR METAL-TERPYRIDINE  
G-QUADRUPLEX BINDING COMPLEXES 
 
3.1 Introduction 
2,2’:6’,2’’-terpyridine (tpy) was selected as the basis for the development of novel 
palladium and platinum complexes capable of quadruplex binding. Terpyridine is a 
widely used scaffold in inorganic synthesis, due to the availability of ligands from 
facile, high yielding syntheses.1,2 
Metal complexes containing metal ions with low oxidation states (the majority 
of transition metal complexes feature +2 or +3 metal ions) are characterised by an 
excess of electron density at the metal atom. Stabilisation of the metal centre is best 
achieved by the use of electron-withdrawing ligands possessing low-lying vacant 
orbitals of appropriate symmetry for overlap with the filled metal orbitals.3 Terpyridine 
is ideally suited to this role, since it possesses a LUMO of suitable energy for 
interactions with metal d orbitals,4 enabling the transfer of electron density from metal 
to ligand (back-bonding). The geometries of complexes containing the terpyridine 
ligand are predominantly determined by the configuration of the ligand, where the 
planarity of the aromatic surface must be compromised with the optimum geometry 
for the metal ion. Therefore, palladium and platinum complexes incorporating 
terpyridine frequently adopt four-coordinate square planar geometry.  
The features of terpyridine itself, along with those it imparts upon complex 
formation explain its widespread success as a ligand in general. In particular, its 
large aromatic surface and planar geometry would indicate its suitability as the basis 
for a metal complex capable of binding to G-quadruplex DNA. However, despite 
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showing a good affinity for G-quadruplexes, terpyridine metal complexes are not 
designed to maximise G-quartet coverage, resulting in π-stacking opportunities being 
missed. It may, therefore, seem an unusual strategy to select terpyridine-based 
complexes for the purpose of quadruplex binding. The reason for doing so lies in the 
ability to tailor the properties of terpyridine-based complexes by utilising appended 
substituent groups.5 This crucial property allows us to move beyond the point of 
binding which is dependent largely upon the ligand surface itself (as observed in 3,3-
biisoquinoline), and towards binding that can be directly influenced by added 
functionality, such as that demonstrated by Pt-MPQ (Chapter I, 1.7) 
This chapter focuses on the methodology explored whilst designing and 
synthesising a suitable terpyridine ligand platform, capable of future modification to 
enable dual modality binding. Initial exploration of metal complexes incorporating the 
established tpy ligand will also be carried out, in order to assess the G-quadruplex 
binding abilities of these complexes. 
 
3.2 Overview of synthetic methodology 
3.2.1 Molecular design of G-quadruplex end-stacking terpyridine complexes 
2,2’:6’,2’’-terpyridine will be modified to incorporate a methylsulphinyl group at the  
C(4’) position of the ligand. It is intended that this substituent will be used in the 
future to add to the complex specific functionality targeted to the G-quadruplex 
structure being probed. This would be achieved via coupling of the appended 
sulphoxide with various types of Grignard reagent (Figure 3.2.1-1), to yield a variety 
of products dependent on the Grignard reagents used. This particular coupling 
method has been effectively demonstrated by Oae et al.,6,7 where in the case of 
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coupling arylsulphinyl groups, the new carbon-carbon bond is formed with retention 
of the configuration.8 
 
 
Figure 3.2.1-1 Grignard coupling of methylsulphinylarene, as demonstrated by Oae et al. 
The methylsulphinyl-substituted terpyridine ‘base unit’ could therefore be modified to 
include any one of a range of substituents that would offer the ‘best match’ to the G-
quadruplex loop region sequences in close proximity. Thus, binding interactions 
between the complex and DNA target would be maximised, leading to an increased 
binding affinity between the two.  
 In an effort to establish this functionalisable terpyridine platform, initial 
exploration involves the successful synthesis of the methylsulphinyl-substituted 
terpyridine ligand, followed by complex formation with both palladium and platinum 
(Figure 3.2.1-2).   
                           
Figure 3.2.1-2 (a) Structure of target ligand (b) Representative structure of target complexes. 
The resulting complexes possess similar features to the 3,3-biisoquinoline 
compounds previously synthesised including a large aromatic surface (albeit not 
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optimised for π-stacking interactions with the G-quartet) along with a central metal ion 
displaying square planar geometry. They will therefore be investigated to determine 
their ability to bind to G-quadruplex regions of DNA before any further modification 
has taken place. This information will allow for comparison between the two ligand 
systems investigated (3,3-biisoquinoline and 2,2’:6’,2’’-terpyridine), as well as serving 
as somewhat of a baseline for future complexes to be compared against (specifically 
those derived from the terpyridine complex with targeted functionality added).  
 
3.2.2 Routes towards 2,2’:6’,2’’-terpyridines 
Two general methodologies exist in the synthesis of 2,2’:6’,2’’-terpyridines, involving 
either the construction of the central ring in situ, or alternatively the coupling of three 
existing pyridine rings, via oxidative coupling of pyridines, or Ullman coupling of 
bromopyridines (Figure 3.2.2-1). Synthetically, several methods have been utitlised 
to prepare this system, some examples of which include condensation methodology, 
Tohda methodology, metal-mediated coupling and cycloaddition (Sauer 
methodology).  
                   
Figure 3.2.2-1 Synthetic routes towards 2,2’:6’,2’’-terpyridine; in situ central ring construction 
or coupling of existing pyridine rings.  
 
N
N
N N
N
N
 147 
Perhaps the most efficient methodology to optimise the preparation of 2,2’:6’,2’’-
terpyridine was reported by Jameson and Guise9 (Figure 3.2.2-2). Reaction of 2-
acetylpyridine with N,N-dimethylformamide dimethyl acetate yields the key 
intermediate enaminone. Condensation of the potassium enolate of 2-acetylpyridine 
with this intermediate results in the loss of dimethyl amine. In situ ring closure of the 
resulting 1,5-enedione with ammonium acetate yields the terpyridine directly.  
        
Figure 3.2.2-2 Preparation of 2,2’:6’,2’’-terpyridine as reported by Jameson and Guise under 
the following conditions: i. DMF dimethyl acetate; ii. t-BuOK, 2-acetylpyridine / NH4OAc, 
HOAc. 
This route was based upon a strategy previously reported by Potts et al., which 
features an α-oxoketene dithioacetal as the key synthetic intermediate in the 
preparation of 2,2’:6’,2’’-terpyridine.10,11 Potts and co-workers first described the 
basis for this strategy in earlier work; reporting a new and versatile synthesis of 1,5-
enediones to enable a variety of 2,6-disubstituted pyridines to be readily produced 
following efficient ring closure of the unsaturated intermediate (Figure 3.2.2-3).12 This 
procedure has found widespread application, particularly in the preparation of 
oligopyridines with a thioalkyl group substituted at C(4’).13,14 
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Figure 3.2.2-3 Preparation of substituted pyridines from the corresponding 1,5-dione and 
hydroxylamine as reported by Potts et al. under the following conditions: i. NaH, CS2, CH3I; ii. 
t-BuOK, 2-acetylpyridine / NH4OAc, HOAc. 
Since we desired a substituted terpyridine ligand, the earlier work of Potts et al. 
formed the basis of the synthetic strategy employed herein.  
 
3.2.3 Preparation of methylsulphinyl-substituted terpyridines  
The desired terdentate binding ligand can be successfully synthesised in high yield in 
a three-step procedure starting with 2-acetylpyridine (Figure 3.2.3-1). This is a readily 
available and relatively inexpensive starting reagent, enabling large-scale synthesis 
to be completed with ease.  
                  
Figure 3.2.3-1 Synthesis of 4’-(methylsulfinyl)-2,2’:6’,2’’-terpyridine under the following 
conditions: i. Method 1: NaH, CS2, CH3I, Method 2: t-BuOK, CS2, CH3I; ii. t-BuOK, 2-
acetylpyridine, NH4OAc, HOAc; iii. H2O2/HOAc. 
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Step i. The first stage towards the desired ligand was preparation of an α-oxoketene 
dithioacetal via the reaction of 2-acetylpyridine with carbon disulphide in the 
presence of a base followed by alkylation.15 The mechanism for this transformation is 
shown in Figure 3.2.3-2. The enolate derived from 2-acetylpyridine reacts with CS2 to 
give an intermediate that is deprotonated to give an unsaturated monothiolate 
anion.16 S-alkylation with the halohydrocarbon results in the desired α-oxoketene 
S,S-acetal product. Several bases can be utilised,17–19 however sodium hydride has 
been shown to be very effective in securing high yields.19  
 
Step ii. The synthesis of a substituted pyridine from the α-oxoketene dithioacetal 
prepared in the first stage is achieved by further reaction with the potassium enolate 
of 2-acetylpyridine (Figure 3.2.3-2). α-oxoketene dithioacetals undergo 1,4-addition 
with ketone enolates followed by elimination of methanethiolate to yield 1,5-enedione 
intermediates.12,20 In situ ring closure is then achieved with the addition of ammonium 
acetate in glacial acetic acid at reflux. This method is particularly advantageous in 
that it enables both symmetric and asymmetrical terpyridine ligands to be 
synthesised in good yields.21  
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Figure 3.2.3-2 Mechanism of 4’-(methylsulfinyl)-2,2’:6’,2’’-terpyridine formation via an α-
oxoketene dithioacetal (step i.) and 1,5-enedione (step ii.)  
 
Step iii. Thioethers can be readily oxidised to sulfoxides (R-S(=O)-R) and sulfones 
(R-S(=O)2-R) using a variety of oxidizing agents,22–26 such as hydrogen peroxide,27,28 
nitric acid29 or sodium periodate.30 The sulphide is either fully oxidised to the sulfone 
or transformed into a sulfoxide. The choice of oxidizing agent determines the 
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products of the reaction, which in the case of hydrogen peroxide will be the desired 
sulfoxide and water. The mechanism for this partial oxidation is shown in Figure 
3.2.3-3. The sulphur atom first attacks the terminal oxygen of the peroxide group, 
causing breakage of the peroxide bond. The resulting alkoxy anion and protonated 
sulfoxide undergo proton exchange to yield the sulfoxide and water.26,31 
     
Figure 3.2.3-3 Mechanism of oxidation of sulphide to sulfoxide using hydrogen peroxide.  
 
3.3 4’-(methylsulphinyl)-2,2’:6’,2’’-terpyridine synthesis and characterisation  
3.3.1 3,3-bis(methylthio)-1-(pyridine-2-yl)prop-2-en-1-one (10) 
Preparation of compound (10) was first attempted using an early method described 
by Potts et al.,12 with the preferred choice of base, NaH (Figure 3.3.1-1; Method a). 
NaH was added to anhydrous DMSO, followed by the dropwise addition of 2-
acetylpyridine, CS2 and CH3I to the vigorously stirred solution. After 12 hours at room 
temperature, iced water was cautiously added to consume any unreacted NaH, 
which otherwise presents a fire hazard due to its violent reactivity with water. 
Analysis of the crude solid following collection and washing showed a combination of 
starting materials to be present, indicating that the reaction had been unsuccessful. 
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Figure 3.3.1-1 Synthesis of 3,3-bis(methylthio)-1-(pyridine-2-yl)prop-2-en-1-one by two 
alternative methods. 
A search of the literature provided an alternative procedure for the preparation of the 
α-oxoketene dithioacetal. Reported by Han et al., this method was itself based on 
procedures described by Potts and coworkers,10,12 however THF was now the 
solvent of choice, and potassium tert-butoxide was used as a source of strong base 
(rather than NaH) (Figure 3.3.1-1; Method b).32 The ratio of reagents used was 
mostly unchanged. As before, operating under an argon atmosphere, 2-
acetylpyridine, CS2 and CH3I were added dropwise with caution to a vigorously 
stirred suspension of base in solvent. Following stirring at room temperature for 
approximately half the time period required previously (5 h cf. 12 h), the reaction was 
poured onto ice water and allowed to stand overnight. The precipitate was washed to 
successfully yield compound (10) as dark yellow solid in good yield. Electrospray 
ionisation mass spectrometry and nuclear magnetic resonance data were in 
accordance with those reported in the literature (Figure 3.3.1-2). 
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Figure 3.3.1-2 1H-NMR spectrum of 3,3-bis(methylthio)-1-(pyridine-2-yl)prop-2-en-1-one (10) 
(300 MHz, CDCl3, 298 °K). 
The use of potassium tert-butoxide in the second method allows successful formation 
of the potassium enolate of 2-acetylpyridine, which is perhaps more reactive than the 
sodium enolate that would be formed under the former method. Additionally, it is 
possible that the NaH utilised in the first attempt (stored as oil dispersion) was not 
sufficiently dry to enable formation of the enolate on that occasion. The only 
remaining variable between the two methods was the solvent choice. Despite the 
relatively unusual solvent choice in the first route (DMSO), this method reports 
widespread success; therefore any failure associated with the solvent is expected to 
be due to issues arising from its dryness. Despite every effort to ensure the 
conditions remained anhydrous throughout, there was no evidence of success in the 
crude analysis. The alternative procedure adapted by Han et al. resulted in first-time 
success.  
 
3
2 N
1
6
5
4
7
8
O
9
SCH3
11
SCH3
10
 154 
3.3.2 4’-(methylthio)-2,2’:6’,2’’-terpyridine (11) 
Reaction of the prepared α-oxoketene dithioacetal (10) with a further equivalent of 
the potassium enolate of 2-acetyl pyridine followed by ring closure with NH4OAc 
yields the desired terpyridine product (Figure 3.3.2-1).  
          
Figure 3.3.2-1 Synthesis of 4’-(methylthio)-2,2’:6’,2’’-terpyridine via 1,5-enedione. 
Following the successful synthesis of compound (10) using a method described by 
Han et al., compound (11) was prepared following a similar method also described by 
Han and coworkers.32 The reaction proceeded well. Isolation and purification of the 
crude product was achieved by cooling, precipitation and filtration, as described by 
Potts and coworkers.12 The product was obtained in good yield as brown solid. 
Despite its alternative physical appearance (it has been previously reported as yellow 
solid), characterisation of the product by ESI-MS and 1H NMR was in full accordance 
with the literature.33  
 
3.3.3 4’-(methylsulphinyl)-2,2’:6’,2’’-terpyridine (12) 
The desired methylsulphinyl-substitued terpyridine was prepared by oxidising the 
existing methylthio-substituted terpyridine. This was achieved using hydrogen 
peroxide in glacial acetic acid, as demonstrated by Oae et al.34 (Figure 3.3.3-1).  
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Figure 3.3.3-1 Synthesis of 4’-(methylsulphinyl)-2,2’:6’,2’’-terpyridine  
The addition of just one equivalent of 30% H2O2 causes only a single oxidation to 
occur. This ensures that the methylsulphinyl group is retained (i.e. it cannot undergo 
further oxidation to the sulfone, S(=O)2CH3), potentially allowing functionality to be 
later added to the terpyridine scaffold at the C(4’) position  through Grignard coupling 
routes (see 3.2.1).  
The reaction proceeded well under acidic conditions. Neutralisation followed by 
extraction of the product into chloroform produced a pale brown solid in good yield. 
The 1H NMR spectrum shows a downfield shift in the H3’/5’ peak, on account of the 
close proximity of these protons to the sulphinyl oxygen atom following successful 
oxidation. Previously appearing at 8.30 ppm, the peak now resides at 8.63 ppm. 
Similarly, the thiomethyl peak shifts downfield from 2.66 ppm (R-S(CH3)) to 2.83 ppm 
(R-S(=O)(CH3) (Figure 3.3.3-2). The ESI-MS spectrum showed peaks at m/z 296 
corresponding to [M + H]+.  
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Figure 3.3.3-2 1H NMR spectra overlay of 4’-(methylthio)-2,2’:6’,2’’-terpyridine (11) and  
4’-(methylsulphinyl)-2,2’:6’,2’’-terpyridine (12) (300 MHz, CD3CN, 298 °K).  
3.3.4 Synthesis and characterisation of palladium and platinum complexes 
incorporating 4’-(methylsulphinyl)-2,2’:6’,2’’-terpyridine (12) 
3.3.5 [Pd(12)(CH3CN)](BF4)2 (13) 
A single terpyridine ligand was bound to a palladium metal centre following a ligand 
substitution reaction. Replicating the conditions used to prepare the palladium  
3,3-biisoquinoline compound, tetrakis(acetonitrile)palladium tetrafluoroborate was 
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reacted with the ligand, this time in a 1:1 ratio, to form the desired complex (Figure 
3.3.5-1).  
         
Figure 3.3.5-1 Synthesis of [Pd(12)(CH3CN)](BF4)2  
The crude product was washed with chloroform, methanol and diethyl ether before 
drying under vacuum to yield pure [Pd(12)CH3CN)](BF4)2 as a pale beige solid in 
62% yield. The complex shows good solubility in acetonitrile. The ESI-MS spectrum 
showed a peak at m/z 442 corresponding to [Pd(12)(CH3CN)]. The 1H-NMR 
spectrum shows both the same splitting pattern and number of peaks as those 
observed for the unbound ligand. Upon comparison of these two spectra, noticeable 
shifts can be observed in the complex spectrum. This is due to the electron 
withdrawing effect of the palladium metal centre, and is most evident when 
comparing the positions of the peaks attributed to protons H(4/4’’) and H(5/5’’), as shown 
in Figure 3.3.5-2. 
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Figure 3.3.5-2 1H NMR spectra overlay of 4’-(methylsulphinyl)-2,2’:6’,2’’-terpyridine (12) and 
Pd(12)(CH3CN)](BF4)2 (13) (300 MHz, CD3CN, 298 °K). 
3.3.6 [Pt(12)Cl](PF6) (14) 
Referring back to the method used to prepare the platinum 3,3-biisoquinoline 
compound and owing to the similar solubilities of the ligands, the same solvent and 
reaction conditions were employed to produce the platinum tpy complex (Figure 
3.3.6-1). One minor exception was the 1:1 ratio in which the ligand was reacted with 
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the potassium tetrachloroplatinate starting compound; a direct result of its terdentate 
binding mode, thus accommodating only one ligand per metal centre.  
        
Figure 3.3.6-1 Synthesis of [Pt(12)Cl](PF6)  
Following heating under reflux overnight, the solution was hot filtered and a 
methanolic solution of ammonium hexafluorophosphate added. The desired product 
immediately precipitated from solution as a vibrant raspberry purple solid. Careful 
washing with chloroform, methanol and diethyl ether yielded the title compound as 
purple solid in 68% yield. The compound shows good solubility in acetonitrile.  
The ESI-MS spectrum showed a peak at m/z 525 corresponding to 
[Pt(C16H13N3SO)Cl]. In a similar pattern to that observed for the palladium analogue, 
comparison of the 1H-NMR spectra of the unbound ligand and complex shows some 
prominent downfield signal shifts, owing to the withdrawal of electron density from the 
terpyridine ring system upon complex formation (Figure 3.3.6-2). The presence of 
195Pt-1H coupling satellites confirms metal coordination of the ligand. 
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Figure 3.3.6-2 1H-NMR spectra overlay of 4’-(methylsulphinyl)-2,2’:6’,2’’-terpyridine (12) and 
[Pt(12)Cl](PF6) (14) (300 MHz, CD3CN, 298 °K). 
3.4 UV-Visible spectroscopy studies 
3.4.1 Absorbance characteristics 
Unbound tpy ligand (12) and both palladium and platinum complexes (13) and (14) 
were characterised by UV/Vis spectroscopy. Solutions of each were prepared in 
acetonitrile. The absorbance spectrum of 4’-(methylsulphinyl)-2,2’:6’,2’’-terpyridine 
(12) shows strong π-π* ligand transitions in the UV region at 251 and 277 nm. These 
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transitions are also observed in the spectra recorded for both complexes, appearing 
between 241-283 nm (Figure 3.4.1-1).   
                 
 
Figure 3.4.1-1 UV-Vis absorption spectra for 4’-(methylsulphinyl)-2,2’:6’,2’’-terpyridine (12), 
[Pd(12)CH3CN)]2+ (13) and [Pt(12)Cl]+ (14) in acetonitrile.  
Further charge transfer bands are observed between 319-398 nm in the metal 
complexes containing the ligand. These bands do not appear in the spectrum for the 
unbound ligand and are therefore due to interactions between the metal centre and 
the terpyridine ligand. The bands at 351 and 368 nm in the palladium complex and 
334 and 398 nm in the platinum complex originate from spin-allowed MLCT (metal to 
ligand charge transfer) transitions. These occur due to the overlap of orbitals of 
appropriate symmetry, allowing electron density to be donated from metal dπ orbitals 
to vacant low-lying π* ligand orbitals. The presence of these MLCT bands is evidence 
for coordination of the terpyridine moiety. Furthermore, the MLCT bands observed for 
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these two complexes are comparable to those reported for similar complexes 
containing tpy ligands, such as [Pt(tpy)Cl]Cl35 and [Pd(tpy)Cl]PF6.36  
Table 3.4.1-1 shows the UV-Vis absorption data obtained for ligand (12) and 
complexes (13) and (14). The UV-Vis transitions reported in the literature for both 
[Pt(tpy)Cl]Cl and [Pd(tpy)Cl]PF6 are included for comparison.  
 
Compound π - π* λmax (nm) MLCT λmax  (nm) 
4’-(methylsulphinyl)-tpy (12)a 251 (21800)  
 277 (24500)  
[Pd(12)(CH3CN)](BF4)2 (13)a 241 (26900) 335 (7700) 
 267 (17200) 351 (10100) 
 	 368 (10100) 
[Pt(12)Cl](PF6) (14)a 255 (26300) 319 (12500) 
 283 (25200) 334 (14000) 
 	 398 (3200) 
[Pd(tpy)Cl]PF6b 205 (57500) 328 (8670) 
 246 (25800) 345 (9050) 
 279 (23900) 362 (8180) 
[Pt(tpy)Cl]Clc 284 (23000) 334 (13400) 
    404 (1600) 
 
Table 3.4.1-1 UV-Vis absorption data for synthesised compounds (12)-(14) and two literature 
compounds for comparison. aCH3CN,  bCH3CN, 3 × 10-5 M, data taken from 36; cMeOH:EtOH 
(4:1), 2 × 10-5 M, data taken from 35. Extinction coefficients (ε/ M-1 cm-1) are given in 
parenthesis. 
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3.4.2 Stability in solution  
Before proceeding with DNA binding experiments, the stability of each complex in 
solution was assessed using UV-Vis spectroscopy. Observing the change in 
absorbance over time, complex instability is typically characterised by a decrease in 
the intensity of the λmax signal, with stable complexes exhibiting no change in their 
λmax over time. Solutions of both complexes in acetonitrile were analysed periodically 
over 24 hours. Figure 3.4.2-1 shows the spectra obtained.  
It is immediately evident that the palladium complex (13) is extremely stable, 
showing no loss in signal intensity after 24 hours in solution. By contrast, the 
platinum complex (14) shows a 6% loss of intensity over the same time period. It is 
interesting to note that the signal loss occurs over the first hour in solution, and that 
no further decrease in signal is observed over the remaining 23 hours.  The cause of 
complex instability is therefore likely to be a process that occurs rapidly in solution, 
resulting in no further instability over time. Exchange of the chloride ligand with 
acetonitrile (from the solvent) would account for this. The stability observed for the 
palladium complex further supports this conclusion, since the palladium analogue 
already possesses an acetonitrile ligand and would therefore not be expected to 
undergo such ligand exchange with the solvent.  
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Figure 3.4.2-1 UV-Vis absorption spectra of complex solutions (CH3CN) recorded over a 24 
hour period. (a) [Pd(12)CH3CN)]2+ (13); (b) [Pt(12)Cl]+ (14); (c) Loss in signal intensity of λmax 
peak over 6 hours. 
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3.5 Circular dichroism DNA binding studies 
To qualify as a good G-quadruplex binder, a complex must show specificity for G-
quadruplex sequences over the more commonly occurring duplex form of DNA. To 
begin to determine if this is the case with these complexes, circular dichroism (CD) 
can be used to study the binding (if any) to both types of structure, where a 
comparison between the two types of DNA will inform on the affinity of the complexes 
towards each type of DNA. A stronger interaction observed for G-quadruplex types of 
DNA (compared to duplex DNA) would be the first indication of preferential binding. 
This would provide the impetus to continue studying these compounds as potentially 
selective G-quadruplex binders.   
 
3.5.1 Circular dichroism (CD) 
Circular dichroism is a spectroscopic technique that can be used to probe the 
conformation of different types of DNA. A spectrum is generated by measuring the 
difference in absorbance between left (Al) and right (Ar) circularly polarised light, 
producing a signal known as ellipticity θ (expressed in degrees).37 The circularly 
polarised light utilised in this technique arises from superposition of oscillating vertical 
and horizontal polarised light. The size of electric field vector remains constant, 
however it rotates about the propagation direction in the form of either a left or right 
handed helix, resulting in the production of left or right circularly polarised light 
(Figure 3.5.1-1). At any point in time and space the magnitude vector will be 
perpendicular to the electric field.38 
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Figure 3.5.1-1 Left-handed or counter-clockwise circularly polarized light as defined from the 
point of view of the receiver.  
Only molecules displaying chirality can produce a CD spectrum. Chiral molecules 
interact differently with right and left circularly polarised light due to their non-
superimposable mirror images with no plane of reflection. Each type of light will have 
different extinction coefficients, which may be plotted against wavelength to produce 
a CD spectrum.38 Non-chiral molecules can only be observed by CD when they 
interact with a chiral molecule. Chirality may then be induced in the non-chiral 
molecule by the environment, causing new bands to appear in the spectrum, the 
effect of which is called induced circular dichroism (ICD).  
The phosphate-sugar DNA backbone comprises chiral sugar units that impart 
chirality into the structure and enable it to be studied by CD. Each sequence of DNA 
has a characteristic spectrum that may display alterations as a result of binding with 
a non-chiral molecule. CD is a highly sensitive method allowing conformational 
transitions between complex nucleic acid arrangements to be monitored over time.  
 
3.5.2 Types of DNA investigated  
DNA binding was determined using three types of DNA in the CD experiments. Two 
of these - Htelo and cMyc - represent quadruplex-forming regions of DNA. The other, 
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ct-DNA, is representative of duplex DNA.   
 
Calf-thymus (ct-DNA) 
ct-DNA consists of predominantly double, but also single stranded regions of DNA, 
composed of a variety of DNA sequences containing all four bases. Consequently, 
strand concentration cannot be calculated and the concentration is measured in 
bases, as determined by UV-Vis spectroscopy. This form of DNA is representative of 
genomic duplex DNA and allows the interaction between complexes and double 
stranded DNA to be assessed. The characteristic CD spectrum for ct-DNA shows 
relatively weak bands between 200-300 nm (Figure 3.5.2-1). These signals arise 
from the transitions of purine and pyrimidine bases that experience a weakly chiral 
environment due to the base pairs sitting perpendicular to the double helix.37 Any 
changes observed in this region may indicate conformational changes in the DNA. 
Binding of the complexes to DNA may induce chirality, resulting in the appearance of 
new bands in the spectrum (ICD bands). 
                         
Figure 3.5.2-1 Characteristic CD spectrum of ct-DNA  
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Human telomeric (Htelo) DNA 
Htelo DNA comprises a guanine-rich repeating base sequence of TTA-GGG which is 
capable of forming G-quadruplex structures; 
5’-A-GGG-TTA-GGG-TTA-GGG-TTA-GGG-3’ 
The 22-base sequence mimics the sequence of DNA located at the telomeric ends, 
and is therefore used to assess telomeric quadruplex DNA binding. Prior to 
measuring the CD response of this strand, the DNA must be annealed and slowly 
cooled to room temperature before placing in a fridge overnight. This protocol allows 
the most thermodynamically stable conformation to form during the cooling process, 
with no overnight deterioration. Any conformation adopted by the strand during the 
CD experiment is therefore as a result of the specific experimental conditions only.  
The various different conformations adopted by telomeric DNA are the result 
of the salt conditions of the buffer, which determine the type of cation present in 
solution. Held in place by electrostatic interactions with eight O(6) atoms lining the 
two planes of G-tetrads, both potassium and sodium cations are the correct size to 
occupy the space between the G-tetrads.39 In general, sodium cations sit in the 
central cavity of the quartet, with potassium cations sitting between the quartet 
layers.40 
In potassium-rich solution an antiparallel hybrid conformation forms. This is 
characterised by a major peak at 295 nm originating from antiparallel character, in 
addition to a smaller peak at 265 nm representing its parallel nature. A further peak 
at 253 nm is usually observed due to a small amount of unfolded DNA.  
It has been reported that due to the relative energies of hydration, the 
potassium cation is preferred for G-quadruplex stabilisation.41 Under cellular 
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conditions, the telomeric DNA is therefore most likely to adopt the conformation 
observed in potassium-rich solution, and this buffer system provides the best 
environment to mimic cell conditions.  Consequently, a Tris-HCl/KCl buffer system 
was chosen for these binding experiments; providing the necessary potassium-rich 
environment that favours the antiparallel hybrid conformation. A characteristic CD 
spectrum of Htelo DNA under these conditions is shown in Figure 3.5.2-2. 
 
                        
Figure 3.5.2-2 Characteristic CD spectrum of Htelo DNA in K+ rich buffer conditions, forming 
antiparallel hybrid G-quadruplex.  
In sodium-rich solution a purely antiparallel conformation forms, characterised by a 
single peak at 295 nm. The guanine bases are arranged in both syn and anti 
positions about the glycosidic bond. In the absence of both potassium and sodium 
ions in solution, G-quadruplex formation is less successful, with a defined peak at 
253 nm originating from unfolded DNA. Despite the lack of stabilising cation in 
solution, there is still evidence of some degree of folding to form a G-quadruplex, 
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characterised by a peak at 295 nm which is indicative of antiparallel G-quadruplex 
formation.  
The conformational arrangement of the Htelo strand can be sensitively 
monitored using circular dichroism. Observed changes in the CD spectra of the 
sequence following complex addition are indicative of a binding interaction between 
the DNA and complex. This may constitute stabilisation of the structure, or an 
alteration in its structure altogether; which would be evident from induced peaks 
corresponding to another conformation.   
 
cMyc DNA 
cMyc DNA consists of a guanine-rich base sequence that is therefore capable of 
forming G-quadruplex structures; 
5’-TGA-GGG-TGG-GTA-GGG-TGG-GTA-A-3’ 
The 22-base sequence forms part of an oncogene promoter region and is used to 
assess promotor region quadruplex DNA binding. Oncogenic regions of DNA are 
commonly found to contain guanine-rich sequences that have the potential to form  
G-quadruplexes, and are therefore of much interest experimentally. The cMyc 
sequence consistently forms parallel G-quadruplex structures, regardless of the salt 
conditions used. The characteristic CD spectrum of cMyc DNA shows a peak at 265 
nm originating from its parallel nature (Figure 3.5.2-3). In this conformation all of the 
guanine bases are in an anti position about the glycosidic bond. Once again, any 
change in the CD spectra of the sequence indicates a binding event has occurred.  
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Figure 3.5.2-3 Characteristic CD spectrum of cMyc DNA, forming parallel G-quadruplex. 
Since each quadruplex-forming strand adopts a different conformation, the 
complexes may show a preference for interaction with one sequence over the other. 
This would be most likely due to the variation in the loop regions between the two 
structures, where the exposure of bases for binding is different for each sequence. 
Any selectivity for one type of structure would provide information about the possible 
modes of interaction.   
 
3.5.3 Circular dichroism binding results 
Binding experiments were carried out using complex solutions that were prepared in 
15% acetonitrile: 85% milliQwater to aid solubility. A solution of each complex was 
titrated into a solution of each type of DNA whilst monitoring and recording a CD 
spectrum after each addition. Following the addition of the final titre to the 
experimental solution, the overall percentage of CH3CN did not exceed 3%. Solvent 
control experiments were conducted to verify that the final percentage of non-
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aqueous solvent did not cause any alterations in the observed spectrum (data not 
shown). 
 
ct-DNA 
Both the platinum and palladium complexes generate ICD bands in the MLCT region 
of the ct-DNA spectra at 350 nm and 375 nm respectively, indicating that binding is 
occurring between the two species (Figure 3.5.3-1). The degree to which the CD 
spectrum responds to DNA binding differs between the two species, with a more 
intense ICD peak emerging for the platinum species.  
The peak at 275 nm corresponding to the B-DNA configuration undergoes two 
transitions during platinum complex (14) addition; initially increasing in intensity at 
low concentrations, the peak then decreases at concentrations above 15 µM. By 
contrast, palladium complex (13) addition results in an initial decrease in intensity, 
followed by an increase at concentrations above 30 µM.  
The intensity of the peak at 253 nm (unfolded DNA) decreases substantially in 
both cases, indicating that complex addition causes the DNA to adopt a more defined 
conformation, most likely as a result of complex-DNA interactions.  
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ct-DNA 
(a)                                                            (b) 
 
Figure 3.5.3-1 (a) CD spectrum showing the titration of [Pt(12)Cl](PF6) (top) and 
[Pd(12)CH3CN](BF4)2 (bottom) in increasing concentrations to ct-DNA (150 µM, 20 mM NaCl, 
1 mM  Na(CH2)2AsO2.3H2O, pH 6.8). Ratio of complex:DNA shown in the legend beneath 
each plot. (b) Peak intensity versus complex concentration for [Pt(12)Cl](PF6) (top) and 
[Pd(12)CH3CN](BF4)2 (bottom) at λmax 275 and 350 (Pt)/375 nm (Pd).  
 
-15 
-10 
-5 
0 
5 
10 
225 275 325 375 425 
C
D
 (m
de
g)
 
Wavelength (nm) 
ct only 0.02:1 0.03:1 
0.035:1 0.05:1 0.07:1 
0.10:1 0.13:1 0.17:1 
0.25:1 0.33:1 0.50:1 
-1 
0 
1 
2 
3 
5 
6 
7 
8 
9 
10 
0 10 20 30 40 50 60 70 
C
D
 (m
de
g)
 3
50
 n
m
 
C
D
 (m
de
g)
 2
75
 n
m
 
Complex concentration / µM 
 275 nm 
350 nm 
-30 
-20 
-10 
0 
10 
225 275 325 375 425 
C
D
 (m
de
g)
 
Wavelength (nm) 
ct only 0.02:1 0.03:1 
0.035:1 0.05:1 0.07:1 
0.10:1 0.13:1 0.17:1 
0.25:1 0.33:1 0.50:1 
0.25 
0.75 
1.25 
-1 
1 
3 
5 
7 
9 
0 15 30 45 60 75 90 
C
D
 (m
de
g)
 3
75
 n
m
 
C
D
 (m
de
g)
 2
75
 n
m
 
Complex concentration / µM 
 275 nm 
375 nm 
 174 
Htelo DNA 
Addition of the platinum complex (14) to telomeric DNA alters the intensity of both 
characteristic Htelo peaks. The peak at 295 nm increases, indicating that complex 
addition causes stabilisation of the antiparallel G-quadruplex structure (Figure 
3.5.3-2). The observed increase in this peak levels off at approximately 12 µM, 
indicating a 2:1 complex:DNA binding ratio. Binding of the complex at both faces (top 
and bottom) of the G-quartet stack would account for such a ratio. The peak at 253 
nm decreases in intensity, demonstrating the ability of the complex to induce further 
G-quadruplex formation amongst any previously unfolded regions of DNA. Despite 
the lack of ICD peaks at longer wavelengths, it is evident that the platinum species 
interacts with the Htelo DNA, both to stabilise existing G4 structures and induce 
further folding. 
 Interestingly, similar alterations are not observed in the spectra upon addition 
of the palladium complex (13) to telomeric DNA. Comparable stabilisation of G-
quadruplex structures is not observed, rather, an increase in the intensity of the 253 
nm peak indicates unfolding of the DNA. The peak at 295 nm fluctuates a little, but 
shows no consistent pattern of increasing or decreasing signal. The interaction of the 
palladium complex is evidently weaker than its platinum analogue.  
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Htelo DNA 
(a)                                                           (b) 
 
Figure 3.5.3-2 (a) CD spectrum showing the titration of [Pt(12)Cl](PF6) (top) and 
[Pd(12)CH3CN](BF4)2 (bottom) in increasing concentrations to Htelo (3 µM per strand, 100 
mM KCl, 10 mM Tris/HCl, pH 7.4). Ratio of complex:DNA shown in the legend beneath each 
plot. (b) Peak intensity versus complex concentration for [Pt(12)Cl](PF6) (top) and 
[Pd(12)CH3CN](BF4)2 (bottom) at λmax 253 and 295 nm.  
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cMyc DNA 
Addition of the platinum complex (14) to promoter regions cMyc DNA causes an ICD 
peak to emerge at 295 nm (Figure 3.5.3-3). This new peak plateaus in intensity at 
approximately 12 µM, indicating a 2:1 complex:DNA binding mode, in a similar 
fashion to that observed between the platinum complex and Htelo DNA. The 
appearance of this ICD peak is paired with a decrease in the peak at 265 nm 
(characteristic of the parallel G4 structure adopted by cMyc). These combined 
observations confirm that interaction is occurring, resulting in a change in G-
quadruplex conformation from parallel to antiparallel.  
The palladium complex (13) also induces ICD formation at 295 nm. However, 
the peak at 265 nm does not simply decrease as witnessed for the platinum complex. 
Rather, the peak initially decreases, before increasing at higher concentrations. The 
structural transitions responsible for these observed alterations appear more 
complex, but it seems possible that the G4 structures that begin with parallel 
conformation are transitioning to structures with some antiparallel nature, possibly 
hybrid structures.  
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cMyc DNA 
(a)                                                             (b) 
 
Figure 3.5.3-3 (a) CD spectrum showing the titration of [Pt(12)Cl](PF6) (top) and 
[Pd(12)CH3CN](BF4)2 (bottom) in increasing concentrations to cMyc (3 µM per strand, 100 
mM KCl, 10 mM Tris/HCl, pH 7.4). Ratio of complex:DNA shown in the legend beneath each 
plot. (b) Peak intensity versus complex concentration for [Pt(12)Cl](PF6) (top) and 
[Pd(12)CH3CN](BF4)2 (bottom) at λmax 265 and 295 nm.   
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Overall, the results of these CD studies demonstrate the presence of binding 
interactions between both complexes and each type of DNA, though the exact nature 
of these interactions is not yet fully understood. Both complexes interact with ct-DNA 
in similar manners, resulting in the presence of ICD peaks. When titrated into Htelo 
and cMyc DNA sequences, it is evident that there are some differences between the 
two complexes, whereby the platinum complex (14) induces more defined changes in 
both DNA spectra indicating its potentially preferential binding.  
To further elucidate the binding interactions occurring between each complex 
and these DNA structures, gel electrophoresis was employed. 
 
3.6 Gel electrophoresis DNA binding studies 
Owing to the negatively charged sugar-phosphate backbone, DNA molecules will 
migrate through a gel matrix towards a positively charged electrode during gel 
electrophoresis. Depending upon their size, DNA fragments migrate at varying 
speeds, with smaller fragments moving more rapidly through the gel than larger 
fragments.42 Movement of the DNA fragments through the gel may also be affected 
by overall charge and conformation.  
 
3.6.1 Polyacrylamide gel electrophoresis (PAGE) 
Due to the small pore size created by the gel forming process43 polyacrylamide gel 
electrophoresis (PAGE) is commonly used for small DNA sequences (typically tens 
of bases), offering improved resolution of the DNA (compared to alternative gel 
methods such as agarose), but with a limited range of separation.  
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3.6.2 PAGE results 
Visualisation of DNA bands can be achieved using a variety of techniques including 
the use of radiolabelled fragments that can be recorded by an autoradiogram,44 
fluorescently labelled DNA strands that can be easily and sensitively detected,45,46  
and UV-Visible spectroscopy of the gel. In these experiments, DNA bands were 
visualised following staining of the gel with SyBr gold, which exhibits a 10,000-fold 
increase in fluorescence upon binding to DNA. The use of SyBr gold (as opposed to 
more commonly used ethidium bromide) means that extremely small volumes of 
DNA can be detected, saving both materials (particularly DNA) and limiting the 
electrophoresis run-time, which saves both time and money.47 
The quadruplex-forming DNA strands (Htelo and cMyc) used in the PAGE 
experiments were annealed in a potassium-rich buffer before use, ensuring that the 
G-quadruplex structure has pre-formed in solution and the test conditions represent 
binding of the complexes to existing G-quadruplexes. Each complex was incubated 
with the DNA for one hour prior to loading the wells on the gel. Control samples - 
DNA alone, DNA + solvent (10% CH3CN) - were loaded alongside the DNA:complex 
samples. Once loaded, application of an electric field causes the DNA to migrate 
towards the positive electrode.  
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cMyc and Htelo DNA 
The results of the PAGE experiments with cMyc and Htelo DNA are shown in Figure 
3.6.2-1. On first glance, the results seem somewhat disappointing, with few striking 
observations. On closer inspection, there appear to be some new bands appearing, 
although these are rather faint.  
              
Figure 3.6.2-1 PAGE (15%) showing the migration of cMyc (lanes 1-7) and Htelo (lanes 8-14) 
DNA when an electric potential is applied. Samples were left at room temperature for 1 hour 
before loading and electrophoresis of the gel.  
cMyc DNA appears to interact more strongly with the platinum complex (14), as 
evidenced by the presence of new bands in lanes 2 and 4. There is no significant 
difference between these two lanes, with a single new species observed in both 
cases, indicating a 1:1 binding mode. No effect is seen with the palladium species.  
By contrast, Htelo DNA appears to interact more strongly with the palladium 
complex (13), as evidenced by the presence of new bands in lanes 10 and 12. The 
effect here is certainly less pronounced than that seen between cMyc and the 
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platinum species, possibly indicating a weaker binding interaction between Htelo and 
the palladium species. Again, little difference is observed between lanes 10 and 12, 
indicating a 1:1 binding mode. There doesn’t appear to be any interaction with the 
platinum species. 
Comparison of these results with the CD data appears to show some disparity. 
Although confusing, this highlights the importance of employing a combination of 
methods to study quadruplex-ligand interactions, in order to build a complete picture 
of the interactions taking place. The CD data shows that the platinum complex (14) 
interacts with both G-quadruplex forming sequences, despite it only appearing to 
interact with cMyc in the gel studies. The palladium complex (13) induced less 
pronounced changes in the CD spectra, but did indicate some interaction with both 
DNA sequences, appearing to induce conformational changes in G-quadruplex 
structures rather than stabilisation. The weak interaction observed between the 
palladium complex and Htelo in these gel studies is in agreement with the CD data, 
however the cMyc data is currently inconsistent, since there is no comparable 
interaction observed in the gel in support of the CD data. 
 
ds26 DNA 
ds26 is a reverse complementary 42 base DNA sequence that forms double-
stranded DNA when two strands base pair (head-to-tail) with one another; 
5’-CCT-TCA-CGC-GAA-CGT-AAT-CCT-AGG-ATT-ACG-TTC-GCG-TGA-AGG-3’ 
ds26 can be used in gel electrophoresis experiments as representative duplex DNA, 
since ct-DNA cannot be used due to the variable lengths of DNA sequences it 
contains. The result of the PAGE experiment with ds26 is shown in Figure 3.6.2-2. 
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Figure 3.6.2-2 PAGE (15%) showing the migration of ds26 DNA when an electric potential is 
applied. Samples were left at room temperature for 1 hour before loading and 
electrophoresis of the gel. 
There is no observable interaction between either complex and ds26, as evidenced 
by the absence of any new bands in the gel. It is somewhat unusual to see no 
interaction with duplex DNA, particularly in light of the induced peaks observed in the 
CD studies with ct-DNA, which indicated the presence of some interaction for both 
complexes. It is possible that the interaction observed in the CD studies was due to 
each complex interacting with non-duplex components in the ct-DNA (which is 
predominantly but not solely duplex), however this seems unlikely given the response 
observed. The absence of any evidence suggesting binding of either complex to 
ds26 is therefore questionable and requires repeat experiments for validation. 
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3.7 Conclusions 
The incorporation of the terpyridine moiety into novel metal complexes fulfils the 
requirements for G-quadruplex binding compounds to possess both a planar 
aromatic surface for π-stacking interactions, along with a central metal atom to 
withdraw electron density from the aromatic ligands, thus providing electrostatic 
interactions.  
Preparation of the desired tpy-based ligand was achieved using a combination 
of methods centred on the highly successful work of Potts et al., whereby the central 
tpy ring was constructed in situ. The selected methods enabled the desired 
methylsulphinyl-substituted tpy ligand to be prepared in good yield. The syntheses of 
platinum and palladium complexes incorporating this ligand have been described. 
Both complexes show good stability in solution, along with some early 
indications that they are capable of interacting with both duplex and G-quadruplex 
forming regions of DNA. On account of the discrepancies between the CD and PAGE 
data, repeat studies are required to determine the binding interactions taking place. 
To supplement this, it would be beneficial to conduct UV-Vis spectroscopy titration 
experiments with both complexes and each type of DNA to compare with the existing 
CD data. 
 
3.8 Experimental materials and methods 
3.8.1 General chemistry 
Reagents and solvents were obtained from Sigma Aldrich, Fisher Scientific, Scientific 
Lab Supplies, Acros Organics and VWR. All solvents were of standard grade and 
were used without purification. Unless otherwise stated, all reactions were carried out 
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under standard conditions (298 °K, 1 atm pressure).  
 
3.8.2 Analytical characterisation techniques 
All characterisation techniques were conducted within the School of Chemistry at the 
University of Birmingham. Nuclear Magnetic Resonance (NMR) spectra were 
recorded in deuterated CDCl3 and CD3CN. 1H-NMR spectra were recorded on a 
Bruker AV(III)300 and AV(III)400 instruments, operating at 300 and 400 MHz 
respectively. 13C-NMR spectra were recorded on a Bruker AV(III)400 instrument 
operating at 100 MHz. Electrospray Ionisation Mass Spectrometry (ESI-MS) spectra 
were carried out by Dr. Chi Tsang and Dr. Peter Ashton (Analytical Facility). Spectra 
were recorded on a Waters LCT Time of Flight Spectrometer. Elemental CHN 
Analysis was carried out Dr. Lianne Hill (Analytical Facility) on a CE Instrument 
EA1110. UV-Visible (UV-Vis) spectra were recorded on a Varian Cary 5000 
spectrometer. CD spectra were recorded between 200–800 nm on a ChirascanTM 
circular dichroism spectrometer (Applied Photophysics).  
 
3.8.3 Chemical synthesis 
3,3-bis(methylthio)-1-(pyridine-2-yl)prop-2-en-1-one (10) 
 
Method a. NaH (1.73 g, 60% oil dispersion, 72.0  mmol) was added in small portions 
at a steady rate to anhydrous DMSO (20 mL), so as to prevent frothing. Whilst 
3
2 N
1
6
5
4
7
8
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11
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stirring vigorously, the solution was treated dropwise with 2-acetylpyridine (2.50 g, 
21.0 mmol) over 15 min, followed by dropwise addition of carbon disulphide (1.65 g, 
21.7 mmol) before the final dropwise addition of methyl iodide (5.71 g, 40.0 mmol). 
The resulting dark green mixture was stirred at room temperature for 15 h after which 
the mixture was cautiously quenched by the addition of iced water (10 mL). The dark 
solid was collected and washed with water and ice-cold ethanol until the washings 
were colourless. Crude analysis was carried out on the dried solid. 1H NMR (300 
MHz, CDCl3) spectrum showed no peaks corresponding to the desired product.  
Method b. Operating under an argon atmosphere, a suspension of potassium tert-
butoxide (4.85 g, 43.2 mmol) in anhydrous THF (115 mL) was vigorously stirred at 
room temperature. A solution of 2-acetylpyridine (2.50 g, 20.7 mmol) in anhydrous 
THF (15 mL) was added dropwise and with caution over 5 minutes, followed by the 
addition of carbon disulphide (1.65 g, 21.7 mmol) over 20 minutes, resulting in a 
viscous, heterogeneous orange mixture. Methyl iodide (6.15 g, 43.4 mmol) was 
added over 1 h and the reaction mixture left stirring at room temperature for 5 h. The 
tan reaction mixture was poured into cold water (500 mL) and left to stand overnight. 
The resulting precipitate was collected by vacuum filtration and air dried to afford the 
title compound as brown solid (3.02 g, 65%).   
1H NMR (300 MHz, CDCl3): δ 8.64 (1H, d, J = 4.5, H(2)), 8.16 (1H, d, J = 7.5, H(5)), 
7.83 (1H, t, J = 7.4, H(3)), 7.64 (1H, s, H(8)), 7.40 (1H, t, J = 6.0, H(4)), 2.64 (3H, s, 
H(10)), 2.56 (3H, s, H(11)). 13C NMR (100 MHz, CDCl3): δ 180.0, 161.7, 148.5, 148.2, 
137.0, 135.9, 125.9, 122.7, 108.8, 17.5, 15.1. m/z (ESI +): 226 ([C10H11NOS2 + H]+). 
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4’-(methylthio)-2-2’:6’2’’-terpyridine (11) 
 
Operating under an argon atmosphere at room temperature, a suspension of 
potassium tert-butoxide (2.50 g, 22.0 mmol) in anhydrous THF (70 mL) was 
vigorously stirred. The addition of 2-acetylpyridine (1.15 mL, 10.2 mmol) resulted in 
the reaction mixture taking on a deep orange complexion, after which 3,3- 
bis(methylthio)-1-(2-pyridinyl)-2-propen-1-one (2.32 g, 10.2 mmol) was added. 
Following 16 h stirring at room temperature, ammonium acetate (7.93 g, 0.10 M) and 
glacial acetic acid (20 mL) were added before heating under reflux for a further 4 h 
with continuous removal of THF. The solution was cooled to 15 °C, diluted with ice 
and allowed to stand for 3 h. Water was then added, and the resulting precipitate 
collected by filtration and air dried to afford the title compound as a brown solid  
(2.16 g, 76%). 
1H NMR (300 MHz, CDCl3): δ 8.71 (2H, d, J = 7.4, H(3/3’’)), 8.60 (2H, d, J = 7.2, H(6/6’’)), 
8.30 (2H, s, H(3’/5’)), 7.85 (2H, t, J = 7.6, H(4/4’’)), 7.34 (2H, t, J = 6.9, H(5/5’’)), 2.66 (3H, 
s, H(7)).13C NMR (100 MHz, CDCl3): δ 155.9, 154.8, 153.6 149.0, 136.9, 123.9, 121.7, 
117.0, 14.0. m/z (ESI +): 280 ([C16H13N3S + H]+). 
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4’-(methylsulfinyl)-2-2’:6’2’’-terpyridine (12) 
 
4’-(methylthio)-2-2’:6’2’’-terpyridine (1.60 g, 5.73 mmol) was added to a solution of 
glacial acetic acid (10 mL) and 30% H2O2 solution (2 mL) and heated at 45 °C for  
18 h. Following the addition of CHCl3 (5 mL), the solution was basified to pH 8 by the 
addition of 30% NH3 solution. The solution was extracted with CHCl3 and the organic 
phases combined and dried over MgSO4. Removal of the solvent under reduced 
pressure yielded the product as brown solid (1.38 g, 82%). 
1H NMR (300 MHz, CD3CN): δ 8.71 (2H, d, J = 7.4, H(3/3’’)), 8.63 (2H, s, H(3’/5’)), 8.62 
(2H, d, J = 7.2, H(6/6’’)),  7.95 (2H, t, J = 7.5, H(4/4’’)), 7.45 (2H, t, J = 7.0, H(5/5’’)), 2.83 
(3H, s, H(7)). 13C NMR (100 MHz, CD3CN): δ 160.1, 156.9, 155.3, 150.0, 137.9, 
125.3, 121.7, 117.9, 115.3, 43.3. m/z (ESI +): 296 ([C16H13N3SO + H]+). UV-Vis 
(CH3CN) λmax / nm (εmax dm3mol-1cm-1): 251 (21800), 277 (24500). 
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[Pd(12)CH3CN](BF4)2 (13) 
 
Operating under an argon atmosphere 4’-(methylsulfinyl)-2-2’:6’2’’-terpyridine (6.60 
mg, 23.0 µmol) was dissolved in dry acetonitrile (15 mL). 
Tetrakis(acetonitrile)palladium(II) tetrafluoroborate (10.0 mg, 23.0 µmol) was added 
under a strong flow of argon and the solution stirred for 18 h at room temperature. 
The solution was filtered through a fine filter membrane and the filtrate concentrated 
in vacuo to form a brown solid. The solid was washed with chloroform (2 mL), 
methanol (2 mL) and diethyl ether (2 mL) and left to dry under vacuum to yield 
[Pd(12)CH3CN](BF4)2 as a beige solid (8.70 mg, 62%). 
1H NMR (300 MHz, CD3CN): δ 8.59 (2H, d, J = 7.4, H(3/3’’)), 8.50 (2H, s, H(3’/5’)), 8.45 
(4H, overlapping m, H(6/6’’)/(4/4’’)), 7.88 (2H, t, J = 6.9, H(5/5’’)), 2.97 (3H, s, H(7)). m/z 
(ESI +): 442 ([Pd(C16H13N3SO)(CH3CN)]). UV-Vis (CH3CN) λmax / nm (εmax dm3mol-
1cm-1): 241 (26900), 267 (17200), 335 (7700), 351(10100), 368 (10100). Elemental 
analysis: Calculated for [Pd(C16H13N3SO)(CH3CN)](BF4)2 1/3 Et2O: C, 36.21; N, 8.74; 
H, 3.04. Found: C, 36.40; N, 8.33; H, 2.39.  
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[Pt(12)Cl](PF6) (14) 
 
A solution of 4’-(methylsulfinyl)-2-2’:6’2’’-terpyridine (7.10 mg, 25.0 µmol) in 
acetonitrile was added to a solution of potassium tetrachloroplatinate (10.0 mg, 25.0 
µmol) in water. The mixture was heated under reflux at 105 °C for 18 h. Following hot 
filtration through a fine membrane, a methanolic solution of ammonium 
hexafluorophosphate (slight excess) was added to the orange filtrate. Raspberry pink 
precipitate immediately formed and was collected by filtration and washed carefully 
with CHCl3, MeOH and Et2O, before drying under vacuum to yield [Pt(12)Cl](PF6) as 
raspberry purple solid (11.4 mg, 68%).  
1H NMR (300 MHz, CD3CN): δ 9.08 (2H, d, J = 7.4, H(3/3’’)), 8.49 (2H, s, H(3’/5’)), 8.40 
(4H, overlapping m, H(6/6’’)/(4/4’’)), 7.90 (2H, t, J = 6.9, H(5/5’’)), 2.96 (3H, s, H(7)). m/z 
(ESI +): 525 ([Pt(C16H13N3SO)Cl]). UV-Vis (CH3CN) λmax / nm (εmax dm3mol-1cm-1): 
255 (26300), 283 (25200), 319 (12500), 334 (14000), 398 (3200). Elemental 
analysis: Calculated for [Pt(C16H13N3SO)Cl](PF6) 1/4 CHCl3: C, 27.85; N, 6.00; H, 
1.91. Found: C, 27.78; N, 5.89; H, 2.01.  
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3.8.4 Circular dichroism (CD) 
Calf-thymus DNA (ct-DNA) was purchased from Sigma Aldrich. Htelo and cMyc DNA 
sequences were purchased from Eurofins. DNA stock solutions were made up in 
ultrapure water (18.2 MΩ). Solutions were contained within a quartz cuvette with a 1 
cm pathlength. Solutions A-C (see below) were prepared for each experiment. A CD 
spectrum of solution A was initially recorded, before equal volumes of solutions B 
and C were added. Following each addition, a new CD spectrum was recorded. The 
addition of solution B ensures the DNA concentration remains constant over the 
duration of the experiment, whilst increasing the complex concentration accordingly.  
ct-DNA was stored in a 3000 µM frozen stock solution. DNA solutions were analysed 
by UV-Vis to determine an accurate DNA concentration (ε258 = 6600 mol-1dm3cm-1 
calculated per base). 
A. 150 µM DNA in 20 mM NaCl, 1 mM sodium cacodylate 
B. 300 µM DNA in 40 mM NaCl, 2 mM sodium cacodylate 
C. 250 µM complex solution 
Htelo DNA was stored in a 200 µM frozen stock solution. DNA solutions were 
analysed by UV-Vis to determine an accurate DNA concentration (ε252 = 228000  
mol-1dm3cm-1 calculated per strand). 
A. 3 µM DNA in 10 mM tris-HCl, 100 mM KCl 
B. 6 µM DNA in 20 mM tris-HCl, 200 mM KCl 
C. 150 µM complex solution 
n.b. Htelo DNA sequences were annealed at 95 °C for 5 minutes prior to overnight 
storage in the fridge in preparation for use the following day. 
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cMyc DNA was stored in a 100 µM frozen stock solution. DNA solutions were 
analysed by UV-Vis to determine an accurate DNA concentration (ε250 = 231000  
mol-1dm3cm-1 calculated per strand). 
A. 3 µM DNA in 10 mM tris-HCl, 100 mM KCl 
B. 6 µM DNA in 20 mM tris-HCl, 200 mM KCl 
C. 150 µM complex solution 
n.b. cMyc DNA sequences were annealed at 95 °C for 5 minutes prior to overnight 
storage in the fridge in preparation for use the following day. 
 
3.8.5 Polyacrylamide gel electrophoresis (PAGE) 
Sample preparation completed by L. Bright. Electrophoresis completed by P. Cail. 
Gel Preparation. 15% native polyacrylamide gel solution containing 2x TB buffer (1x: 
890 mM tris(hydroxymethyl)amino methane, 890 mM boric acid, 25 mL, pH 8.3), 40% 
acrylamide (29:1, 18.75 mL) and dd H2O (6.25 mL) was mixed before the addition of 
10% (w/v) ammonium persulfate solution (234 µL) and TEMED (25 µL). The solution 
was poured between a set of glass electrophoresis plates (20 cm x 20 cm) and a 14 
well comb inserted into the top. The gel was left for 45 minutes to polymerise before 
removal of the comb and thorough washing of each well with running buffer (1x TB 
buffer). The gel slab was mounted into an electrophoresis unit (Bio-rad) and pre-run 
at 300 V for 10 minutes. 
Electrophoresis. Samples were prepared in eppendorfs (1.5 mL) containing the 
components of interest (DNA, tris HCl-KCl buffer, complex) and incubated at room 
temperature for 1 h. 30% glycerol solution (5 µL) was added to each sample to help 
the sample sink into the gel wells whilst in buffer. The samples were then loaded into 
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separate lanes on the gel. DNA loading dye (5x gelPilot™, QIAGEN) was loaded into 
the first well to monitor the progress of the experiment. The gel was run at a constant 
10 V/cm for 5 h. The gel was then removed from the glass plates and immersed in a 
1x SyBr Gold DNA staining solution (ThermoFisher) for 40 minutes. The gel was 
imaged and photographed directly in a photo illuminator (UviPro). 
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IV. EXPLORING ROUTES TO ALTERNATIVE LIGANDS 
 
4.1 Introduction 
This chapter details the synthetic methodology employed whilst exploring several 
routes towards alternative G-quadruplex binding ligands. Attempted with varying 
degrees of success, they are presented herein for the purposes of completeness, 
and in order to demonstrate their feasibility for future work. These routes include the 
design and synthesis of unsymmetrical ligand systems, the exploration of N^C 
coordination points and the incorporation of ‘click’-capable functionalities. Several 
coupling methodologies are explored, including Suzuki, Stille, Grignard and 
Sonogashira. 
 
4.2 Incorporating isoquinoline into an unsymmetrical ligand 
4.2.1 Target compound 1: 3-(pyridine-2-yl)isoquinoline 
On account of its demonstrated ability to achieve G-quadruplex binding interactions, 
incorporation of the isoquinoline motif into unsymmetrical ligands was explored. 
Chosen due to its structural simplicity, the first synthetic target was 3-(pyridine-2-
yl)isoquinoline (Figure 4.2.1-1). Unsymmetrical ligands such as this have the 
potential to bind to a metal atom in the same bidentate fashion as 3,3-biisoquinoline 
to yield novel metal complexes. Such complexes may contain two unsymmetrical 
ligands, or a combination of unsymmetrical and symmetrical ligands in a mixed 
system.  
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Figure 4.2.1-1 Synthetic target: 3-(pyridine-2-yl)isoquinoline 
4.2.2 Palladium-catalysed α-arylation of ketones with aryl halides 
Originally reported by Palucki and Buchwald,1 Hamann and Hartwig2 and Miura and 
coworkers,3 the palladium-catalyzed α-arylation of ketone enolates represents a 
powerful reaction in synthetic chemistry.4 Utilising a disconnection approach, 
Donohoe et al. recently reported that pseudo-1,5-dicarbonyl intermediates can be 
accessed via the Pd-catalyzed α-arylation of ketones with aryl halides possessing a 
protected ketone or aldehyde in the ortho position.5,6 Subsequent treatment with an 
acidic ammonium source results in acetal deprotection and aromatization to yield the 
corresponding isoquinoline (Figure 4.2.2-1). This route represents an entirely 
different approach towards isoquinoline formation than that previously employed in 
Chapter II. Requiring commercially available or readily-prepared precursors, it also 
offers an attractive method for regioselective substitution of isoquinoline in a single 
step. 
 
Figure 4.2.2-1 Preparation of substituted isoquinolines utilizing i. palladium-catalysed α-
arylation of ketones followed by ii. ammonium chloride mediated deprotection and 
cyclization, as reported by Donohoe and coworkers.6 
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4.2.3 3-(pyridine-2-yl)isoquinoline  (15) 
Utilising the one-pot procedure reported by Donohoe et al. for sequential arylation 
and cyclisation, preparation of 3-(pyridine-2-yl)isoquinoline was attempted (Figure 
4.2.3-1).  
 
Figure 4.2.3-1 Synthesis of 3-(pyridine-2-yl)isoquinoline. 
Catalyst loading of 4.0 mol % was used during the initial α-arylation of 2-
acetylpyridine with aryl bromide. Following overnight heating, the cooled solution was 
acidified to pH 5 to enable acetal hydrolysis. Subsequent heating of the intermediate 
(not isolated) in a solution of ammonium chloride failed to yield the desired product, 
with the reaction unfortunately proving unsuccessful.  
The possible cause for the reaction failure was unclear. Donohoe and 
coworkers have reported the successful preparation of structurally similar 3-
phenylisoquinoline in 74% yield using the one-pot method. Evidently, the use of 2-
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acetylpyridine instead of acetophenone to achieve the pyridine-substituted 
isoquinoline (15) instead of the phenyl-substituted isoquinoline creates a problem.  
Unclear whether or not the failure was as a result of unsuccessful α-arylation 
in the first instance, or problems arising from the base-mediated deprotection and 
cyclisation that follows, the reaction was repeated. On this attempt, the 
transformation was carried out in two discrete synthetic steps rather than the one-pot 
procedure previously employed.   
Disappointingly, preparation of the intermediate product, 2-(2-(1,3-dioxolan-2-
yl)phenyl)-1-(pyridine-2-yl)ethanone (16) was unsuccessful, indicating an apparent 
inability of 2-acetylpridine to undergo α-arylation. Following multiple attempts with no 
success, a discussion with the Donohoe group confirmed that preparation of the 
desired pyridine-substituted isoquinoline (15) can not be achieved via this route. 
Indeed, they had attempted such transformations themselves and determined the 
nitrogen atom from the pyridine ring to interfere with the catalytic cycle, thus 
preventing isoquinoline formation. This particular route towards an unsymmetrical 
bidentate N-donor ligand was consequently abandoned.  
 
4.3 Incorporating isoquinoline into an unsymmetrical N^C-coordinating 
ligand with “click” capable functionality 
4.3.1 Target compound 2: 3-(4-ethynylphenyl)isoquinoline  
Maintaining the intention to synthesise unsymmetrical ligands incorporating the 
isoquinoline unit, the next synthetic target incorporated two additional features; an 
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alkyne group for the purpose of introducing future functionality via “click chemistry” 
and a modified N^C metal binding system (Figure 4.3.1-1). 
                                          
Figure 4.3.1-1 Synthetic target: 3-(4-ethynylphenyl)isoquinoline  
4.3.2 “Click chemistry” 
Introduced by K. Barry Sharpless in 2001, the term "click chemistry" denotes 
the development of a set of reactions that are highly reliable and selective, enabling 
the rapid synthesis of useful novel compounds through heteroatom links.7 These 
reactions are described as high-yielding, wide in scope, stereospecific, simple to 
perform, and can be conducted in easily removable solvents with by-products that 
can be easily removed without chromatography.  
Click chemistry is demonstrated well for many cycloaddition reactions, 
especially 1,3-dipolar cycloadditions that bring together two unsaturated reactants to 
provide a variety of five- and six-membered heterocycles.8,9 The Huisgen 1,3-dipolar 
cycloaddition of azides and terminal alkynes to give 1,2,3-triazoles is a powerful click 
reaction, regarded as the ‘cream of the crop’.7,10 This concerted, Cu(I)-catalyzed 
reaction is effective in producing 1,4-regioisomers of 1,2,3-triazoles as the single 
products  (Figure 4.3.2-1).11 
N
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Figure 4.3.2-1 Azide-alkyne cycloaddition to produce 1,2,3-triazoles.  
The addition of alkyne functionality to the target ligand facilitates future 
functionalization of the ligand with a wide variety of components such as a cationic 
side-chain capable of promoting G-quadruplex interactions via binding duality. There 
is also the potential to attach a fluorophore at this site for the purposes of imaging. 
Click chemistry finds widespread application for this very purpose, with an excellent 
selection of azide functionalised molecular probes commercially available. The para 
position is an ideal site for such modifications to be made; avoiding future hindrance 
to complex formation that may occur as a result of bulky substituents occupying 
either the ortho or meta positions. Furthermore, there is good availability of para 
substituted alkyne reagents for synthesis.  
Incorporating such functionality into the target ligand enables it to serve as a 
‘base unit’ which can undergo several modifications to generate a panel of novel 
ligands, each tailored towards maximising G-quadruplex binding interactions.  
 
4.3.3 N^C coordination 
Square planar complexes possessing simple bipyridine or terpyridine ligands are 
typically non-emissive at room temperature, due to their metal-centred d-d states 
being subject to efficient non-radiative deactivation, providing a decay pathway for 
the emissive state.12,13 The incorporation of a cyclometallated carbon raises the 
R N3 R1
N N
N
R1
R
0.25 - 2 mol % CuSO4.5H2O
5 - 10 mol % sodium ascorbate
H2O/t-BuOH (1:1), r.t., 6-12 h
R: alkyl, CH2OBn
R1: Ph, CO2H
+
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energy of the metal-centred excited states due to the strong ligand field influence of 
the aromatic carbon atom, therefore limiting non-radiative decay.14  
Several examples of cyclometallated organometallic platinum complexes 
based on N^C aromatic chelates have been reported in the literature, including 
homoleptic complexes (N^C)2,15 heteroleptic complexes (N^C)(N’^C),16 and 
complexes containing a single cyclometallating ligand (N^C) and a non-
cyclometalling ancillary ligand (LX).17,18 Many of these cyclometallated complexes 
are strongly emissive and exhibit long luminescent lifetimes (microseconds) in 
solution, indicative of emission from the triplet excited state.  
Consequently, the incorporation of a cyclometallated carbon represents an 
alternative route to luminescent complexes suitable for in vitro imaging, possibly 
negating the need for molecular probe attachment at all. The wide variety of 
complexes reported to date, reinforce the desire to develop mixed-ligand complexes 
incorporating 3,3-biisoquinoline, which will very likely exhibit varying photophysical 
properties to the homoleptic complexes.  
 
4.3.4 Palladium-catalysed Suzuki-coupling of organoboranes with 
organohalides 
First published by Akira Suzuki in 1979, the Suzuki reaction is a palladium-catalysed 
coupling reaction between an organoborane and an organohalide.19–21 A carbon-
carbon bond is formed between the coupling partners, using a Pd-catalyst and base 
(Figure 4.3.4-1).  
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Figure 4.3.4-1 Suzuki cross-coupling between an organoborane and organohalide. 
Oxidative addition of the organohalide to palladium(0) to form an organopalladium(II) 
species is followed by its reaction with base. Transmetallation with a boronate 
complex (produced by reaction of the boronic acid with base) then occurs.22 The 
desired coupled product is generated through reductive elimination of the 
palladium(II) species, regenerating the palladium(0) reagent and completing the 
catalytic cycle (Figure 4.3.4-2).  
      
Figure 4.3.4-2 Mechanism for palladium catalysed Suzuki cross-coupling via oxidative 
addition, transmetallation and reductive elimination.  
This route was chosen due to the availability of common boronic acids, their lower 
toxicity (compared to organostannane or organozinc compounds), mild reaction 
conditions and the convenience of already having prepared suitable halide-
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L
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substituted isoquinolines in good yields (compounds (3) and (6), Chapter II).   
 
4.3.5 3-(4-ethynylphenyl)isoquinoline (17) 
The first attempt to prepare this compound involved the coupling of 3-
chloroisoquinoline (3) and 4-ethynylphenylboronic acid pinacol ester. Using a method 
described by Yamashita et al.,23 tetrakis(triphenylphosphine)palladium(0) and 
aqueous sodium carbonate solution were added to the coupling partners in 
anhydrous 1,4-dioxane and heated under an argon atmosphere overnight (Figure 
4.3.5-1, Method a). Following cooling and filtration, analysis of the crude product 
showed the reaction had been unsuccessful, with no evidence of compound 
formation (analysed by 1H NMR, ESI-MS, TLC). On reflection, the use of an aqueous 
solution of base, within a procedure that requires air sensitivity seemed somewhat 
counterproductive. For this reason, an alternative method was selected for a second 
attempt. 
Utilising more common Suzuki coupling reagents, 4-
(dihydroxyborophenyl)acetylene and compound (3) were added to 
tetrakis(triphenylphosphine) palladium(0) and potassium carbonate in anhydrous 
DMF and heated under an argon atmosphere overnight (Figure 4.3.5-1, Method b).24 
Rather disappointingly, following an identical work-up, this method also proved to be 
unsuccessful. Analysis showed the clear presence of unreacted isoquinoline-halide. 
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Figure 4.3.5-1 Synthesis of 3-(4-ethynylphenyl)isoquinoline by two alternative palladium-
catalysed Suzuki coupling routes. 
Owing to the demonstrated ability of bromine to improve reaction success by acting 
as a better leaving group than chlorine, the reaction was attempted using 3-
bromoisoquinoline (6), to no avail.  
 
Following several further unsuccessful attempts utilising both isoquinoline-halides 
(3/6) and both organoborane reagents, method (b) was trialled for a similar 
transformation available in the literature (Figure 4.3.5-2).24 
         
Figure 4.3.5-2 Synthesis of 4-(pyridine-2-yl)aniline 
 
a. BR, (PPh3)4Pd, sat. soln. Na2CO3 
1,4-dioxane, 100 °C, Ar atm. 24 h
b. BR, (PPh3)4Pd, K2CO3
DMF, 100 °C, Ar atm. 24 h
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A solution of 2-bromopyridine, 4-aminophenylboronic acid pinacol ester, 
tetrakis(triphenylphosphine) palladium(0) and potassium carbonate in anhydrous 
DMF was heated under an argon atmosphere overnight. The reaction mixture was 
cooled, filtered, extracted into EtOAc and purified by column chromatography to yield 
an orange liquid which analysis confirmed to be the desired product, 4-(pyridine-2-
yl)aniline (18) albeit in poorer yield than that reported (51% vs. 79%).  
Clearly, the method being employed is a suitable method for the successful 
coupling of organoboranes and organohalides. Consequently, the failure of this 
method to achieve the target ligand is most likely due to the specific coupling 
reagents involved in this route. There are many examples of Suzuki couplings 
involving isoquinolines in the literature, therefore it is unlikely to be due to this 
reagent. It is proposed that the presence of the alkyne moiety on the borane reagent 
is causing some interference with the catalytic cycle. Formation of a metal alkyne 
complex in solution may prevent oxidative addition of the organohalide to the 
palladium catalyst, halting the catalytic cycle. This would account for the repeated 
presence of unchanged organohalide peaks in 1H NMR and ESI-MS analysis of the 
crude product.  
Owing to the repeated failure of several routes towards the desired N^C, click-
capable ligand, and the proposed interference of the alkyne moiety, coupling 
reactions involving an in situ alkyne were no longer pursued. 
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4.4 An alternative route to an unsymmetrical N^C-coordinating isoquinoline 
ligand: coupling in the absence of an alkyne 
4.4.1 Target ligand 3: 3-(4-chlorophenyl)isoquinoline 
Following the repeated failure of Suzuki coupling routes towards the desired ligand, a 
new method was selected. In addition to employing an alternative coupling 
procedure, it was also decided to attempt coupling with a halide-substituted aromatic, 
rather than an alkyne-substituted aromatic. Any possible interference or hindrance 
experienced by the presence of the alkyne moiety is therefore avoided during the 
coupling process. The alkyne may then be added to the already coupled product, via 
palladium catalysed Sonogashira cross-coupling of a terminal alkyne and the existing 
halide. The target ligand still possesses the desired N^C coordination, differing only 
in the presence of a halide in place in of the alkyne (Figure 4.4.1-1). 
                                          
Figure 4.4.1-1 Synthetic target: 3-(4-chlorophenyl)isoquinoline 
4.4.2 Palladium-catalysed Stille-coupling of organostannanes with halides 
Developed by John Stille in 1978, the Stille reaction is a palladium-catalysed coupling 
reaction between an organotin compound and an organic electrophile (Figure 
4.4.2-1).25,26 
           
N
Cl
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Figure 4.4.2-1 Stille cross-coupling between an organostannane and organohalide. 
Oxidative addition of the halide to palladium(0) to form an organopalladium(II) 
species is followed by transmetallation with an organotin reagent. Reductive 
elimination of the palladium(II) species yields the coupled product and the 
regenerated palladium(0) catalyst (Figure 4.4.2-2).27 Organnostannane reagents are 
both air and moisture stable, with many reagents commercially available or readily 
synthesised.28 
 
    
Figure 4.4.2-2 Mechanism for palladium-catalysed Stille cross-coupling via oxidative addition, 
transmetallation and reductive elimination.  
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4.4.3 3-(4-chlorophenyl)isoquinoline (19) 
Based on a method described by Buchwald et al.,29 utilising a biarylphosphine-based 
catalyst system, 3-bromoisoquinoline (6) was coupled with tributyl(4-
chloro)phenylstannane (Figure 4.4.3-1).  
 
Figure 4.4.3-1 Synthesis of 3-(4-chlorophenyl)isoquinoline by palladium-catalysed Stille 
coupling  
Reduction of the palladium(II) source (Pd(OAc)2), by added phosphine ligands 
(XPhos) generates the active palladium(0) catalyst. Fluoride ions have been found to 
have two useful effects on the catalytic cycle in their ability to increase rates of 
reactions of organotriflates, and act as scavengers for tin by-products, therefore 
making them easier to remove by filtration.30 For these reasons, caesium fluoride is a 
common additive to the Stille reaction and was used herein.  
Under an argon atmosphere, the reaction was heated for 48 hours and 
monitored by TLC. The reaction proceeded well. Purification of the crude solid by 
column chromatography yielded the desired product in good yield. Electrospray 
ionisation mass spectrometry and nuclear magnetic resonance data were in 
accordance with those reported in the literature.  
The Stille reaction has proved to be an effective and successful method for the 
preparation of this compound. Previously prepared via silver-catalysed cyclization of 
N
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Sn((CH2)3CH3)3
+
Pd(OAc)2, XPhos, CsF
t-BuOH, 110 °C, Ar atm. 48 h
                  72%
N
Cl196
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2-alkynyl benzyl azides,31 the Stille method represents a novel route towards this 
compound, securing a higher yield than that previously reported (72% vs. 56%). 
 Following the successful synthesis of this N^C coordinating ligand, future work 
would include attachment of an alkyne moiety via Sonogashira coupling at the halide 
site. The formation of metal complexes with various metal centres including Pt, Pd 
and Au could then be attempted.  
 
4.5 Incorporating N^C-coordination into a terdentate ligand system 
Whilst exploring the aforementioned modifications to the bidentate ligand system 
utilised in Chapter II, namely the incorporation of N^C coordination and the ability to 
introduce further functionality via a suitably located organohalide, it was a natural 
progression to determine if these features could also be introduced into terpyridine-
based systems such as those described in Chapter III.  
 
4.5.1 Target ligand 4: 5-chloro-1,3-di(2-pyridyl)benzene 
In addition to complexes with bidentate N^C coordination (see 4.3.3), three classes of 
tridentate cyclometallating ligands have been investigated, comprising N^N^C,32 
C^N^C33 and N^C^N34 coordination modes. Most notably, Williams and co-workers 
have reported a class of cyclometallated Pt(II) complexes of the N^C^N-coordinating 
ligand 1,3-di(2-pyridyl)benzene, which exhibit remarkably high luminescence 
quantum yields.35 They have further demonstrated the ability to fine-tune the 
emission energy of this class of platinum complexes, enabling the emission spectra 
to be shifted to a shorter or longer wavelength with the use of electron-withdrawing or 
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electron-donating aryl substituents at the 5-position of the phenyl ring. Modification 
via the para substituent on the phenyl ring leaves the quantum yields and 
luminescent lifetimes largely unaffected.36 
The target ligand is a 5-substituted derivative of 1,3-di(2-pyridyl)benzene 
(Figure 4.5.1-1). This N^C^N-coordinating ligand possesses a chloride substituent at 
the para position on the phenyl ring, ideally positioned for further modification to the 
chelate. This positioning (on the opposite side to the N^C^N-coordination sites), 
ensures that any appendages will extend away from the complex centre, thus 
avoiding steric hindrance. In the event of enhancing G-quartet interaction, the 
interacting moiety is not shackled to the complex core (which will likely sit above or 
below the G-quadruplex stack, aligned with the core), rather it extends freely out 
towards the quadruplex backbone, facilitating loop/groove region interaction or 
intercalation between G-quartets (dependent on the linker length). A halide was 
chosen due to its versatility to engage in several coupling routes (including 
Sonogashira, Suzuki, Stille, Grignard), enabling a wide variety of modifications to be 
made.  
                                                
Figure 4.5.1-1 Synthetic target: 5-chloro-1,3-di(2-pyridyl)benzene 
N N
Cl
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4.5.2 5-chloro-1,3-di(2-pyridyl)benzene (20) 
Utilising the approach demonstrated by Williams et al.,37 the desired N^C^N ligand 
was prepared by palladium-catalysed Stille cross-coupling (Figure 4.5.2-1). A mixture 
of 1,3-dibromo-5-chlorobenzene, 2-tributylstannylpyridine, LiCl and 
bis(triphenylphosphine)palladium chloride in toluene was degassed via five freeze-
pump-thaw cycles and then heated at reflux under an inert atmosphere for 3 days. A 
solution of potassium chloride was added, and the mixture stirred for 30 minutes. 
Purification of the crude product by column chromatography yielded the desired 
product as colourless solid in reasonable yield. 
 
Figure 4.5.2-1 Synthesis of 5-chloro-1,3-di(2-pyridyl)benzene by palladium-catalysed Stille 
coupling. 
Future studies with this ligand would focus on modification of the base unit to explore 
the full scope of functionalities that can be added to the tpy unit via several of the 
coupling methods mentioned thus far. Determining what conditions can be tolerated 
by the ligand is key to establishing the most effective strategy towards G-quadruplex 
specific ligands.  
Cl
Br Br
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4.6 Exploring an alternative coupling route towards 3,3-biisoquinoline 
4.6.1 Grignard-mediated homocoupling of sulphoxide ligands 
In addition to cross-coupling reactions of sulphoxides with Grignard reagents (as 
described in Chapter III, Fig. 3.2.1-1), Oae et al. have also demonstrated a 
convenient method for ligand coupling between two methylsulphinylarenes using 
Grignard reagent (Figure 4.6.1-1).38 This represents an alternative route towards 3,3-
biisoquinoline; potentially circumventing the issues relating to poor yield, currently 
arising from the zinc-catalysed Colon-coupling route.  
                    
Figure 4.6.1-1 Ligand coupling between two heteroaryl groups using a Grignard reagent 
4.6.2 Method trial: 5,5’-dibromo-2,2’-bipyridine synthesis 
Implementation of the Grignard coupling method was first tested on a known system, 
in order to establish the procedure (Figure 4.6.2-1). 
                   
Figure 4.6.2-1 Synthesis of 5,5’-dibromo-2,2’-bipyridine under the following conditions:  
i. NaSMe; ii. H2O2/HOAc iii. EtMgBr. 
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Step i. The first step involves the reaction of a halogenopyridine with sodium 
alkanethiolate to form the methylthio-substituted pyridine. This nucleophilic aromatic 
substitution reaction proceeds via the bimolecular displacement mechanism 
SNAr.39,40 Rate-determining addition of -SCH3 is followed by elimination to yield the 
methylthio-substituted pyridine.  
       
Figure 4.6.2-2 Nucleophilic aromatic substitution (step i.) via SNAr mechanism.      
Step ii. Partial oxidation of the sulphide to sulfoxide using hydrogen peroxide occurs 
in the same manner as that described previously (Chapter III, Fig. 3.2.3-3).  
 
Step iii. Ligand coupling between two heteroaryl groups proceeds via an σ-sulfurane 
intermediate as shown in Figure 4.6.2-3. The initial step of the reaction involves 
ligand exchange between the (2-pyridyl group) methylsulphinyl subsituent and 
Grignard reagent. The 2-pyridyl magnesium bromide formed immediately attacks the 
sulphinyl sulphur atom of the starting sulphoxide to form the crucial σ-sulfurane 
intermediate. Orbital overlap of the two ligands within this intermediate, results in 
biaryl formation.41 Grignard reagents inherently have poor functional group tolerance 
requiring low-temperature syntheses.  
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Figure 4.6.2-3 Mechanism for ligand coupling (step iii.) through an σ-sulfurane intermediate, 
following treatment of sulphoxides with Grignard reagent. 
Specific details relating to each step of the synthesis are now briefly described, and 
summarised in Figure 4.6.2-4.  
 
            
Figure 4.6.2-4 Three-step synthesis of 5,5’-dibromo-2,2’-bipyridine.  
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Step i. 5-bromo-2-(methylthio)pyridine (21) 
Preparation of compound (21) was completed using a method described by 
Testaferri et al.42 A solution of 2,5-dibromopyridine and NaSMe in DMF was stirred 
under an inert atmosphere and monitored by TLC. The reaction proceeded well. 
Isolation of the crude product after 24 hours yielded yellow crystalline solid in good 
yield, and requiring no further purification.  Electrospray ionisation mass spectrometry 
and nuclear magnetic resonance data were in accordance with those reported in the 
literature.  
 
Step ii. 5-bromo-2-(methylsulphinyl)pyridine (22) 
Owing to prior success in achieving partial oxidation of the sulphide to sulphoxide 
(see Chapter III, 3.2.3-3), the method described by Oae et al. was once again 
employed.43 A solution of (21) in 30% H2O2 and glacial acetic acid was stirred for 24 
hours. Following extraction of the crude product and overnight drying over P2O5 in a 
dessicator, the desired product was afforded as a yellow solid in very high yield. 
Electrospray ionisation mass spectrometry and nuclear magnetic resonance data 
were in accordance with those reported in the literature. 
 
Step iii. 5,5’-dibromo-2,2’-bipyridine (23) 
In accordance with the standard method reported by Oae et al.,38 EtMgBr was added 
to an ice-cold solution of (22) in Et2O. The resulting suspension was stirred at room 
temperature for 1 hour. Addition of water, followed by extraction with toluene isolated 
crude solid that was recrystallized with EtOAc to afford the desired product as gold-
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brown crystals in good yield. Electrospray ionisation mass spectrometry and nuclear 
magnetic resonance data were in accordance with those reported in the literature.    
 
4.6.3 Synthesis of 3,3-biisoquinoline via Grignard-mediated homocoupling 
Having successfully trialled Grignard-mediated ligand coupling, the method was 
applied to the formation of 3,3-biisoquinoline (Figure 4.6.3-1). Utilising the same 
three-step procedure as that demonstrated above, conversion of isoquinoline-halide 
is followed by partial oxidation of the resulting sulphide to sulphoxide. Ligand 
coupling through an σ-sulfurane intermediate produces the coupled biisoquinoline 
product. 
                   
Figure 4.6.3-1 Synthesis of 3,3-biisoquinoline under the following conditions: i. NaSMe;  
ii. H2O2/HOAc iii. EtMgBr. 
3-(methylthio)isoquinoline (24) 
In accordance with Testaferri et al.,42 a solution of 3-chloroisoquinoline (3) and 
NaSMe in DMF was stirred under an inert atmosphere overnight (Figure 4.6.3-2).  
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Figure 4.6.3-2 Synthesis of 3-(methylthio)isoquinoline 
An identical work-up to that previously employed yielded a yellow solid in good yield. 
Electrospray ionisation mass spectrometry and nuclear magnetic resonance data 
were in accordance with those reported in the literature. 
 
3-(methylsulphinyl)isoquinoline (25) 
Oxidation of the existing methylthio-substituted isoquinoline to the desired 
methylsulphinyl-substituted isoquinoline was achieved using hydrogen peroxide in 
glacial acetic acid as described by Oae et al.43 (Figure 4.6.3-3).  
                        
Figure 4.6.3-3 Synthesis of 3-(methylsulphinyl)isoquinoline 
The reaction proceeded well under acidic conditions, producing a dark yellow solid in 
good yield. Electrospray ionisation mass spectrometry and nuclear magnetic 
resonance data were in accordance with those reported in the literature. Partial 
oxidation of the sulphide is confirmed by an observable downfield shift in all peaks 
(Figure 4.6.3-4). In particular, the thiomethyl peak from 2.63 ppm (R-S(CH3)) to 3.29 
ppm (R-S(=O)(CH3), and the aromatic proton in closest proximity and thus that which 
N
Cl
N
SCH3
NaSMe, DMF
r.t, Ar atm. 24 h
        65%
3 24
N
SCH3
N
S
O
CH3
30% H2O2
AcOH, r.t, 24 h
        81%
24 25
 220 
experiences the greatest degree of deshielding due to the nearby oxygen atom from 
7.43 ppm to 8.55 ppm. 
 
Figure 4.6.3-4 1H-NMR spectra overlay of 3-(methylthio)isoquinoline (24) and  
3-(methylsulphinyl)isoquinoline (25) (300 MHz, CDCl3, 298°K) 
3,3-biisoquinoline (26) 
In accordance with Oae et al.,38 EtMgBr was added to a cold solution of 3-
(methylsulphinyl)isoquinoline (25) in THF and stirred under an inert atmosphere at 
room temperature (Figure 4.6.3-5). 
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Figure 4.6.3-5 Synthesis of 3,3-biisoquinoline 
White cloudy suspension formed upon addition of the Grignard to the yellow solution. 
Monitoring of the reaction by TLC saw no change, even after 24 hours (Oae et al. 
report ligand coupling typically achieved in under one hour).38 At this point, the 
reaction was ‘worked up’, with analysis unfortunately confirming the reaction to be 
unsuccessful. The 1H NMR spectrum showed the clear presence of unreacted 
starting material.  
Further attempts were made, with no noticeable developments or success. 
Following the repeated failure of this method, it was proposed that the solvent may 
have some effect, since the trial coupling to prepare (23) was completed in diethyl 
ether, whilst the attempted synthesis of 3,3-biisoquinoline had been carried out in 
tetrahydrofuran due to insolubility of the ligand in Et2O.  
To assess this hypothesis, preparation of trial compound (23) was revisited, 
and upon confirming solubility of the methylsulphinylpyridine (22) in THF, the reaction 
was repeated under otherwise identical conditions. The reaction was surprisingly 
unsuccessful, with evidence of only the starting material in crude analysis. Despite 
THF being both a common and widely used solvent for reactions involving Grignard 
reagents, the success of this particular transformation was shown to be solvent-
dependent.  
N
S
O
CH3
N N
EtMgBr, 0 °C
Et2O, r.t, Ar atm. 24 h
25 26
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Assuming that the use of THF hinders 3,3-biisoquinoline formation in a similar 
way to that observed for the trial reaction, attempting the coupling in Et2O would likely 
be more successful. Unfortunately, 3-(methylsulphinyl)isoquinoline (25) is insoluble in 
Et2O, which currently limits the reaction from proceeding via this route. Future 
attempts would benefit from the exploration of mixed-solvent systems that could 
mediate the Grignard coupling, whilst assisting solubility.  
 
4.7 Incorporating alkyne functionality 
Whilst exploring alternative syntheses not included within this thesis, Sonogashira 
cross-coupling was one method employed. Since this method is implicated in the 
further development/modification of the ligands discussed herein, the successful 
implementation of this method is now described, by way of demonstration of its 
suitability and scope. 
 
4.7.1 Palladium- and copper-catalysed Sonogashira-coupling of terminal 
alkynes with halides 
First reported by Kenkichi Sonogashira and coworkers in 1975, the sonogashira 
reaction is a palladium and copper catalysed coupling reaction between a terminal 
alkyne and halide (Figure 4.7.1-1).44 Simultaneous catalyst use increases the rate of 
reaction, rendering the Sonogashira cross-coupling reaction highly useful, particularly 
in the alkynylation of aryl and alkenyl halides.45  
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Figure 4.7.1-1 Sonogashira cross-coupling between a terminal alkyne and halide 
The mechanism of the catalytic cycles involved is not clearly understood, particularly 
with regards to the copper co-catalyst.46 Oxidative addition of the halide to the active 
palladium(0) species produces an organopalladium(II) species. Transmetallation of 
this species with a copper(I) acetylide species (produced in the copper cycle) expels 
the copper halide. Reductive elimination yields the coupled alkynye product, 
alongside regeneration of the palladium(0) catalyst, completing the cycle (Figure 
4.7.1-2).  
       
Figure 4.7.1-2 Mechanism for palladium and copper catalysed Sonogashira cross-coupling 
via oxidative addition, transmetallation and reductive elimination of the palladium catalyst, 
alongside a less-understood copper cycle. 
R H + R1 X R R'
X: halide (Cl, Br, I), pseudohalide (OTf, OSO2CF3, OPO(OR)2
R: H, aryl, alkyl, SiR3
R1: aryl, alkenyl, alkyl
catalytic Pd(0)
catalytic Cu(I) salt
base (e.g. Et3N)
Pd(0)Ln
Pd(II)R2 X
L
L
Pd(II)R2
L
L
R1
R2-X
R1 R2
Cu R1
Cu X
R1
R1
Cu X
Et3N
Et3NH X
oxidative 
addition
reductive
elimination
transmetallation
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4.7.2 6-(2-trimethylsilyl)ethynyl-3-chloroisoquinoline (27) 
A solution of 6-bromo-3-chloroisoquinoline, ethynyltrimethylsilane, PdCl2(PPh3)2 and 
copper iodide in triethylamine was heated under an inert atmosphere for 4 hours, 
whilst monitoring with TLC  (Figure 4.7.2-1).   
 
            
Figure 4.7.2-1 Synthesis of 6-(2-trimethylsilyl)ethynyl-3-chloroisoquinoline by palladium and 
copper catalysed Sonogashira coupling.  
Triethylamine acts as both the base and solvent. The reaction medium must be basic 
to facilitate deprotonation of the terminal alkyne to form the corresponding alkyne 
anion, which is then able to bind to the oxidised copper.47 Removal of the solvent and 
column chromatography purification of the crude solid yielded the desired product in 
reasonable yield. The success of the coupling reaction is evidenced by the presence 
of a new peak attributed to Si(CH3)3 (Figure 4.7.2-2). Furthermore, the alkynyl 
substituent has a greater shielding effect than the halide atom it replaces, resulting in 
an upfield shift in the peaks attributed to the neighbouring protons (H(6): 8.15 ppm to 
8.02 ppm; H(8): 7.78 ppm to 7.65 ppm). 
N
ClBr
N
Cl
TMS
PdCl2(PPh3)2, CuI, Et3N
Ethynyltrimethylsilane
50 °C, Ar atm. 4 h
                57%
27
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Figure 4.7.2-2 1H-NMR spectra overlay of 6-bromo-3-chloroisoquinoline and 6-(2-
trimethylsilyl)ethynyl-3-chloroisoquinoline (26) (300 MHz, MeOD, 298 °K) 
Preparation of this product (26) has demonstrated the feasibility of the Sonogashira 
cross-coupling method for coupling alkynes to isoquinolines. Despite its original role 
in an alternative synthetic scheme, this target still represents a very useful building 
block in the preparation of novel ligands incorporating isoquinoline. The additional 
halide group facilitates further modification through a variety of coupling routes, 
several of which have been explored within this chapter. 
H6         H8 
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4.8 Conclusions 
This chapter demonstrates synthetic success and failure in equal measure. Initial 
attempts to prepare an unsymmetrical ligand via α-arylation were hindered due to the 
presence of an additional nitrogen during the catalytic cycle. Attempts to utilise an 
N^C coordination system alongside an alkyne moiety also failed, on account of the 
interference of the unprotected alkyne. The preparation of an unsymmetrical ligand 
with N^C coordination, prepared via Stille coupling in the absence of an alkyne were 
successful. This ligand possesses a halide substituent that can be exploited to 
introduce alkyne functionality via Sonogashira cross-coupling. Alternatively, the 
halide serves as a versatile coupling partner for a variety of methodologies, should 
alternative functionalities be desired. The incorporation of N^C coordination into a 
terdentate system also proved successful. Grignard homocoupling routes have been 
explored, so far proving unsuccessful for the preparation of 3,3-biisoquinoline due to 
solubility. Mixed solvent-systems are anticipated to resolve this issue in the future.  
 
4.9 Experimental materials and methods 
4.9.1 General chemistry 
Reagents and solvents were obtained from Sigma Aldrich, Fisher Scientific, Scientific 
Lab Supplies, Acros Organics and VWR. All solvents were of standard grade and 
were used without purification. Unless otherwise stated, all reactions were carried out 
under standard conditions (298 °K, 1 atm pressure).   
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4.9.2 Analytical characterisation techniques 
All characterisation techniques were conducted within the School of Chemistry at the 
University of Birmingham. Nuclear Magnetic Resonance (NMR) spectra were 
recorded in deuterated CDCl3, CD3CN, CD3OD and d6-DMSO. 1H-NMR spectra were 
recorded on a Bruker AV(III)300 and AV(III)400 instruments, operating at 300 and 
400 MHz respectively. 13C-NMR spectra were recorded on a Bruker AV(III)400 
instrument operating at 100 MHz. Electrospray Ionisation Mass Spectrometry (ESI-
MS) spectra were carried out by Dr. Chi Tsang and Dr. Peter Ashton (Analytical 
Facility). Spectra were recorded on a Waters LCT Time of Flight Spectrometer.  
 
4.9.3 Chemical synthesis 
3-(pyridine-2-yl)isoquinoline  (15) 
 
A resealable reaction tube was sealed with a rubber septum and flame dried under a 
flow of argon. (DtBPF)PdCl2 (4.0 mol%, 3.80 mg, 5.82 µM) and sodium tert-butoxide 
(69.9 mg, 728 µM) were added to the tube. The aryl halide (66.7 mg, 291 µM) was 
dissolved in dry THF (5 mL) and the resulting solution was added via syringe to the 
tube. The ketone (42.0 mg, 349 µM) was then added via syringe to the tube. The 
rubber septum was replaced with a screw cap and the tube heated at 70 ˚C for 18 h. 
Upon cooling to room temperature, the reaction was acidified to pH 5 by the addition 
of aqueous HCl (1.0 M). A solution of NH4Cl (10 eq., 1.0 M in 3:1 EtOH/H2O) was 
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then added and the tube resealed and heated at 90 °C for 24 h. The reaction was 
cooled to room temperature and quenched by the addition of saturated aqueous 
NaHCO3 (10 mL). The aqueous layer was extracted with Et2O and the combined 
organics were dried over Na2SO4, filtered and the solvent removed in vacuo. Analysis 
of crude 1H NMR showed the presence of starting materials and deprotected aryl 
halide only.  
 
2-(2-(1,3-dioxolan-2-yl)phenyl)-1-(pyridine-2-yl)ethanone (16) 
 
A resealable reaction tube was sealed with a rubber septum and flame dried under a 
flow of argon. (DtBPF)PdCl2 (4.0 mol%, 3.80 mg, 5.82 µM) and sodium tert-butoxide 
(69.9 mg, 728 µM) were added to the tube. The aryl halide (66.7 mg, 291 µM) was 
dissolved in dry THF (5 mL) and the resulting solution was added via syringe to the 
tube. The ketone (42.0 mg, 349 µM) was then added via syringe to the tube. The 
rubber septum was replaced with a screw cap and the tube heated at 70 ˚C for 18 h. 
The reaction was then cooled to room temperature and quenched by the addition of 
H2O (25 mL). The aqueous layer was extracted with Et2O and the combined organics 
were dried over Na2SO4, filtered and the solvent removed in vacuo to give crude 
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product. Analysis of crude 1H NMR showed the presence of starting materials only. 
 
3-(4-ethynylphenyl)isoquinoline (17) 
  
Method a. A mixture of 3-chloroisoquinoline (3) (93.4 mg, 0.57 mmol), 4-
ethynylphenylboronic acid pinacol ester (156 mg, 0.68 mmol), 
tetrakis(triphenylphosphine)palladium(0) (32.8 mg, 0.03 mmol), 2M Na2CO3 aqueous 
solution (1 mL) and 1,4-dioxane (3 mL) was degassed and heated at 100 °C for 18 h. 
Upon cooling to room temperature, the reaction mixture was filtered through celite, 
which was rinsed with EtOAc. The filtrate was concentrated in vacuo and dried under 
reduced pressure. Purification of the remaining brown, oily residue was attempted by 
flash column chromatography on silica gel, eluting with EtOAC:hexane (1:1). No 
product was obtained.  
Method b. A mixture of 3-chloroisoquinoline (3) (93.4 mg, 0.57 mmol), 4-
(dihydroxyborophenyl)acetylene (92.0 mg, 0.63 mmol), K2CO3 (237 mg, 1.72 mmol), 
tetrakis(triphenylphosphine)palladium(0) (19.5 mg, 17.0 µmol) and anhydrous DMF 
(20 mL) was degassed and heated at 100 °C for 18 h. Remainder of method as 
stated above (method a). No product was obtained. 
 
N
2
1
10
5
4
9
8
7
6
3 4'
3'
2'
1'
6'
5'
11
12
 230 
4-(pyridine-2-yl)aniline (18) 
 
2-bromopyridine (144 mg, 0.91 mmol) and 4-aminophenylboronic acid pinacol ester 
(300 mg, 1.37 mmol) were dissolved in anhydrous DMF (30 mL). To the solution 
were added tetrakis triphenylphosphine palladium (73.7 mg, 0.06 mmol) and K2CO3 
(629 mg, 4.56 mmol) and the mixture was stirred under an inert atmosphere for 2 h at 
100 °C. The reactant was poured into water and filtered, and the filtrate was 
extracted with ethyl acetate. The organic layer was washed with water and brine, and 
dried over MgSO4. The solvent was removed under reduced pressure and the 
residue purified by column chromatography on silica gel, eluting with EtOAc/Hexanes 
(3:7) to afford the desired product as orange liquid (79.0 mg, 51%).  
1H NMR (300 MHz, d6-DMSO): δ 8.51 (1H, dt, J = 8.5, H(6)), 7.79 (2H, d, J = 7.8, 
H(5’/3’)), 7.75-7.72 (2H, m, H(4/3)), 7.14 (1H, td, J = 7.1, H(5)), 6.63 (2H, d, J = 8.0, 
H(6’/2’)), 5.44 (s, 2H, H(7)). 13C NMR (MHz, d6-DMSO): δ 154.6, 149.2, 144.2, 137.2, 
129.0, 128.4, 123.6, 120.5, 115.1. m/z (ESI+): 171.1 [C11H10N2 + H]+  
 
3-(4-chlorophenyl)isoquinoline (19) 
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An oven-dried Schlenk tube was charged with palladium(II) acetate (2 mol%), 3-
bromoisoquinoline (6) (100 mg, 0.48 mmol), caesium fluoride (161 mg, 1.06 mmol), 
and XPhos (4 mol%). The vessel was evacuated and backfilled with argon three 
times before the addition of tributyl(4-chloro)phenylstannane (0.20 mL, 0.58 mmol) 
and t-BuOH (2 mL) via syringe. The solution was heated to 110 °C for 48 h. Upon 
cooling to room temperature, the reaction mixture was filtered through a plug of silica 
(eluting with EtOAc) and concentrated in vacuo. Purification by column 
chromatography on silica gel eluting with DCM:MeOH (grading from 100:0 to 95:5) 
yielded the desired product as white solid (82.6 mg, 72%)  
1H NMR (300 MHz, CDCl3): δ 9.33 (1H, s, H(1)), 8.11-8.04 (3H, m, H(5’/3’/4)), 8.00 (1H, 
d, J = 7.9, H(9)), 7.88 (1H, d, J = 8.0, H(6)), 7.72 (1H, ddd, H(8)), 7.61 (1H, ddd, H(7)), 
7.41 (2H, m, H(2’/6’)). 13C NMR (MHz, CDCl3): δ 152.2, 149.9, 137.7, 136.6, 134.9, 
130.5, 128.8, 128.0, 127.7, 127.1, 126.8, 116.5.  m/z (ESI+): 240.2 [C15H10ClN + H]+ 
 
5-chloro-1,3-di(2-pyridyl)benzene (20) 
 
A mixture of 1,3-dibromo-5-chlorobenzene (149 mg, 549 µmol), 2-
tributylstannylpyridine (500 mg, 1.36 mmol), lithium chloride (37.0 mg, 828 µmol) and 
bis(triphenylphosphine)palladium(II) chloride (102 mg, 144 µmol) in anhydrous 
toluene was degassed via three freeze-pump-thaw cycles and heated at reflux (130 
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°C) under an inert atmosphere for 3 days. Upon cooling to room temperature, a 
saturated aqueous solution of potassium chloride (10 mL) was added, and the 
mixture stirred for 30 min. The insoluble residue was removed by filtration and 
washed with toluene. The filtrate was concentrated in vacuo and taken into DCM, 
before washing with aqueous NaHCO3 (2 × 30 mL). The organic phased was dried 
over Na2SO4 and concentrated under reduced pressure. Purification of the crude 
solid by column chromatography on silica gel, eluting with EtOAc:hexanes (grading 
from 10:90 to 50:50) yielded the desired product as white solid (77.6 mg, 53%). 
1H NMR (300 MHz, d6-DMSO): δ 8.78 (1H, s, H(2)), 8.73 (2H, ddd, J = 4.8, 1.8, 1, 
H(6’/6’’)), 8.21-8.15 (4H, m, H(6/4/3’/3’’)), 7.95 (2H, m, H(4’/4’’)), 7.44 (2H, ddd, J = 6.8, 4.8, 
1.6, H(5’/5’’)). 13C NMR (MHz, d6-DMSO): δ 150.2, 149.7, 138.1, 137.9, 127.0, 124.7, 
123.6, 121.3, 120.9 m/z (ESI+): 267.2 [C17H11ClN2 + H]+, 289.1 [C17H11ClN2 + Na]+ 
 
5-bromo-2-(methylthio)pyridine (21)  
 
2,5-dibromopyridine (2.51 g, 10.6 mmol) and NaSMe (0.74 g, 10.6 mmol) were 
dissolved in anhydrous DMF (40 mL) and the solution stirred under an inert 
atmosphere at room temperature for 24 h. The solution was poured onto water (200 
mL) and extracted with EtOAc. The organic phases were combined, dried over 
MgSO4 and concentrated in vacuo to yield the desired product as yellow solid  
(1.50 g, 69%). 
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1H NMR (300 MHz, CDCl3): δ 8.47 (1H, s, H(6)), 7.56 (1H, dd, J = 8.5, 2.4, H(4)), 7.06 
(1H, d, J = 8.5, H(3)), 2.53 (3H, s, H(8)). 13C NMR (100 MHz, CDCl3): δ 158.7, 150.2, 
138.3, 122.6, 115.7, 13.4. m/z (ESI+): 203.9 [C6H6BrNS + H]+ 
 
5-bromo-2-(methylsulphinyl)pyridine (22)  
 
5-bromo-2-(methylthio)pyridine (21) (1.50 g, 7.30 mmol) was dissolved in glacial 
acetic acid (10 mL) and 30% H2O2 (1 mL) added. The solution was stirred at room 
temperature for 24 h. Following the addition of chloroform (10 mL), the solution was 
basified to pH 8 with 30% NH3 solution. The solution was extracted with chloroform  
(2 × 20 mL) and DCM (2 × 20 mL) and the combined organics washed with water, 
dried over MgSO4 and concentrated in vacuo. Overnight drying of the resulting white 
liquid in a dessicator with P2O5 yielded the desired product as yellow solid (1.53 g, 
95%). 
1H NMR (300 MHz, CDCl3): δ 8.67 (1H, s, H(6)), 8.07 (1H, dd, J = 8.3, 2.2, H(4)), 8.02 
(1H, d, J = 8.3, H(3)), 2.84 (3H, s, H(8)). 13C NMR (100 MHz, CDCl3): δ 163.5, 149.6, 
139.7, 121.1, 119.8, 40.3. m/z (ESI+): 219.9 [C6H6BrNOS + H]+ 
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5,5’-dibromo-2,2’-bipyridine (23)  
 
5-bromo-2-(methylsulphinyl)pyridine (22) (740 mg, 3.36 mmol) was dissolved in 
anhydrous Et2O (30 mL) and the solution cooled in an ice bath to 0 °C. EtMgBr  
(0.9 M in Et2O, 2.46 mL, 2.22 mmol) was added via syringe and the solution warmed 
to room temperature before stirring for 1 h. Following the addition of water (5 mL), the 
resulting suspension was extracted with toluene and the organic fractions combined 
and dried over MgSO4, before reducing under reduced pressure. Recrystallisation of 
the crude product with hot EtOAc yielded the desired product as golden-brown 
crystals. (337 mg, 64%). 
1H NMR (300 MHz, CDCl3): δ 8.69 (2H, s, H(6)), 8.28 (2H, d, J = 8.4, H(3)), 7.92 (2H, 
d, J = 8.2, H(4)). m/z (ESI+): 314.9 [C10H6Br2N2 + H]+ 
 
3-(methylthio)isoquinoline (24)  
 
Operating under an argon atmosphere, 3-chloroisoquinoline (3) (2.50 g, 15.3 mmol) 
and sodium thiomethane (1.07 g, 15.3 mmol) were dissolved in anhydrous DMF (45 
mL) and the solution stirred at room temperature for 2 days. The solution was poured 
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into water (250 mL) and the resulting milky solution extracted with Et2O (3 × 100 mL). 
The organic phases were combined, dried over MgSO4 and the solvent concentrated 
in vacuo. Purification of the remaining orange-brown, oily residue was carried out via 
flash column chromatography on silica gel, eluting with DCM:MeOH (19:1). The 
desired product was obtained as yellow solid (1.74 g, 65%).  
1H NMR (300 MHz, CDCl3): δ 9.08 (1H, s, H(1)), 7.86 (1H, d, J = 6.0, H(9)), 7.71-7.68 
(2H, m, H(6/7)), 7.60-7.55 (1H, m, H(8)), 7.43 (1H, s, H(4)), 2.63 (3H, s, H(12)).  13C NMR 
(400 MHz, CDCl3): δ 152.6, 136.6, 130.8, 127.7, 127.4, 126.6, 125.8, 125.4, 119.7, 
115.6. m/z (ESI+): 176.2 [C10H9NS + H]+ 
 
3-(methylsulphinyl)isoquinoline (25)  
 
3-(methylthio)isoquinoline (24) (1.00 g, 5.71 mmol) was added to glacial acetic acid 
(3 mL) and 30% H2O2 solution (1 mL) and heated at 45 °C. After 2 days, CHCl3 (5 
mL) was added and the solution basified to pH 8 by the addition of 30% NH3 solution. 
The solution was extracted with CHCl3 (3 × 10 mL) and the organic phases combined 
and dried over MgSO4. Removal of the solvent in vacuo yielded orange oil that was 
purified by column chromatography on silica gel, eluting with DCM:MeOH (3.5%) to 
afford the desired product as pale yellow solid (0.88 g, 81%). 
1H NMR (300 MHz, CDCl3): δ 9.33 (1H, s, H(1)), 8.55 (1H, s, H(4)), 8.13 (1H, d, J = 6.0, 
H(9)), 8.04 (1H, d, J = 6.0, H(6)), 7.90-7.83 (2H, m, H(7/8)), 3.29 (3H, s, H(12)). 13C NMR 
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(400 MHz, CDCl3): δ 153.5, 151.3, 135.3, 132.2, 130.4, 129.8, 128.3, 128.0, 120.4, 
40.6. m/z (ESI+): 230.1 [C10H9NOS + K]+  
 
3,3-biisoquinoline (26)  
 
3-(methylsulphinyl)isoquinoline (25) (122 mg, 0.63 mmol) was dissolved in anhydrous 
THF (10 mL) and the solution cooled in an ice bath to 0 °C. MeMgBr (1.0 M in THF, 
0.50 mL, 0.42 mmol) was added via syringe and the solution warmed to room 
temperature before stirring for 1 h. Following the addition of water (5 mL), the 
resulting suspension was extracted with toluene and the organic fractions combined 
and dried over MgSO4, before reducing under reduced pressure. Crude analysis 
confirmed the reaction to be unsuccessful. No product was obtained.  
 
6-(2-trimethylsilyl)ethynyl-3-chloroisoquinoline (27) 
 
Under an argon atmosphere, an oven-dried Schlenk tube was charged with 6-bromo-
3-chloroisoquinoline (380 mg, 1.57 mmol), PdCl2(PPh3)2 (66.0 mg, 0.09 mmol) and 
copper iodide (52.0 mg, 0.28 mmol). Triethylamine (10 mL) was thoroughly de-
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gassed before addition to the vessel. Ethylnyltrimethylsilane  
(0.50 mL) was then added via syringe before heating the solution to 50 °C for 1 h. 
The solvent was then removed in vacuo and the residue purified by flash column 
chromatography on silica gel, eluting with hexane/EtOAc (9:1), to afford the desired 
product as pale cream solid (231 mg, 57%).  
1H NMR (300 MHz, MeOD): δ 9.11 (1H, s, H(1)), 8.12-8.07 (1H, d,  J = 15.0, H(9)), 
8.02 (1H, s, H(6)), 7.91 (1H, s, H(4)), 7.68-7.63 (1H, d, J = 15.0, H(8)), 0.3 (9H, s, H(14)). 
13C NMR (100 MHz, MeOD): δ 153.9, 141.5, 133.3, 131.7, 130.7, 129.4, 128.1, 
121.8, 121.0, 98.6, 71.3. m/z (ESI+): 260.1 [C14H14ClNSi + H]+ 
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V. CONCLUSIONS AND FUTURE WORK 
 
The aim of this work was to develop ligands and complexes capable of interacting 
with G-quadruplex DNA structures. Utilising 3,3-biisoquinoline, the synthetic route 
towards two pre-existing palladium and platinum complexes incorporating this ligand 
has been modified to secure higher yields through more facile routes. The interaction 
of both complexes with model nucleobases has been investigated, with each 
complex demonstrating a preference for binding to guanine.  A range of in vitro 
studies have been conducted, all providing further information about the mechanism 
of action of these compounds. Both compounds have been shown to exhibit 
cytotoxicity in the low micromolar range and exceeding that of cisplatin. The 
palladium complex was shown to be more cytotoxic, although this difference was not 
significant. It has been demonstrated that treatment with either complex induces a 
small degree of double-strand breaks in cells, alongside G2/M phase cell cycle 
arrest. Both cells have demonstrated excellent cell uptake and nuclear localisation, 
again exceeding that of cisplatin.  
The precise cause of the increased cytotoxicity displayed by the palladium 
complex remains to be established. ICP-MS data has so far shown the cellular 
concentration of each complex to be within the same order of magnitude following 3 
hours incubation. There may, however, be changes in the cellular concentration of 
each complex over a longer period of time. Such changes may account for the 
differences observed in the MTT cytotoxicity assay, which was conducted over a 24 
hour timeframe.  To investigate this hypothesis further, it would be beneficial to carry 
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out further ICP-MS studies in the future, at multiple timepoints between 3 and 24 
hours. The potential role of any influx or efflux mechanisms may then be probed.  
These compounds continue to show great promise as G-quadruplex binders. It 
would be highly beneficial to carry out the telomerase repeat amplification assay 
(TRAP assay) with both compounds, in order to assess their ability to inhibit 
telomerase. Determining the potential contribution of telomerase inhibition to the 
overall cytotoxicity of these compounds would enable their mechanism of action to be 
further elucidated. In addition to the further biological exploration of the palladium and 
platinum biisoquinoline compounds, attempted synthesis of the gold analogue needs 
revisiting in order to ascertain the success of this preparation and make any 
necessary changes to the procedure to isolate this compound. The full range of 
biophysical and biological testing so far carried out on the palladium and platinum 
species would then be repeated with this novel analogue for comparison.  
 
A terpyridine platform capable of further modification via an appended 
methylsulphinyl group has been successfully prepared and incorporated into two 
novel complexes. UV-Vis spectroscopy studies on these palladium and platinum 
compounds have demonstrated them to be stable in solution (acetonitrile) over a 
period of 24 hours. Initial DNA binding studies have proved quite complex, with some 
discrepancies between the CD and PAGE data obtained thus far.  
Future studies will endeavour to determine the exact nature of these proposed 
DNA binding interactions. To aid this, it would be beneficial to conduct UV-Visible 
spectroscopy titration studies with the same DNA sequences investigated in the CD 
and PAGE studies. Fluorescent intercalator displacement studies would also help to 
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elucidate any binding preference for G-quadruplex forming regions of DNA. Despite 
the seemingly inferior G-quadruplex binding activity displayed by these terpyridine 
complexes so far (compared to their palladium and platinum biisoquinoline 
counterparts), terpyridine itself is a far easier ligand platform to work with 
synthetically, affording higher yields from simpler syntheses. It is anticipated that the 
introduction of further functionality to the terpyridine platform will be achieved with 
greater ease than previous attempts with 3,3-biisoquinoline (work not included 
herein). For these reasons, and on account of the huge potential for further 
functionality to be added at the methylsulphinyl site, the terpyridine ligand still 
represents a viable ligand target for G-quadruplex binding. Moving forward, the focus 
with this system should undoubtedly rest on the incorporation of moieties capable of 
enhancing G-quadruplex binding interaction, appended via Grignard coupling routes 
at the methylsulphinyl site. Complexes containing such ligands would then be 
analysed in a similar manner to that described within this work, to compare their 
activity to that of the compounds herein. 
 
A variety of alternative synthetic methodologies have been explored, each with the 
intention of securing novel ligands with desirable features such as alkyne or N^C 
coordination. The most promising route involved the use of Stille-coupling to 
generate an unsymmetrical N^C coordinating ligand that is poised for further 
modification due to the presence of a halide substituent in the para position. 
Incorporation of an alkyne moiety at this site via Sonogashira cross-coupling is the 
natural progression with this ligand. Complex formation with the resulting alkyne-N^C 
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ligand will produce novel compounds that can be tested for G-quadruplex binding 
potential (as assessed by CD, FID, UV-Vis, PAGE and ESI-MS).  
A terpyridine-based N^C^N ligand has also been successfully prepared. Again 
incorporating a halide atom, further functionalization of this ligand is anticipated. The 
incorporation of a linked appendage that is capable of imparting dual-modality 
binding (such as that seen in Pt-MPQ) into any future complexes is the end goal.  
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concentration 
inside cells 
(µmol/106 cells) 
 
14.3 
5.83 
37.6 
 
5.49 
4.25 
18.6 
 
12.6 
1.08 
22.8 
molecules/ 
cell 
 
3.45E+07 
1.30E+07 
9.05E+07 
 
1.32E+07 
1.02E+07 
4.47E+07 
 
3.03E+07 
2.59E+06 
5.49E+07 
moles/ 
cell 
 
5.73E-17 
2.15E-17 
1.50E-16 
 
2.20E-17 
1.70E-17 
7.42E-17 
 
5.04E-17 
4.31E-18 
9.11E-17 
moles/sample 
(pmol/106 cells) 
 
57.3 
21.5 
150 
 
22.0 
17.0 
74.2 
 
50.4 
4.31 
91.1 
mass in 
sample (g) 
 
1.12E-08 
4.20E-09 
1.59E-08 
 
4.28E-09 
3.32E-09 
7.87E-09 
 
9.83E-09 
8.40E-10 
9.66E-09 
sample 
mass (g) 
 
4.20 
4.20 
6.90 
 
4.20 
4.20 
6.90 
 
4.20 
4.20 
6.90 
concentration 
(ppb) 
 
2.66 
1.00 
2.31 
 
1.02 
0.79 
1.14 
 
2.34 
0.20 
1.40 
Ar of 
metal 
 
195 
195 
106 
 
195 
195 
106 
 
195 
195 
106 
Cell fraction 
Whole cell 
[Pt(i-biq)2][PF6]2 
cisplatin 
[Pd(i-biq)2][BF4]2 
Cytoplasmic 
[Pt(i-biq)2][PF6]2 
cisplatin 
[Pd(i-biq)2][BF4]2 
Nuclear 
[Pt(i-biq)2][PF6]2 
cisplatin 
[Pd(i-biq)2][BF4]2 
